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Summary 
The ADP-ribosyltransferase Diphtheria toxin like (ARTD; formerly called PARP) 
enzyme family consists of 18 members that can either mono- or poly-ADP-ribosylate 
acceptor proteins. ADP-ribosyltransferase D-type 1 (ARTD1, PARP1) synthesizes 
poly-ADP-ribose (PAR) and is a chromatin-associated enzyme that regulates 
chromatin compaction and transcription during various cellular processes. Adipocyte 
differentiation goes along with a dynamic modulation of the chromatin landscape and 
fundamental changes in the transcriptome, which are mainly controlled by the 
transcription factor PPARγ. It was the aim of this thesis to study the role of ARTD1 
and PAR formation during adipogenesis, with a focus on PPARγ-dependent gene 
expression, and to elucidate the molecular mechanism by which ARTD1 regulates 
transcription in this context. 
 The results presented in this thesis reveal an involvement of ARTD1 and its 
enzymatic activity during the late phase of adipocyte differentiation. Knockdown of 
ARTD1 as well as inhibition of PAR formation hampered adipogenesis. Moreover, 
adipose stem cells derived from ARTD1-/- mice failed to differentiate into adipocytes. 
Mechanistic studies provided evidence that ARTD1 and PPARγ are recruited to the 
promoters of PPARγ-dependent genes. PPARγ ligand was able to enhance the 
interaction of PPARγ with ARTD1 in cells as well as in vitro. Topoisomerase IIβ site-
specific double strand-DNA breaks induced PAR formation, which was important for 
the decrease of the NCoR co-repressor and for the increased p300 co-activator 
recruitment to PPARγ target genes. This co-factor exchange was prevented by PARP 
inhibitors, but an excess of PPARγ ligand could overcome this inhibition. In addition, 
mice treated with PARP inhibitor showed significantly reduced bodyweight, smaller 
adipocytes and fat depots on high fat diet (HFD). Interestingly, ARTD1-/- mice 
showed a similar phenotype as the inhibitor-treated mice, but additionally 
accumulated triglycerides in the liver. 
Together, the results presented in this thesis define the role of ARTD1 for the 
maintenance of PPARγ2-dependent gene expression in the late phase of adipocyte 
differentiation and in adipocyte function. 
Zusammenfassung 
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Zusammenfassung 
Die intrazellulären ADP-Ribosyltransferasen mit Ähnlichkeit zum Diphtheria Toxin 
(ARTDs) bilden eine Enzymfamilie, welche aus 18 Mitgliedern besteht, die 
Akzeptorproteine entweder mono- oder poly-ADP-ribosylieren können. ARTD1 ist 
ein Chromatin-assoziiertes Enzym, welches poly-ADP-Ribose (PAR) synthetisiert 
und dadurch die Transkription von Genen reguliert, welche in vielen 
unterschiedlichen zellulären Prozessen beteiligt sind. Die Differenzierung von 
Adipozyten wird von massiven Veränderung auf Chromatin- und Transkriptionsebene 
begleitet, die hauptsächlich durch den Transkriptionsfaktor PPARγ kontrolliert 
werden. Es war das Ziel dieser Arbeit, die Rolle von ARTD1 und PAR während der 
Adipozytendifferenzierung, insbesondere den Effekt auf die PPARγ-abhängige 
Genexpression, zu charakterisieren und den molekularen Mechanismus zu 
entschlüsseln, der dieser transkriptionellen Regulation durch ARTD1 zugrunde liegt.  
 Die hier präsentierten Ergebnisse beschreiben den Einfluss von ARTD1 und 
seiner enzymatischen Aktivität auf die Adipozytendifferenzierung. Die Reduktion der 
ARTD1 Proteinmenge oder die Inhibierung der PAR Bildung hemmten die 
Differenzierung. Stammzellen, die aus dem Fettgewebe von ARTD1-/- Mäusen 
gewonnen wurden, konnten nicht mehr zu Adipozyten differenzieren. Mechanistische 
Analysen zeigten eine gemeinsame Bindung von ARTD1 und PPARγ an die 
Promotoren PPARγ-abhängiger Gene. PPARγ Liganden verstärkten die Interaktion 
von PPARγ mit ARTD1 in Zellen sowie in vitro. Topoisomerase IIβ generierte 
Doppelstrangbrüche induzierten PAR Bildung, welche für die Reduktion des 
Corepressors NCoR und die Zunahme des Coaktivators p300 an PPARγ-abhängigen 
Genen wichtig war. Dieser Cofaktor-Austausch wurde durch PARP Inhibitoren 
verhindert, was aber durch einen Überschuss an PPARγ Liganden kompensiert 
werden konnte. Zusätzlich zeigten wildtyp Mäuse auf Hochfettdiät unter PARP 
Inhibitor Behandlung reduziertes Gewicht, kleinere Fettpolster und kleinere 
Adipozyten. Intereressanterweise zeigten ARTD1-/- Mäuse unter gleichen 
Bedingungen einen ähnlichen Effekt, hatten aber zusätzliche Fetteinlagerungen in der 
Leber.  
Zusammengefasst zeigen unsere Ergebnisse eine neue Funktion von ARTD1 in der 
Aufrechterhaltung der PPARγ-abhängigen Genexpression und Adipozytenfunktion.  
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Abbreviations 
 
aa     Amino acid 
ADP     Adenosine diphosphate 
AID    Activation-induced deaminase 
ARH3     ADP-ribosyl hydrolase 3 
ART     ADP-ribosyltransferase 
ARTD    ADP-ribosyltransferase diphtheria toxin-like 
ARTC     ADP-ribosyltransferase cholera toxin-like 
ATGL    Adipose triglyceride lipase 
ATM    Ataxia telangiectasia mutated 
ATP    Adenosine triphosphate 
BAT     Brown adipose tissue 
BER     Base excision repair 
bp     Base pair 
BRCT     BRCA1 carboxy-terminal domain 
CBP    CREB-binding protein 
cAMP    Cyclic adenosine monophosphate 
Cat     Catalytic 
Cdk     Cyclin-dependent kinase 
C/EBP    CCAAT/enhancer binding protein 
ChIP     Chromatin immunoprecipitation 
CLOCK   Circadian locomotor output cycles kaput 
CLS     Centriole localization signal 
CRBP    cold-inducible RNA-binding protein 
DAPI     4',6-diamidino-2-phenylindole 
DBD     DNA binding domain 
Dbp    AlbuminD-element binding protein 
DDR     DNA damage response 
DNA     Deoxyribonucleic acid 
DNMT    DNA methyltransferase 
DSB     Double-strand break 
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dsDNA   Double-stranded DNA 
FCS     Fetal calf serum 
Flp    Flippase 
Frt    Flp-recombinase target 
GTT    Glucose tolerance test 
GTP    Guanosintriphosphat 
γH2AX    gamma-histone 2A variant X (phosphorylated) 
HDAC    Histone deacteylase 
HIF     Hypoxia-inducible factor 
HMGB    High mobility-group box 
HSL    Hormone sensitive lipase 
H2O2     Hydrogen peroxide 
IBMX    3-Isobutyl-1-methylxanthin 
IL6     Interleukin 6 
iNOS    Inducible nitric oxide synthase 
IR     Ionizing radiation 
KLF    Krüppel-like factor 
LBD     Ligand binding domain 
LPS     Lipopolysaccharide 
MEF     Mouse embryonic fibroblasts 
MPTP     1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin 
NAD     Nicotinamide adenine dinucleotide 
NAFLD   Non alcoholic fatty liver disease 
NAM     Nicotinamide 
NCOR    Nuclear Receptor Corepressor 
NF-κB  Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 1 
NLS    Nuclear localization signal 
PAR     Poly-ADP-ribose 
PARG    Poly-(ADP-ribose)-glycohydrolase 
PARP     Poly-(ADP-ribose)-polymerase 
PARylation    Poly-ADP-ribosylation 
PBS     Phosphate buffered saline 
PCNA    Proliferating cell nuclear antigen 
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Pol II     Polymerase II 
PPAR     Peroxisome proliferator-activated receptor 
PPRE    PPARγ response elements 
PRC    Polycomb repressive complex 
PTM     Post-translational modification 
rDNA     Ribosomal DNA 
RNA     Ribonucleic acid 
rRNA     Ribosomal RNA 
RXR    Retinoid-X receptor 
SREBP   sterol regulatory element-binding protein 
SMRT silencing mediator of retinoic acid and thyroid hormone 
receptor 
SSB     Single-strand break 
SUMO    Small ubiquitin-like modifier 
T2D    Type II diabetes 
TDG    Thymine DNA glycosylases 
TdT    Terminal deoxynucleotidyl transferase 
Tip60    HIV-Tat-Interactive protein 60 
TNFα     Tumor necrosis factor α 
TopoII    Topoisomerase II 
UCP-1    Uncoupling protein 1 
UTR    Untranslated region 
WAT     White adipose tissue 
XRCC1/4    X-ray repair cross-complementing protein 1/4 
ZF     Zinc finger 
5mc    5-methyl-cytosine 
5hmc    5-hydroxymethyl-cytosine 
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1 Introduction 
Intracellular signaling pathways control the processes of differentiation and cell 
determination. Often these pathways are induced by external or internal signals and 
are tightly controlled within the cell by proteins regulating different cascades. These 
proteins are often enzymes modifying targets in a precise manner by posttranslational 
modifications (PTMs). PTMs include acetylation, phosphorylation, ubiquitylation, 
sumoylation, methylation or ADP-ribosylation of target proteins 1. 
 
1.1 ADP-ribosylation 
An emerging PTM is the enzymatic attachment of ADP-ribose to target proteins by 
members of the ADP-ribosyltransferase (ART) family that use NAD+ as substrate 2. 
Protein ADP-ribosylation can affect the enzymatic activity of the modified protein or 
the interaction with DNA or other proteins. Consequently, ADP-ribosylation is 
implicated in a variety of processes, including genomic stability, transcriptional 
control, energy metabolism, and cell death 2-6. The process of ADP-ribosylation 
encompasses the attachment of one or more ADP-ribose units to proteins, resulting in 
the formation of poly- or mono-ADP-ribosylated proteins. 
 
1.1.1 Mono-ADP-ribosylation 
Mono-ADP-ribosylation was first discovered as a pathogenic mechanism used by 
bacterial toxins such as cholera, pertussis, diphtheria or clostridia toxins 7. Once they 
enter the host cell, the ADP-ribsoylation activity of these toxins causes various 
pathological changes by modifying host proteins such as tubulin, actin, alpha and beta 
subunits of GTP-binding proteins, and histones 8-10. ADP-ribosylation exerts its 
pathological function mainly by inhibiting the function of the host proteins. Mono-
ADP-ribosylation is however also found in bacteriophages or in eukaryotic cells. 
Intracellular mono-ADP-ribosylation is implicated in the regulation of cellular 
processes such as signal transduction, gene expression, proliferation, inflammation 
and differentiation 3,7,11-14.  
Introduction   
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1.1.2 Poly-ADP-ribosylation 
Poly-ADP-ribosylation (PARylation) was first described in 1963 in the laboratory of 
P. Mandel 15. The modification occurs most likely on lysines, arginines and 
glutamates, but other acceptor sites have been discussed as well 2,16-19. Within the 
polymer of ADP-ribose (PAR), the ADP-ribose units are linked to each other via 
glycosidic ribose-ribose bonds. The resulting polymer can be linear or branched and 
comprise the considerable length of up to 400 moieties when generated in vitro 2,16,20. 
The PARylation reaction can be divided into three different steps (Fig. 1) 2,21. After 
the cleavage of NAD+, the first ADP-ribose moiety is transferred during the initiation 
step to an acceptor amino acid. Subsequently, this mono-ADP-ribose can be 
elongated to oligo- and ultimately poly-ADP-ribose. Finally, the polymers can be 
branched in an irregular manner with one branching point every 20-50 units of linear 
ADP-ribose 2,22,23. 
 
Figure 1: PAR metabolism      
Different steps in the formation and catabolism of poly-ADP-ribose are shown. Modified from Hassa 
and Hottiger 2.  
 
The functional consequences of PARylation on different target proteins are often 
unknown and depend on the nature of the modified protein. The methods for 
analyzing the cellular APD-ribosylome are up to now very limited due to lack of good 
antibodies especially against mono-ADP-ribose. In addition, the modification seems 
to be unstable during extraction which makes it extremely difficult to detect it by 
mass spectrometry. However, recently two publications using different approaches 
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identified several hundred modified or PAR interacting proteins after treatment of 
cells with genotoxic compounds 24-26. However, most of these studies are biased, 
since they are performed in absence or knockdown of PARG (see chapter 1.5) and it 
is thus of great importance to establish new methods to analyse the ADP-ribosylome. 
Among the identified proteins are a large number of chromatin-associated proteins 
such as topoisomerases, histones, PCNA and ARTs of the diphtheria toxin-like 
(ARTD) subgroup 27-32. The endogenous cellular PAR levels are usually very low, but 
upon mitogenic or genotoxic stress these levels can increase up to 50-100 fold within 
only a few minutes, which is accompanied by a reduction of the cellular NAD+ pool 
to 10-20% of the normal levels 2. In vivo, the majority of PAR formed upon genotoxic 
stress is rapidly degraded with a half-life of less than 40s 2,33,34. This is in contrast to 
the much longer half-life (7 hours) of the PAR that is supposed to be continuously 
formed in the absence of genotoxic stress 33,34. The fast degradation of PAR is 
mediated by the cellular activities of enzymes capable of hydrolyzing the protein-
ADP-ribose or the ADP-ribose-ADP-ribose bonds. Among these, poly-ADP-ribose-
glycohydrolase (PARG) or ADP-ribosylhydrolase 3 (ARH3) are the most important 
members 35-38. Earlier studies suggest that PARG is unable to remove the first, 
protein-bound ADP-ribose unit 39. Recently, we and others reported that some 
macrodomains are able to hydrolyze mono-ADP-ribose modifications 13,40,41. This 
supports the view that there are ADP-ribose writers and erasers and that PARylation 
is indeed a highly dynamic and reversible PTM. 
 
1.2 The ARTD family 
The enzymes responsible for ADP-ribosylation are the ADP-ribosyltransferases 
(ARTs). Previously, these enzymes were called poly-ADP-ribosylpolymerases 
(PARPs). To acknowledge the fact that not all members possess ADP-ribosylation 
activity and that ADP-ribosylation does not constitute a template driven 
polymerization reaction, these enzymes have been renamed 11. The ARTs are further 
divided into ARTDs (ARTs of the diphtheria toxin family) and ARTCs (ARTs of the 
cholera toxin family). ARTCs are ecto-enzymes or secreted proteins, whereas ARTDs 
are all localized within the cell 11. ARTD1 (PARP1) is estimated to contribute around 
85% of the PAR formation 42,43 and for many years it was believed to be the only 
ARTD capable of synthesizing PAR. However, residual PAR formation was observed 
Introduction   
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in ARTD1-/- cells, which led to the discovery of other ARTD family members. 
Among these members, ARTD2 is responsible for the majority of the residual PAR 
formation and shows high sequence homology to the catalytic domain of ARTD1 
44,45. To date, the ARTD family contains 18 members in human. ARTD 1-6 share a 
catalytic domain with a conserved glutamic acid (i.e. E988 of ARTD1). The other 
ARTD members share a characteristic homology to ARTD1 but lack the conserved 
E988 residue of ARTD1, which is implicated in chain branching and elongation. It 
was therefore suggested that these members only possess mono-ADP-ribosylation 
activity. 
 
1.3 ARTD1 
ARTD1 is the founding member of the ARTD family. Human ARTD1 has a 
molecular weight of 113 kDa, is a chromatin-associated protein and consists of three 
main domains with distinct functions 2 (Fig. 2):  
 
 
Figure 2: Domain structure of ARTD1 
Different domains of ARTD1 are shown. ZFI-III= Zincfinger I-III, NLS=Nuclear localization signal, 
BRCT=BRCA1 carboxy-terminal domain, cat=catalytic domain WGR=domain containing central 
W/G/R motif. 
 
The N-terminal DNA binding domain, the auto-modification domain in the middle 
and the C-terminal catalytic domain. The two structurally and functionally unique N-
terminal Zinc fingers I and II (ZFI and ZFII) convey the DNA binding activity of 
ARTD1. Recently, a third zinc-binding motif (ZFIII), which is structurally completely 
unrelated to ZF I and II, was discovered 46,47. ZFIII is not required for DNA binding, 
but rather for the ADP-ribosyltransferase activity of ARTD1, as well as for its ability 
to compact chromatin 46-48. The auto-modification domain contains a BRCT domain, 
which is supposed to mediate protein-protein interactions. The auto-modification 
domain also contains most of the amino acids that are auto-ADP-ribosylated. The 
WGR domain is named after the most conserved central motif (W/G/R) of the 
domain. This domain was suggested to be involved in DNA binding, but no detailed 
!"#$%&'$(')*$+,---$+,$-$ +,$--$
NLS PARP 
motif 
1014 
DNA binding 
domain 
Auto- 
modification- 
domain 
Catalytic 
domain 
hARTD1 
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analysis has been performed yet and its function remains largely unknown 2. The 
catalytic domain is located at the C-terminus of the protein and conveys NAD+ 
binding and hydrolysis. It contains the “PARP-signature” that comprises the amino 
acids required for initiation, elongation and branching of PAR. Several studies 
indicate that ARTD1 forms a dimer and is catalytically active in a dimer form 49,50. 
Therefore, dimerization of ARTD1 seems to be an important step in DNA-dependent 
activation 18,51. Several studies have provided evidence that ARTD1 can bind to and 
its activity is induced by single and double stranded DNA lesions as well as various 
physiologically relevant structural discontinuities in DNA duplexes in the absence of 
DNA strand breaks 2. These include DNA hairpin and cruciform structures 52-54. To 
address ARTD1 functions in vivo, ARTD1-/- mice were established in three different 
laboratories by targeting different exons 55-59. Surprisingly, ARTD1 knockout mice 
are fertile and healthy. However, they show increased sensitivity to ionizing radiation 
and alkylating agents 55,57-60. On the other hand, these mice are protected from tissue 
injury in various oxidative stress-related disease models including stroke, 
Lipopolysaccharide (LPS) induced septic shock, streptozotocin induced diabetes, 
arthritis, colitis and 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP)-induced 
parkinsonism 3,55,61. Interestingly, knockout of ARTD2 also produces only a mild 
phenotype, while the double knockout of ARTD1 and ARTD2 is embryonically lethal 
62.  
 ARTD1 plays a role in various nuclear processes such as the maintenance of 
genomic integrity, regulation of chromatin structure and transcription, cell death 
pathways and the establishment of DNA methylation which will be subsequently 
discussed 2,3,16,17 (Fig.3).  
Introduction   
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Figure 3. ARTD1 interacts with and modifies different nuclear proteins  
Interaction with ARTD1 or modification influence different nuclear processes Modified from 
Krishnakumar and colleagues 17 
 
1.3.1 ARTD1 in genomic integrity 
The finding that ARTD1 can recognize and bind to DNA lesions led to the idea that 
ARTD1 can act as a DNA nick sensor. ARTD1 has been described to play a role in 
different DNA repair pathways including base excision repair (BER), single-strand 
break (SSB), repair and double strand break (DSB) repair 63,64. Cellular ARTD1 is 
activated by genotoxic stress including oxidative stress (e.g. H2O2), ionizing radiation, 
and alkylating reagents 63-68 and is readily recruited to sites of microlaser-induced 
damage 69,70. Furthermore, many proteins involved in DNA damage repair, including 
XRCCI, DNA polymerase β or PCNA, interact with ARTD1 and are in some cases 
direct targets of ARTD1 71-74. Ample data suggest that ARTD1 is involved in DNA 
damage signaling and genomic integrity 6. However, at the molecular level the 
function of ARTD1 in these processes is still under debate. ARTD1-/- mice show no 
tumor formation under physiological conditions and cells lacking ARTD1 have a 
normal capacity to repair DNA lesions 56,60. Thus, the exact contribution of ARTD1 in 
these processes remains to be elucidated.  
 
1.3.2 ARTD in the regulation of chromatin structure  
ARTD1 was also described to act as a structural component of chromatin 2. Decades 
ago, it has been described that PARylated chromatin is more relaxed than unmodified 
chromatin 75,76. This led to the assumption that ARTD1 acts as a compactor of 
chromatin, which is released upon auto-modification. It was also proposed, that 
ARTD1 
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ARTD1 can dissociate nucleosomes/histones from the DNA to render it more 
accessible for the transcription or repair machinery 77,78. Although histones can be 
ADP-ribosylated, only a small fraction (1%) is modified in vivo 79,80. Histone H1 is 
the main ADP-ribose acceptor in native chromatin, whereas in H1-depleted chromatin 
(open status), H2B is the preferential target of ARTD1 81. ARTD1 and H1 bind 
mutually exclusive to promoters of some genes, possibly by competing for binding to 
nucleosomes or by modification of H1 by ARTD1 17. In addition, ARTD1 activity 
increases the amount of chromatin-bound HMGB1, a chromatin structural protein that 
enhances transcription in certain chromatin context 4,82. Another level of chromatin 
regulation is mediated by the association of the insulator protein CTCF with PAR, 
which may regulate even higher order chromatin structures 83,84. 
 
1.3.3 ARTD1 in the control of transcription 
A recent study has shown that ARTD1 binds to the promoters of most actively 
transcribed genes 85. This binding correlates with the binding of polymerase II (PolII) 
and the presence of trimethylated lysine 4 on H3 (H3K4me3). This suggests a role of 
ARTD1 in transcriptional control. Indeed, ARTD1 has been described to influence 
transcription under various conditions. ARTD1 interacts with and modifies various 
transcription factors and thereby co-regulates their function 2,3. During NF-κB-
dependent gene expression, ARTD1 can synergistically co-activate transcription by 
physically interacting with the Mediator complex, p300/CBP and with the p50 and 
p65 subunits of NF-κB 86-90. ARTD1 has also been described as a negative co-factor 
for SMADs 91 and to interact with histone modifying enzymes such as histone 
deacetylases (HDACs) 1-3 87. This led to the hypothesis that ARTD1 can function as 
a promoter-specific exchange factor that promotes the release of inhibitory cofactors 
and subsequently the recruitment of stimulatory factors 87,92,93. Retinoic acid 
signaling, for example, has been described to depend on ARTD1 as well 93. In this 
model, ARTD1, but not its catalytic activity, is required to switch Mediator to its 
transcriptionally active form and to activate gene transcription. However, there are 
also scenarios where ARTD1 catalytic activity is important for the induction of such a 
co-factor switch 82,92,94. This has been described for neuronal differentiation, where 
ARTD1 is a component of the co-repressor complex, but upon induction of 
differentiation it is activated and in turn required for co-activator recruitment and de-
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repression 92. In line with this, Ju and coworkers described a role of ARTD1 in 
estrogen-dependent gene expression 82,94. Estrogen-induced Topoisomerase II 
(TopoII) β-dependent dsDNA break formation on the promoter leads to the 
recruitment of a co-activator complex, and the release of a co-repressor complex. 
ARTD1 activity leads to the exchange of H1 for HMGB1 and subsequently 
transcriptional activation of estrogen-dependent target genes. 
 
1.3.4 ARTD1 and DNA methylation 
DNA methylation is established by de novo methyltransferases DNMT3a and 
DNMT3b, while after DNA replication, DNMT1 maintains the methylation status of 
the cells 95-97. ARTD1 was described to influence DNA methylation through different 
mechanisms 98-104. On one hand, ARTD1 co-regulates the activity and expression of 
DNA methyltransferase 1 (DNMT1) by binding to its promoter and protecting the 
DNA from methylation in a PAR-dependent manner 98,99,102. On the other hand, the 
DNMT1 protein itself forms a complex with PAR, which inhibits DNMT1 activity 
103. A functional crosstalk of ARTD1 and DNMT3 has not been described yet. 
 
1.4 ARTD3 
ARTD3 is the smallest and least studied of the “bona fide” ARTD enzymes. It exists 
in two splice variants containing 540 or 533 amino acids, respectively 105. The longer 
isoform contains the centriole localization signal that targets it to the centrosomes. 
ARTD3 is thus a much smaller protein than ARTD1 and its domain structure 
resembles rather the structure of ARTD2. It contains a small DBD of only 54 residues 
and a targeting motif that can localize the longer isoform to the centrosome whereas 
the shorter isoform is rather located in the cytoplasm (Fig. 4) 105,106. 
 
 
Figure 4: Domain structure of ARTD3 
Different domains of ARTD3 are shown. CLS= Centriole localization signal, cat=catalytic domain. 
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Although the catalytic domain of ARTD3 shows sequence similarity to ARTD1 and 
ARTD2 and also contains the critical glutamic acid residue (i.e. E988 in ARTD1), 
PARylation activity could not be demonstrated. Some studies detected short ADP-
ribose oligomer formation, while other reported only mono-ADP-ribosylation activity 
107,108. Both reports agreed, that in comparison to ARTD1 and ARTD2 the in vitro 
activity of ARTD3 is significantly lower 18. In addition, ARTD1 is strongly 
stimulated by DNA, while the regulation of ARTD3 by DNA is controversial. While 
some groups state that ARTD3 is not activated by DNA, there are reports claiming 
the contrary as well 18,107,108. Unlike ARTD1 and ARTD2, ARTD3 shows a tissue 
specific distribution and the highest expression levels were recorded in lung, liver, 
spleen, kidney, ovary and heart 109. Particularly low ARTD3 expression was observed 
in thymus, small intestine and colon tissue. While ARTD2 partially compensates for 
ARTD1 deficiency, ARTD3 cannot compensate for the absence of ARTD1 or 
ARTD2 62,110,111. These results suggest that ARTD3 has a function that is distinct 
from ARTD1 and ARTD2, despite significant structural similarities. Endogenous 
ARTD3 shows a widespread nuclear distribution and appears in small, but also larger 
foci 112. Experiments with overexpressed ARTD3 describe a change in its cellular 
localization during cell cycle. ARTD3 was enriched in the centrosomal and nuclear 
region during the G0/G1 phase and detected in the cytoplasm during S-phase 113. 
Knockdown of ARTD3 neither affected cell viability nor induced any obvious 
morphological phenotype. Stable complexes between ARTD3 and ARTD1 at the 
centromeres have been implicated in DNA damage surveillance at the mitotic fidelity 
checkpoint 2,106. Knockdown of ARTD3 significantly delayed the removal of ionizing 
radiation (IR)-induced γH2AX foci and led to an increase in the formation of IR-
induced DSBs 107,114. This effect is possibly mediated by ATM-dependent 
phosphorylation of APLF at Ser116 that is important for association of APLF with 
chromatin and is dependent on ARTD3 115. In addition, ARTD3 was described to 
influence microtubule organization and to stabilize and promote telomere integrity 
and to thereby interfere with the progression through mitosis, which is impaired in 
cells lacking ARTD3 107,114. ARTD3-mediated PAR formation was proposed to 
regulate PRC2 and PRC3 mediated silencing and it was shown to interact with DNA-
PK and Ku70/80 112. In addition, ARTD3 plays a role in ectodermal specification and 
neural crest development in zebrafish 111. ARTD3 was shown to activate ARTD1 in a 
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DNA-independent manner 108. However, the underlying mechanism for this remains 
elusive and further experiments are needed to confirm this hypothesis. In summary, 
ARTD3 seems to be important for physiological processes, but a detailed description 
of its biochemical properties and cellular functions is still missing.  
 
1.5 Poly-ADP-ribose glycohydrolase (PARG) 
PARG is the main PAR-degrading enzyme that shows both endo- and exo-
glycosidase activity 39,116. The enzyme has been first described in 1986 as a 59 kDa 
protein, but since then differential splicing resulting in PARG proteins that vary 
considerably in size and cellular localization have been discovered 116-123. The 
mammalian PARG gene encodes at least four isoforms: The full length PARG-110 
isoform is found in the nucleus because of a nuclear localization signal encoded in 
exon 1. This isoform shows a lower abundance than the three cytosolic forms PARG-
102, -99 and -59, which arise through alternative splicing and differential translation 
start sites 38,124,125. Transgenic mice carrying a PARG that lacks exon 2 and 3 (thereby 
inactivating PARG-110/102 and 99 and thus abrogating the presence of nuclear 
PARG) are viable and phenotypically normal, but show an increased sensitivity to 
alkylating agents and ionizing radiation 126. However, mice carrying a deletion of 
exons 3 and 4, which leads to a depletion of all PARG isoforms, display embryonic 
lethality, suggesting an important role for PARG-59 in embryonic development 127. 
PARG activity was described to generate a large amount of free PAR that can 
function as signal transduction molecules 16. But recent reports suggest that PARG 
mainly acts as exo-glycohydrolase and is unable to remove the initial protein-bound 
ADP-ribose unit 39. To remove mono-ADP-ribose modifications and to completely 
reverse ADP-ribosylation, a second enzyme, an ADP-ribosyllyase, is required 128-130. 
Comparable to ARTD1, PARG has been implicated in pathophysiological conditions 
such as shock, reperfusion and ischemia 131. The importance of PAR catabolic 
activities for cell survival and homeostasis is underlined by experiments in yeast, 
which does not have any ARTDs or PARG 130,132,133. The detrimental effect of an 
over-abundance of PAR is illustrated by the observation that the overexpression of 
human ARTD1 cDNA in yeast is toxic unless PARG cDNA is co-expressed or PARP 
inhibitors are included in the experiments. This suggests that the anabolism and 
catabolism of PAR are essential for the cell’s function and required for cell survival. 
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1.6 Adipose tissue 
At the beginning of the 20th century, adipose tissue was regarded as a depot with only 
one function, namely the storage and release of lipids 134,135. However, already in the 
middle of the 20th century, the view of adipose tissue changed drastically 136. It was 
acknowledged already then that the adipose tissue is an active tissue that can 
influence whole body homeostasis. Today, we know that adipose tissue is a complex, 
organ-like, multifunctional compartment 137. Pioneering studies in the Spiegelman 
laboratory in the 80s, the discovery of leptin, and the finding that recombinant leptin 
can lower bodyweight in mice, proved that adipose tissue can secrete physiologically 
important molecules 138-145. To date, adipose tissue is seen as a central player in the 
control of energy and whole-body lipid homeostasis. Deregulation of adipose tissue is 
associated with many pathophysiological changes such as obesity, type II diabetes, 
cancer and artherosclerosis 146-149. Adipose tissue can be divided into two types with 
different morphology and function: White and brown adipose tissue (WAT and BAT, 
respectively)135. 
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1.6.1 Brown adipose tissue 
Brown adipose tissue consists of brown adipocytes, which are adipocytes that contain 
many small lipid droplets (multilocular) and feature a characteristic dark brownish 
color due to the large number of mitochondria 150,151. The functionality of these brown 
adipocytes is to produce heat by a process called non-shivering thermogenesis 152. 
The protein uncoupling protein 1 (UCP-1) uncouples oxidative phosphorylation and 
thereby leads to increased substrate oxidation in the absence of ATP production, 
which in turn generates heat 150,153. This helps the organism maintain a stable body 
temperature, especially in hibernators and newborns. To date, UCP-1 is the only 
marker known for BAT 150,154. Whereas in human and mammals BAT dominates in 
newborns, these pure BAT depots disappear quickly after birth 155-158. Nonetheless, 
there have been studies showing that individuals exposed to cold, or patients suffering 
from pheochromocytoma, show “nests” of BAT within their white adipose tissue 
159,160. Recent studies, however, provide strong evidence for the presence of 
metabolically active BAT in healthy adult humans 161-165. Interestingly, the amount of 
BAT negatively correlates with obesity 162. Mice possess a life-long classical BAT 
depot between their shoulder blades. In addition to this, brown adipocytes can be 
found in WAT depots in response to stimuli such as cold exposure, chronic β3-
adrenergic receptor activators or PPARγ-agonists 166-168. These brown adipocytes, 
however, differ from those cells arising early during development 167 (Fig. 5). 
Classical brown adipocytes and myocytes share a common precursor that expresses 
the myogenic lineage marker Myf5 169,170. Brown adipocytes that arise by “browning” 
of white adipose tissue are typically called beige or brite (brown in white) adipocytes 
167, but their origin is controversial. Some groups suggest that beige adipocytes 
develop from Myf5 negative (Myf5-) precursors that reside in the WAT. It was also 
suggested that white adipocytes have the potential to interconvert to brown adipocytes 
by a process called transdifferentiation 168,171-173.  
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Figure 5: Schematic representation of the main pathways of adipocyte differentiation. 
White adipocytes arise from Myf5- precursor cells, classical brown adipocytes from Myf5+ precursors. 
Inducible (beige/brite) adipocytes can arise through differentiation of a subset of Myf5- precursors or 
through transdifferentiation via an intermediate state (paucilocular adipocyte). Whether these cells can 
give rise to cells comparable to classical brown adipocytes is unknown. Norephinephrine can influence 
the formation of brown adipocytes. Modified from Giralt and Villaroya167. 
 
1.6.2 White adipose tissue 
Although it forms later during development, in adult humans WAT dominates in size 
over BAT 167. WAT is important for energy storage, adipokine secretion, as an 
insulator for the body, and as a mechanical buffer for the organs 135. WAT is 
composed of different cell types, including fibroblasts, endothelial cells, immune 
cells, adipocyte precursors and mature, lipid-laden adipocytes. White adipocytes are 
unilocular, containing only one large lipid droplet. They differentiate from Myf5- 
precursor cells (Fig. 5). WAT secretes diverse adipokines such as adiponectin, IL-6 
and TNFα that regulate blood pressure, immune function and energy balance 174. 
Disturbances in the production of these factors may contribute to diseases such as 
insulin resistance or impaired insulin secretion in patients with type 2 diabetes or 
atherosclerosis and cancer 146,147,175,176. WAT is one of the largest organs of the body; 
even lean men have a fat mass of 3.5-4 kg 177. It is located either subcutaneously or 
viscerally at several locations in the body where it protects the inner organs. 
Epidemiological studies have shown that only central obesity (visceral fat) is 
associated with health risks such as artherosclerosis, cancer or overall mortality 178-183. 
WAT can dynamically respond with shrinking or expanding to different types of 
stimuli such as food intake and temperature 184. As increased levels of fatty acids 
transdifferentiation 
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circulate in the blood, more triglycerides are taken up and incorporated into the lipid 
droplet of the adipocyte, thereby increasing in size. Upon starvation, these 
triglycerides can be broken down through lipolysis and fatty acids are released as 
energy source. In humans, increased fat cell storage and consequently enlarged fat 
cells is the most important mechanism of increased fat depots 185-188. However, there 
is also a difference in adipocyte cell number of lean and obese individuals 188. 
Interestingly, this number only increases during childhood and adolescence, leading 
to a stable cell number in adulthood, in both lean and obese individuals. There is a 
constant turnover of adipocytes, which is tightly controlled and thus leads to a stable 
number of adipocytes in adults. Since adipocytes are postmitotic, there has to be a 
reservoir of stem cells that can differentiate into new adipocytes. There is strong 
evidence, that these adipocyte stem cells reside within the adipose tissue close to the 
vasculature 184,189,190. Interestingly, these cells are not committed to the adipocyte 
phenotype, but can also differentiate into bone, cartilage and muscle and thus need to 
be determinated by stimuli 189.  
 
1.6.3 The 3T3-L1 model system 
The most widely used model to study adipogenesis in vitro is the 3T3-L1 cell line 191-
193. Most of our understanding of the molecular mechanism of adipogenesis was 
obtained from studies with these cells 191-193. The 3T3 cell line was isolated and 
established from disaggregated Swiss mouse embryos 194. From this cell line, two 
clones with lipid accumulating potential were isolated (3T3-L1 and L-2). During 
differentiation, these cells acquire multilocular lipid droplets and therefore resemble 
brown adipocytes 195,196. However, after the completion of differentiation they appear 
like mature white adipose cells. 3T3-L1 cells were used to establish the protocols that 
were commonly used today for the differentiation to adipocytes. 1975 Green and 
colleagues could show that Insulin is beneficial for differentiation 195. Glucocorticoids 
and cAMP elevating agent (IBMX) further increase the differentiation of 3T3-L1 
cells in vitro. The differentiation of 3T3-L1 can be divided into three phases: growth 
arrest, mitotic clonal expansion and terminal differentiation (Fig. 6) 192.  
  Introduction    
 23 
 
Figure 6: Differentiation of 3T3-L1 cells 
Shown is the protocol for differentiation of 3T3-L1 cells and the corresponding stages that are 
explained in the text. 
 
In the first phase, the cells in the culture plate reach confluency and arrest growth due 
to contact inhibition. Upon hormonal induction the arrested cells reenter the cell cycle 
and undergo one or two rounds of cell division, which is described as mitotic clonal 
expansion. The expression of the transcription factor peroxisome proliferator-
activated receptor γ (PPARγ) and of the CCAAT/enhancer binding protein (C/EBP) 
coincides with a permanent growth arrest and the terminal differentiation into lipid-
laden adipocytes that express adipocyte specific genes.  
 
1.7 Transcriptional network in adipogenesis 
The process of adipocyte differentiation is controlled by a variety of different 
transcription factors 191. It involves a massive chromatin remodeling and the 
establishment of so called hotspots, where multiple transcription factors bind to open 
chromatin regions and promote transcription of adipogenic genes 197-199. Adipogenesis 
involves two different stages that are characterized by specific sets of transcription 
factors (Fig.7). The early phase of adipogenesis is characterized by the expression of 
C/EBPβ and C/EBPδ. These transcription factors in turn induce in a later phase the 
expression of PPARγ and C/EBPα, which consecutively activate the transcription of 
adipocyte specific genes. 
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Figure 7: Different phases of differentiation 
During the early phase of adipogenesis, C/EBPβ and C/EBPδ induce the expression of PPARγ that in 
turn induces the expression of adipocyte specific genes during the late phase of adipogenesis. Picture 
from Lefterova and coworkers. 200. 
  
1.7.1 C/EBPs  
Three members of the CCAAT/enhancer-binding protein (C/EBP) family play 
important roles in adipogenesis 191,201,202. Within few hours after the induction of 
differentiation in 3T3-L1 cells, the transcription of C/EBPβ and -δ is induced, which 
in turn activates transcription of PPARγ and C/EBPα 191,201,203,204 (Fig. 8). 
 
Figure 8: Overview of the transcriptional network in adipogenesis 
PPARγ is the master regulator of adipogenesis. The picture shows how PPARγ is influenced by and 
influences other factors. In addition, it is shown how the hormonal cocktail used for induction of 
differentiation influences this network. Dex: dexamethasone, MIX:methylisobutylxanthine, 
GlyK:Glycerol kinase Picture modified from Tontonoz and Spiegelman 202. 
 
Consistently, ectopic expression of C/EBPβ and -δ induces expression of PPARγ and 
C/EBPα 203,205-207. In line with these findings, double knockout mice for C/EBPβ and -
δ show reduced adipose tissue, whereas single knockouts only show mild phenotypes 
208. As mentioned above, C/EBPβ and -δ activity induces C/EBPα expression. This 
member of the C/EBP family is expressed together with PPARγ in the late phase of 
adipogenesis. In vitro and in vivo studies showed that C/EBPα is able to induce 
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adipogenesis when ectopically expressed and is required for the formation of WAT, 
but not of BAT 56,209,210. PPARγ can induce adipogenesis in C/EBPα deficient MEFs, 
whereas C/EBPα is not sufficient to induce adipogenesis in cells lacking PPARγ 211. 
C/EBPα expression is not only dependent on C/EBPβ and -δ, but also on PPARγ 212. 
In addition, a positive feedback loop between PPARγ and C/EBPα expression is well 
described 211,213. PPARγ and C/EBPα are able to sustain each other’s expression and 
thereby maintain the phenotype of the mature adipocyte.  
 
 
1.7.2 PPARγ 
PPARγ is the master regulator of adipogenesis 191,192,200,202,214. Early evidence from 
Spiegelman and collaborators showed that the nuclear factor first named ARF6, was 
able to bind an enhancer element in the 5’ flanking region of the aP2 gene and to 
induce aP2 expression 215. ARF6 was later shown to be PPARγ and to interact with its 
heterodimeric partner RXR 216. The PPARγ domain structure resembles the 
composition of many nuclear receptors (Fig. 9) 202.  
 
 
Figure 9: Structure of PPARγ  
The domain structure of PPARγ 1 and 2 is shown. Picture modified from Tontonoz and Spiegelman 202 
 
The N-terminal region contains a non-conserved A/B domain, followed by a DNA 
binding domain (DBD) and the C-terminal ligand-binding domain (LBD) with the 
activating fragment 2 (AF-2). The C-terminal domain is required for the interaction 
with RXRs, the AF2 domain is important for ligand-dependent interactions with 
cofactors. The ligand binding is conveyed by the LBD that harbors multiple 
hydrophobic residues in its pocket. The N-terminal domain of PPARγ comprises 
important regulatory functions. Upon its deletion, the transcriptional activity of 
PPARγ is increased 217. This inhibitory function is partially conveyed through 
phosphorylation of Ser112 by members of the MAP kinase family, which strongly 
hampers transcriptional activity 218,219. In addition, the N-terminal domain was shown 
to interact with cofactors such as p300, HIV-Tat-Interactive protein 60 (Tip60) and 
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MED14 in a ligand-independent manner 220-222. Recently, it was shown that this 
domain is required for the transactivation of only a subset of PPARγ target genes 223. 
High affinity binding to DNA is mediated by the two zinc-fingers in the DBD 
together with RXR to direct hexanucleotide repeats spaced by 1 nucleotide (DR1) 
named PPARγ response elements (PPREs) that are located in upstream enhancer 
regions of PPARγ-target genes 202,216,224. Thiazolidinediones (TZDs), such as 
rosiglitazone or troglitazone, are synthetic ligands of PPARγ that increase insulin 
sensitivity in rodents and humans and are used for the treatment of type 2 diabetes 
(T2D) 225. The identity of the biological ligand of PPARγ remains controversial and is 
actively investigated. During adipogenesis in 3T3-L1 cells, a PPARγ activating 
substance is produced, but its identity remains elusive 226. Several groups have shown 
that polyunsaturated fatty acids and related molecules can activate PPARγ in 
micromolar concentrations 227-230. Free fatty acids are present at these concentrations 
in the blood, however, the concentration inside the cell and near the receptor is 
unknown 231. Certain prostaglandins such as 15-deoxy-1 12,14prostaglandin J2 (15-
dPGJ2) are strong activators of PPARγ in vitro, although it is not clear whether these 
substances are present in the cell in significant amounts 202,232,233. In addition, other 
lipids such as oxidized fatty acids, nitrated fatty acids, or lysophosphatic acids seem 
able to activate PPARγ 234-236. Especially oxidized fatty acids can be found in low-
density lipoprotein and might play a role in artherosclerotic lesions, where they reach 
a considerable local concentration. In addition, during adipogenesis, the cells acquire 
a high lipogenic capacitiy237-239. Both the expression of enzymes important for de 
novo fatty acid synthesis as well as for triacylglycerol synthesis is tremendously 
increased. These fatty acids are stored in form of triglycerides in lipid droplets 240. It 
is currently unknown if fatty acids can activate PPARs before being incorporated into 
lipid droplets or if rehydrolysis of the triglycerides by hormone sensitive lipase (HSL) 
or adipose triglyceride lipase (ATGL) is required before they can signal through 
PPARγ 241. Both ATGL and HSL deficient mice show decreased PPAR activity 
indicating the requirement of lipases for the activation of PPAR 241-243. However, it is 
currently unclear how this process is regulated and how PPAR activity is maintained 
during adipogenesis. 
Since the discovery of PPARγ, a series of in vitro and in vivo experiments 
have proven PPARγ’s role in adipogenesis. Ectopical expression of only PPARγ in 
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non-adipogenic fibroblasts can initiate the differentiation into functional adipocytes 
217. PPARγ null mice die during embryogenesis due to placental insufficiency (E 
10.5) 244. Different strategies were used to circumvent this problem and to confirm the 
role of PPARγ in adipose tissue formation 244,245. The generation of tetraploid 
embryos partially rescued the lethality 244. The only mouse that was born died shortly 
after birth, but the investigators observed a failure in adipose tissue formation in this 
animal. Embryonic stem cells devoid of PPARγ fail to differentiate into adipocytes in 
vitro 245. Heterozygous mice with a ubiquitous reduction of PPARγ in all tissues have 
normal body weight and fat depots 246,247. However, these mice are insulin sensitive 
and resistant to diet induced obesity. Deletion of PPARγ2 leads to severe 
lipodystrophy 248. Only the development of tissue specific knockout mice allowed to 
properly assess the contribution of PPARγ to adipogenesis in vivo. Deletion of 
PPARγ in adipose tissues of mice protects the animals from high fat diet–induced 
obesity and insulin resistance 249-251. Interestingly, these mice display increased lipid 
deposition in muscle and liver. Similar results were obtained in mice with 
pharmacological inhibition of PPARγ by antagonist treatment 252,253. In addition, the 
ablation of PPARγ2 in ob/ob mice results in decreased fat mass, severe insulin 
resistance, β-cell failure and dyslipidemia 254. PPARγ is a nuclear receptor and 
belongs to the family of PPARs. This family consists of three subtypes, namely PPAR 
α, γ, ∂ which are encoded by three different genes but are all important regulators of 
glucose and lipid metabolism in different tissues 201,255-257. PPARγ is induced during 
the differentiation of pre-adipocytes into adipocytes and is highly expressed in white 
and brown adipose tissue (WAT and BAT) 216. It exists in two different protein 
isoforms, PPARγ1 and PPARγ2 that arise through alternative promoter usage of the 
same gene and the generation of four different mRNAs. The mRNAs PPARγ1, 3 and 
4 encode the PPARγ1 protein, while PPARγ2 encodes isoform 2 216,258-260. This 
isoform contains 30 additional amino acids at the N-terminus 216,258-260. PPARγ1 is 
expressed in many tissues, whereas the expression of PPARγ2 under normal 
physiological conditions is restricted to adipose tissue. In vitro, PPARγ1 can 
compensate for PPARγ2 deficiency and adipose-selective PPARγ2 depletion results 
in mice that still contain considerable amounts of fat 261,262. However, these mice are 
insulin-resistant, suggesting that PPARγ2 may play a selective role in regulating 
insulin sensitivity.  
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1.7.3 PPARγ  co-repressors and co-activators 
PPARγ is a ligand gated transcription factor that is activated by cofactors that are also 
used by other nuclear receptors 202. Following dissociation of corepressors, PPARγ 
exerts its influence on transcription by binding to PPREs, where it recruits 
coactivators in a ligand-dependent manner. The LXXLL motif that is present in most 
coactivators is responsible for the interaction with nuclear receptors in a ligand-
dependent manner 263. Binding of a ligand to PPARγ triggers a conformational switch 
in PPARγ that induces change in confirmation of the AF2 domain and exposes a 
surface that can interact with LXXLL-containing coactivator domains 264,265. Prior to 
activation of PPARγ by the ligand, co-repressors that suppress transcription of target 
genes bind PPARγ. Important corepressors that are dislodged from PPARγ upon 
ligand binding are SMRT and NCOR-1. Knockdown of both increases expression of 
PPARγ-target genes 266. HDAC-1 and -3 are also part of the corepressor complex and 
repress C/EBPβ and PPARγ expression through their deacetylating activity 267. Upon 
ligand binding, cofactors of the p160 family, usually TIF2 or SRC-1, are recruited. In 
addition, acetyltransferases p300/CBP can be recruited. Interaction with p300/CBP is 
mediated in two different ways 220. They interact with the N-terminus of PPARγ2 
independently of the ligand whereas binding of p300/CBP to the C-terminus is ligand-
dependent. 
 
1.7.4 Other transcription factors that control adipogenesis 
Recent genome/proteome wide studies have identified many additional transcription 
factors that are required for adipocyte differentiation 268. Krox20, for example, is 
induced immediately after induction of differentiation and stimulates the expression 
of C/EBPβ 269. Krüppel-like factor 5 (KLF5) is one of the target genes that is induced 
by C/EBPβ and in turn supports the transcription of PPARγ 270. In addition to the 
C/EBPβ/-δ axis, other pathways are initiated early and converge upstream of PPARγ. 
ADD1/SREBP1 is induced during adipogenesis and can be regulated by sterol levels 
271,272. The exact mechanism of activation in fat remains unknown, but it can stimulate 
a variety of genes involved in fatty acid and triglyceride metabolism. Additional 
studies have shown that ADD1/SREBP1 contributes to the production of an 
endogenous ligand for PPARγ as well as to the induction of PPARγ 272-274. 
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1.7.5  Transcription factor hot spots during adipogenesis 
Although PPARγ is the master regulator of adipogenesis, a multitude of different 
transcription factors and their exact regulation is required for correct differentiation 
and adipocyte function 199,275. Already within 4 hours after induction of 
differentiation, a massive chromatin remodeling takes place in the pre-adipocytes and 
so called hotspots are established 199,276,277. These hotspots are characterized by 
DNAse-I hypersensitivity, which represents open chromatin regions. In addition, 
hotspots display enriched binding of a variety of transcription factors. Interestingly, 
the number of hotspots is biggest shortly after induction of differentiation and 
decreases again when cells are fully differentiated. Also, these hotspots are enriched 
mostly in early transcription factors such as C/EBPs, GRs and STAT5A and in 
transient histone acetylation. The establishment of hotspots correlated with changes in 
gene expression of nearby genes. However, numerous of these loci seemed to prepare 
the binding of the later transcription factors. Especially binding of complexes 
containing C/EBPs act as pioneering factors for later PPARγ-binding. However, not 
all PPARγ binding sites lie within these early enhanceosomes. It is an interesting 
model that the early establishment of early enhanceosomes primes the chromatin in a 
way that allows late enhanceosomes to bind and to increase transcription. However, 
various PPARγ binding sites do not lie within these early enhanceosomes and are 
unmarked as defined by Siersbaek and colleagues 199,276,277. Various other chromatin 
factors or histone marks as well as three-dimensional structures could however mark 
these sites. It will need further genome-wide studies to answer these remaining 
questions. 
 
1.8 Role of ARTDs in metabolism 
ARTD1 and ARTD2 have been described to play a role in metabolic homeostasis 278. 
ARTD1 is important for food entrainment of circadian clocks in mice 279-281. 
Moreover, ARTD 1-/- and ARTD2-/- mice display increased energy expenditure 280,282. 
Interestingly, several studies provide evidence that deficiency of ARTD1 or ARTD2 
protects mice from an age- or diet-induced increase of bodyweight and that these 
mice display less fat mass deposition 57,280,282,283. In agreement with these results, 
mice with ectopic expression of ARTD1 display increased body weight and adiposity 
with fat deposition in the liver and other organs 284. However, there are also reports 
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describing higher body weight for ARTD1-/- mice, although one of these studies used 
mice of the 129 background instead of C57 BL/6, which could account for the 
observed differences 56,281. ARTD1 knockout mice, but not animals lacking ARTD2, 
also show an increased mitochondrial content, demonstrating that BAT is also 
influenced 280,282. In vitro experiments suggest a role of ARTD2 in PPARγ-dependent 
gene expression 283. Bai and colleagues have shown that ARTD2-/- cells fail to 
differentiate into adipocytes and identified ARTD2 as a cofactor for PPARγ. 
Recently, a role of ARTD1-dependent PAR formation in PPARγ-dependent 5-
hydroxymethylation of PPREs was described 285. This model suggests that a PPARγ-
co-activator complex is PARylated, which leads to recruitment of Tet proteins that 
can induce region-specific demethylation by converting 5-methyl-cytosine (5mC) to 
5-hydroxymethyl-cytosine. However, it is unclear which component of the co-
activator complex is PARylated. 
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2 Aim of the thesis 
In humans, there are 18 ADP ribosyltransferases belonging to the Diphtheria toxin-
like types (ARTD) family, which are located within the cell. Some of these enzymes 
were described to synthesize poly-ADP-ribose, while others can only form mono-
ADP-ribose or are enzymatically inactive. ARTD1 is the best-studied member of this 
family and capable of generating long, branched polymers of ADP–ribose. ARTD1 is 
a chromatin-associated enzyme that affects chromatin compaction and transcription. 
Recent studies suggested a dynamic modulation of the chromatin landscape during 
adipocyte differentiation, which is controlled by the transcription factor PPARγ. 
ARTD1 has been recently described to play a role in metabolic homeostasis, although 
a molecular mechanism was not identified. 
 The aim of this thesis was to investigate the functional role of ARTD1 and 
ARTD1-induced poly-ADP-ribosylation during adipocyte differentiation. Since the 
transcription factor PPARγ is the master regulator of adipogenesis, these studies 
focused mainly on the regulation of PPARγ-dependent gene expression by ARTD1 
and on the molecular mechanism that underlies this regulation. 
Standard and recently developed molecular and cell biology techniques as well as 
animal studies were included in these studies. 
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3 Results 
3.1 Published results 
3.1.1 Poly(ADP-ribose)polymerase-1 (PARP1) controls adipogenic gene 
expression and adipocyte function   
Authors:  Erener, S., Hesse, M., Kostadinova, R., and Hottiger, M.O. 
Journal:  Molecular Endocrinology, 2012 
Contribution:  Planning, performing and evaluating the experiments for Fig.2B, D; 
Fig. 4 A,B,C,D; S1A; S2;S3 Preparation of the figures, revision of 
manuscript.  
 
3.1.2 ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a 
high-fat diet and impairs adipocyte function and differentiation. 
Authors:  Erener, S., Mirsaidi, A., Hesse, M., Tiaden, A.N., Ellingsgaard, H., 
Kostadinova, R., Donath, M.Y., Richards, P.J., and Hottiger, M.O. 
Journal:  FASEB, 2012 
Contribution:  Planning, performing and evaluating the qRT-PCRs for Figure 4A.  
 
3.1.3 PARP inhibitor with selectivity toward ADP-ribosyltransferase 
ARTD3/PARP3 
Authors:  Lindgren, A.E., Karlberg, T., Thorsell, A.G., Hesse, M., Spjut, S., 
Ekblad, T., Andersson, C.D., Pinto, A.F., Weigelt, J., Hottiger, M.O., 
Linusson, A., Elofsson, M., Schüler, H.   
Journal:  ACS chemical biology, 2013  
Contribution:  Planning, performing and evaluating of cellculture experiments (Fig. 
3C, D and E and S 6) 
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Poly(ADP-Ribose)Polymerase-1 (PARP1) Controls
Adipogenic Gene Expression and Adipocyte Function
Su¨heda Erener, Mareike Hesse, Radina Kostadinova, and Michael O. Hottiger
Institute of Veterinary Biochemistry and Molecular Biology (S.E., M.H., R.K., M.O.H.), and Life Science
Zurich Graduate School (S.E., M.H.), Molecular Life Science Program, University of Zurich, 8057 Zurich,
Switzerland
Poly(ADP-ribose)polymerase-1 (PARP1) is a chromatin-associated enzyme that was described to
affect chromatin compaction. Previous reports suggested a dynamic modulation of the chromatin
landscape during adipocyte differentiation.We thus hypothesized that PARP1 plays an important
transcriptional role in adipogenesis and metabolism and therefore used adipocyte development
and function as a model to elucidate the molecular action of PARP1 in obesity-related diseases.
Our results show that PARP1-dependent ADP-ribose polymer (PAR) formation increases during
adipocyte development and, at late time points of adipogenesis, is involved in the sustained
expression of PPAR!2 and of PPAR!2 target genes. During adipogenesis, PARP1 was recruited to
PPAR!2 target genes such as CD36 or aP2 in a PAR-dependent manner. Our results also reveal a
PAR-dependent decrease in repressory histone marks (e.g. H3K9me3) and an increase in stimula-
tory marks (e.g. H3K4me3) at the PPAR!2 promoter, suggesting that PARP1 may exert its regula-
tory function during adipogenesis by altering histone marks. Interestingly, activation of PARP1
enzymatic activity was prevented with a topoisomerase II inhibitor. These data hint at topoisom-
erase II-dependent, transient, site-specific double-strand DNA breaks as the cause for poly(ADP)-
ribose formation, adipogenic gene expression, and adipocyte function. Together, our study identifies
PARP1 as a critical regulator of PPAR!2-dependent gene expression with implications in adipocyte
function and obesity-related disease models. (Molecular Endocrinology 26: 79–86, 2012)
Obesity is a complex metabolic disorder characterizedby an excess of body fat that is closely associated
with other serious health conditions, such as heart disease
and diabetes. White adipose tissue, which is the predom-
inant type of fat in adult humans, serves as a storage depot
for excess energy. Adipose tissue secretes diverse adipo-
kines, such as leptin, Adiponectin, IL-6, TNF", and oth-
ers, that regulate blood pressure, immune function, and
energy balance (1, 2). Disturbed production of these fac-
tors may contribute to the development of insulin resis-
tance or impaired insulin secretion resulting in type 2
diabetes.
During adipogenesis, fibroblast-like preadipocytes dif-
ferentiate into lipid-laden and insulin-responsive adi-
pocytes, which requires a coordinate up-regulation of
many enzymes involved in fatty acid metabolism and
pyridine nucleotides as coenzymes (3). The murine
3T3-L1 cell line (4) has been broadly used as a model
system to study adipogenesis. 3T3-L1 cells undergo a syn-
chronous differentiation process upon addition of an adi-
pogenic cocktail and have been influential for the under-
standing of the complex regulatory networks during
adipogenesis. Adipocyte differentiation is accompanied
by large-scale chromatin changes and by the establish-
ment of transcription factor “hotspots” (5). This process
occurs in several stages and involves a cascade of tran-
scription factors, among which the CCAAT/enhancer-
binding proteins (C/EBP) C/EBP-# and C/EBP-$ are
considered crucial determinants for the expression of
the key factor peroxisome proliferator-activated receptor
! (PPAR!) and of C/EBP-" (6, 7). A positive feedback
loop between PPAR! and C/EBP-" mutually regulates
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Copyright © 2012 by The Endocrine Society
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Abbreviations: C/EBP, CCAAT/enhancer-binding protein; ChIP, chromatin immunopre-
cipitation; NAD!, nicotinamide adenine dinucleotide; PAR, polymers of ADP-ribose;
PARP1, poly(ADP-ribose)polymerase-1; PPAR!, peroxisome proliferator-activated recep-
tor !; shRNA, short hairpin RNA.
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their expression, and together, these two proteins coordi-
nate adipocyte function (7, 8). In contrast to PPAR!1,
PPAR!2 expression is mainly restricted to adipocytes (9).
PPAR!2, together with several coactivators, regulates an
array of target genes, ofwhich aP2,CD36, andAdiponec-
tin have crucial roles for adipocyte function by regulating
fatty acid binding, translocation, and catabolism, respec-
tively (5). Deletion of PPAR!2 in mouse adipose tissues
protects against high-fat diet-induced obesity and insulin
resistance, but these mice display increased lipid deposi-
tion in muscle and liver (10). Similarly, ablation of
PPAR!2 in mice of the ob/ob background results in de-
creased fat mass, severe insulin resistance, "-cell failure,
and dyslipidemia (11).
Poly(ADP-ribose)polymerase-1 (PARP1) (recently re-
named ADP-ribosyltransferase diphtheria toxin-like 1)
(12) is an abundant, ubiquitous chromatin-associated
enzyme that catalyzes the nicotinamide adenine dinucle-
otide (NAD!)-dependent addition of polymers of ADP-
ribose (PAR) onto a variety of target proteins (13). PAR is
a large, negatively charged polymer that functions as
posttranslational protein modification. Most PAR in the
cell is produced by the catalytic activity of PARP1,
which is the main ADP-ribosyltransferase in the nu-
cleus (14). In vitro, PARP1 enzymatic activity is strongly
activated upon binding to various interaction partners,
such as nucleosomes or certain forms of DNA (15). In
vivo, polymer formation by PARP1 is undetectable by
immunofluorescence under basal (unstimulated) condi-
tions but can be detected upon treatment of cells with
DNA-damaging compounds (13). Lack of PARP1 in
cells was reported to affect the gene expression profile
in a genome-wide manner (15). Besides restructuring
the chromatin and influencing transcription indirectly
(16, 17), PARP1 can additionally act as a transcrip-
tional cofactor during transcription by directly inter-
acting with a variety of transcription factors (18).
Previous studies reported the body weight of adult
PARP1"/" mice in diverse genetic backgrounds to be
different than the corresponding controls (19, 20). Here,
we extend these studies to the molecular level and show
with different experimental approaches that PARP1-
dependent PAR formation increases during adipocyte de-
velopment and is involved in regulating adipocyte devel-
opment and function.
Results
ADP-ribosylation is required for sustained
PPAR!2-dependent gene expression
To investigate whether PARP1 and its enzymatic ac-
tivity have an effect on adipogenesis, 3T3-L1 preadi-
pocytes were differentiated into adipocytes by addition of
an adipogenic cocktail (21). Western blot analysis from
the differentiated 3T3-L1 cell extracts revealed a shift of
PARP1 at d 7, suggesting auto-ADP-ribosylation of
PARP1 (Fig. 1A). Further Western blot analysis using an
antibody against the PAR confirmed that PAR formation
was indeed activated after d 3 of adipocyte differentia-
tion. Moreover, PAR formation was strongly reduced in
differentiating 3T3-L1 cells that were treated with the
PARP inhibitor PJ34 (or Olaparib, data not shown), pro-
viding further evidence that ADP-ribosylation was indeed
induced in 3T3-L1 extracts (Fig. 1A). A detailed kinetic
analysis detected PAR formation already at d 4 after
induction of adipocyte differentiation, which remained
elevated until d 10 (Supplemental Fig. 1A, published on
The Endocrine Society’s Journals Online web site at
http://mend.endojournals.org).
Interestingly, PJ34 treatment also inhibited storage of
free fatty acids in the adipocytes as judged by Oil-Red O
staining (Fig. 1B and Supplemental Fig. 1B), suggesting
that adipocyte function might require PAR formation.
Next, we evaluated the functional contribution of PAR
formation for the transcriptional activation of the main
FIG. 1. PAR formation is important during adipogenesis. 3T3-L1
preadipocytes were subjected to adipocyte differentiation during 7 d in
the absence or presence of PARP inhibitor PJ34 (10 #M). Inhibitor was
supplemented daily. A, Total-cell extracts were prepared and analyzed
by Western blotting. An experiment done in duplicates is shown. B,
Cells were stained with Oil-Red O, bound Oil-Red O was extracted, and
quantified colorimetrically. Result show the mean # SEM, n $ 3.
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drivers of adipogenesis by quantitative PCR. The expres-
sion of C/EBP-!, the main transcriptional regulator of
initial PPAR"2 expression, as well as of C/EBP-# and
PPAR"2, was significantly induced upon initiation of ad-
ipogenesis and not affected by the PARP inhibitor PJ34
(at d 3) (Fig. 2A). In contrast, although the sustained
expression level of C/EBP-! at d 7 was not affected by
PARP inhibition, the C/EBP-# and PPAR"2 mRNA lev-
els at this later time point were significantly reduced by
the presence of PJ34 for 6 d (Fig. 2A). The reduction in
PPAR"2 mRNA levels was also mani-
fested in PPAR"2 protein levels, al-
though a residual amount of PPAR"2
was still observed after 6 d of PJ34
treatment (Fig. 2B). Thus, the sus-
tained expression (after d 3 of adipo-
genesis) of C/EBP-# and PPAR"2 re-
quires the formation and presence of
PAR. To elucidate whether the expres-
sion of PPAR"2 target genes might
consequently also be affected by ADP-
ribosylation, we analyzed the expres-
sion of aP2, CD36, and Adiponectin.
AlthoughaP2 expressionwasdetectedat
d 3 and then increased substantially until
the late phase of adipogenesis (d 7),
CD36 or Adiponectinwere significantly
expressed only at d 7 (Fig. 2C). Remark-
ably, the expression of all three genes
was abrogated by the PARP inhibitor
PJ34 (Fig. 2C), suggesting that PPAR"2-
dependent gene expression is indeed reg-
ulated by PAR formation.
To investigate whether known hi-
stone modifications (22, 23) were af-
fected by PJ34 treatment, repressory
(H3K9me3) and stimulatory marks
(H3K4me3) were assessed at the
PPAR"2 promoter. Chromatin im-
munoprecipitation (ChIP) experiments
revealed that the repressory histone
mark H3K9me3 decreased during dif-
ferentiation (d 7), whereas PJ34 treat-
ment blocked the release of this repres-
sory histone mark at the PPAR"2
promoter (Fig. 2D). In contrast, the
stimulatory histone mark H3K4me3
increased at the same promoter during
adipocyte differentiation (d 7), and
PJ34 treatment blocked its accumula-
tion, which is in agreement with the
effects that were observed at the gene
expression level (Fig. 2D).
3T3-L1 adipocyte differentiation is inhibited by
PARP1 depletion
To further assess a specific involvement of PARP1 (but
not other PARP family members) and its enzymatic activ-
ity in PPAR"2-dependent gene expression, undifferenti-
ated 3T3-L1 preadipocytes were transduced with a lenti-
virus expressing short hairpin RNA (shRNA) against
PARP1 (to stably knockdown PARP1) or a scrambled
FIG. 2. PAR formation is required for sustained PPAR"2-dependent gene expression. 3T3-L1
preadipocytes were subjected to adipocyte differentiation for 7 d in the absence or presence
of PARP inhibitor PJ34 (10 $M). Inhibitor was supplemented daily. A, Real-time RT-PCR
analysis for C/EBP-!, C/EBP-#, and PPAR"2 is shown. mRNA levels were normalized with
Cyclophilin A. Results show the mean ! SEM, n " 3. ns, P # 0.05; *, P $ 0.05; **, P $ 001.
B, Total-cell extracts were prepared and analyzed by Western blotting. C, Relative expression
levels of the PPAR"2-dependent genes CD36, aP2, and Adiponectin were determined as in A.
D, ChIP analysis with H3K9me3 and H3K4me3 antibodies on the PPAR"2 promoter. The
experiment was performed twice with similar results, and one experiment is shown.
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control RNA (Fig. 3, A and B). As compared to uninfected
cells, PARP1 mRNA levels decreased slightly in mock-
treated cells, whereas in shPARP1 3T3-L1 cells, PARP1
mRNA and protein expression were below 1% of the
levels observed in shmock cells (Fig. 3, A and B). Further-
more, no PAR formation was detected in the extracts of
differentiated shPARP1 cells (Fig. 3C), suggesting that the
observed PAR formation during adipogenesis was indeed
dependent on PARP1. Next, we investigated whether de-
pletion of PARP1 affects adipocyte differentiation. As
judged by Oil-Red O staining, cells efficiently depleted of
PARP1 were strongly hampered in their development to
mature adipocytes (Fig. 3D). Moreover, the expression of
PPAR!2 itself and the expression of PPAR!2 target genes
such as aP2 and Adiponectin was strongly reduced after
7 d of induced differentiation in shPARP1 3T3-L1 cells
(Fig. 3E). These results suggest that PARP1 and PARP1-
induced PAR formation are required for PPAR!2 expres-
sion and subsequent adipocyte differentiation and that
other PARP family members cannot
compensate for the lack of PARP1 dur-
ing adipocyte differentiation.
Topoisomerase II inhibitor
merbarone inhibits PAR
formation and PPAR!2-dependent
gene expression
Activation of PARP1 and subsequent
induction of transcription can be caused
by topoisomerase II-mediated, transient,
site-specific DNA double-strand breaks
(24).We therefore sought to testwhether
the upstream event that activates PARP1
enzymatic activity requires topoisomer-
ase II-dependent double-strand DNA
break formation. To investigate this pos-
sibility, 3T3-L1 cells were treated during
the last 2 or 3 d of differentiation (treat-
ment at d 5–6 or 4–6, respectively) with
PARP inhibitor (PJ34) or topoisomerase
II inhibitor (merbarone). PJ34 efficiently
inhibited PAR formation even when
added only in the later stages of differenti-
ation (d 5 and 6) (Fig. 4A) and could still
strongly affect PPAR!2-dependent gene
expression, whereas PPAR!2, once ex-
pressed, was minimally changed (Fig. 4B
and Supplemental Fig. 2, A and B). Inter-
estingly,merbarone also reducedPAR for-
mation significantly, indicating that topo-
isomerase II activity may be at least partly
responsible for PARP1 activation.
In addition, the expression of
PPAR!2, aP2, Adiponectin, and CD36 was strongly re-
duced in cells treated withmerbarone during d 5 and 6 (Fig.
4C). To rule out that merbarone directly inhibits PARP1
enzymatic activity, we performed in vitro auto-ribosylation
assays (Supplemental Fig. 2C). Although PJ34 efficiently
blocked PAR formation,merbarone did not have an in vitro
inhibitory effect on PAR formation, even at concentrations
as high as 80 "M (Supplemental Fig. 2C). These results
suggest that topoisomerase II is responsible for the
observed activation of PARP1 during the later phase of
adipogenesis. Unfortunately, we were not able to dem-
onstrate recruitment of topoisomerase II to the CD36
and aP2 promoters in adipocytes with the available
antibodies.
PAR formation enhances PARP1
chromatin recruitment
To further address the direct functional link between
PARP1 and PAR formation for PPAR!2-dependent gene
FIG. 3. Depletion of PARP1 retards 3T3-L1 differentiation into adipocytes. Knockdown of
PARP1 was confirmed by (A) Western blot and (B) quantitative-PCR analyses. C, shmock or
shPARP1 3T3-L1 preadipocytes were differentiated into adipocytes for 7 d. Western blot
analysis with total-cell extracts shows PARP1 and PAR levels in shmock and shPARP1 cells
during adipogenesis (d 0, 3, and 7 of differentiation). D, Oil-Red O staining of shmock and
shPARP1 cultures that were subjected to 7 d of adipocyte differentiation. E, Real-time RT-PCR
analysis of PPAR!2, aP2, and Adiponectin in shmock and shPARP1 cells after 7 d of adipocyte
differentiation. mRNA levels were normalized with Cyclophilin A. Results show the mean !
SEM, n " 3.
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expression, we investigated the recruitment of PARP1 to
PPAR!2 target promoters by ChIP. ChIP analysis re-
vealed that PARP1 was already present at the CD36 and
aP2 promoters in undifferentiated cells, but this associa-
tion was substantially increased at d 7 (Fig. 4D). Interest-
ingly, PARP1 recruitment was abrogated when the cells
were treated either with PJ34 or withmerbarone, suggest-
ing that the association of PARP1with the tested promot-
ers was dependent on PAR formation, which is induced
by topoisomerase II activity.
Discussion
In this study, we provide evidence that PARP1 controls
adipocyte function in vitro. Our results show that PARP1
is activated after the initial phase of adipogenesis and that
either depletion of PARP1 or inhibition of ADP-ribosyla-
tion strongly retard the functional dif-
ferentiation of 3T3-L1 cells. These
findings are in agreement with earlier
results showing that PAR formation
during adipogenesis is increased, al-
though an initial decrease at the begin-
ning of adipocyte differentiation was
observed (25). Furthermore, inhibition
of topoisomerase II strongly reduced
PARP1 activation and adipocyte
function.
Recent genome-wide analyses re-
vealed a dramatic and dynamic modula-
tion of the chromatin landscape during
the first hours of adipocyte differentia-
tion that coincides with cooperative
binding of multiple early transcription
factors (including glucocorticoid recep-
tor, retinoid X receptor, Stat5a, C/EBP-
", and C/EBP-#) to transcription factor
hotspots (5). C/EBP-" marks a large
number of these transcription factor hot-
spots before induction of differentiation
and chromatin remodeling and is re-
quired for their establishment. Because
the expression of C/EBP-" was inde-
pendent of PAR formation during the
whole differentiation period (Fig. 2A),
our experiments suggest that PAR for-
mation is not required for the forma-
tion of the transcription factor hot-
spots. In contrast, although the initial
induced gene expression of PPAR!2
and C/EBP-$ (at d 3) was not affected
by PJ34 treatment, the sustained ex-
pression of both genes was reduced upon inhibition of
PAR formation. Therefore, PAR appears to be necessary
for the positive feedback loop that brings about the mu-
tual stimulation of PPAR!2 and C/EBP-$ expression.
Sustained PPAR!2-dependent gene expression was abro-
gated even after inhibition of PAR formation only for the
last 2 d (d 5 and 6), whereas PPAR!2 protein levels were
affected minimally (Fig. 4B). These results provide con-
vincing evidence that the induction of PAR formation and
its maintenance are important for sustained PPAR!2-
dependent gene expression and adipocyte function.
Moreover, this indicates that the reduced PPAR!2 target
gene expression is not caused by a lack of cellular
PPAR!2 but likely due to an additional function of PAR
in PPAR!2-dependent gene expression. Even though the
genetic experiments and inhibitor studies demonstrate a
strong correlation between PAR formation and adipo-
FIG. 4. PAR formation is dependent on topoisomerase II activity and required for PARP1
chromatin recruitment. A, 3T3-L1 preadipocytes were differentiated for 7 d. At d 4–6 or 5–6,
10 %M PJ34 or 40 %M merbarone was added to the medium. Total-cell extracts were prepared
and analyzed by Western blotting. B, 3T3-L1 preadipocytes were subjected to adipocyte
differentiation. 10 %M PJ34 was supplemented at d 5 and 6. Total-cell extracts from the
indicated days were analyzed for PPAR!2 protein expression. C, Real-time RT-PCR analysis on
d 7 from differentiated 3T3-L1 cells that were treated at d 5 and 6 of differentiation with
dimethyl sulfoxide control or 40 %M merbarone. mRNA levels were normalized with
Cyclophilin A. Results are from three independent experiments, mean ! SEM. D, ChIP analysis
with the PARP1 antibody on CD36 and aP2 promoter. Negative control (beads from d 0
samples) was set as 1. Results are from five independent experiments, mean ! SEM.
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genic gene expression, additional off-target effects of the
PJ34 inhibitor cannot be excluded (e.g. on other NAD!
consuming enzymes). However, given that most of the
observed PAR formation at d 7 was associated with
PARP1 and that PARP1 knockdown hampered adipo-
genesis, it is very likely that PARP1 enzymatic activity
is required for this process, although we can currently
not completely rule out that other ADP-ribosyltrans-
ferases, such as PARP2, also contribute to the observed
effect (26).
PAR formation by PARP1 could affect adipogenesis in
multiple ways: 1) by excluding or retaining transcription
factors from a special chromatin site (7); 2) by dissociat-
ing corepressors that occupy PPAR!2 and PPAR!2 target
promoters during adipocyte differentiation, allowing the
recruitment of transcription coactivators; and finally 3)
by regulating histone modifying enzymes and subse-
quently altering histone modifications (27).
Along this line, mechanistically, our data implicate
that topoisomerase II-induced DNA strand breaks as an
upstream event preceding PAR formation, whereas al-
tered histone modifications may represent the down-
stream effect of PARP1 activation. The reduced H3K4
trimethylation (Fig. 2D) upon PJ34 treatment is in agree-
ment with the finding that PARP1 prevents H3K4me3
demethylation (27). In addition, our data further suggest
an effect of PARP1 on the H3K9me3 modification (Fig.
2D). PAR could affect H3 marks either via histone
demethylases (e.g. lysine demethylases) or through spe-
cific methyltransferases (e.g. EHMT1/2, GLP, SETDB1,
or Suv39h1). Consequently, PAR formation may cause a
shift from repressory to activatory histone marks and
thereby affect adipogenesis. PARP1 itself is activated by
DNA damage, which could be brought about by topo-
isomerase II activity. Topoisomerase II cuts DNA strands
during replication (separation of DNA supercoils). How-
ever, the later stages of adipocyte differentiation are ac-
companied by an exit from the cell cycle (28), thereby
excluding this replication-dependent phenomenon as an
explanation for the regulation by topoisomerase II. The
induction of PARP1 by topoisomerase II in differentiating
adipocytes is therefore likely to be mediated by a tran-
sient, site-specific double-strand DNA break at the pro-
moters of PPAR!2-dependent target genes, as described
for nuclear receptors (29).
PARP1 recruitment to the promoters of different
PPAR!-dependent target genes was strongly enhanced
upon PAR formation. This observation is in contrast to
earlier in vitro studies, suggesting that automodified
PARP1 is released from chromatin (17) or that PJ34 treat-
ment does not affect PARP1 binding to target gene pro-
moters (27). However, in Drosophila, the presence and
activity of PARP1 is also required tomaintain a transcrip-
tion compartment by retaining transcription factors (30),
which also suggests a function for PARP1 enzyme activity
at the promoters of active genes as our findings in this
study.
The cellular PAR levels are determined by the synthe-
sizing activities of PARP and the degradation by poly-
(ADP-ribose)glycohydrolase, the main cellular enzyme
required for PAR degradation. The fact that PAR levels
were reduced upon the inhibition of PARP1 shortly be-
fore the extraction (data not shown) suggests that these
PAR polymers are not stable but rather constantly formed
and degraded. Consequently, the strong PAR formation
during adipocyte differentiation (as compared with the
PAR formation as a response to genotoxic stress such as
H2O2 treatment) must be due to constant synthesis,
which has been documented for the late stages of adipo-
genesis (25). However, activation of ADP-ribosyltrans-
ferases and of PAR formation can drastically affect cellu-
lar metabolite levels, such as NAD!, nicotinamide
adenine dinucleotide phosphate, ATP, or glucose-6-phos-
phate and thereby even indirectly impair cell viability
(31). Interestingly, NAD! levels during adipogenesis
were slightly elevated (Supplemental Fig. 3) or even dras-
tically increased during adipocyte differentiation of
3T3-L1 cells as described by others (3). This explains why
the differentiated cells are not dying upon extensive PAR
formation (due to the extended NAD! and subsequent
ATP depletion) as suggested earlier (32). Thus, high
NAD! levels may maintain PAR formation due to in-
creased substrate availability in a DNA damage-indepen-
dent manner. In summary, these data suggest that in-
creased NAD! synthesis fuels the substantial PAR
synthesis and thus allows a constant PAR turnover during
adipogenesis.
In conclusion, our data reveal a novel metabolic func-
tion of PARP1 in adipose tissue and provide evidence that
PARP1 and topoisomerase II regulate the adipogenic gene
expression program. These observations additionally
provide insight into the link between cellular metabolism
(e.g. production of NAD!), gene expression, and differ-
entiation. It will be interesting to investigate whether the
inhibition of ADP-ribose formation by PARP inhibitors
affects the pathological conditions, such as metabolic
disorders.
Materials and Methods
3T3-L1 cell culture and differentiation
3T3-L1 preadipocytes were cultured in DMEM containing
10% (vol/vol) fetal calf serum. On d 2 (2 d after 3T3-L1 prea-
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dipocytes reached confluence), cells were induced to differenti-
ate by insulin (5 !g/ml), 3-isobutyl-1-methylxanthine (0.5
mmol/liter), and dexamethasone (1 !mol/liter). On d 4, regular
DMEM containing insulin (5 !g/ml) was substituted until d 7.
Cells were differentiated in the presence or absence of PJ34 (10
!M), which was supplemented to cells every 24 h. Differentia-
tion was monitored by morphological assessment and Oil-Red
O staining. For Oil-Red O staining, cells were washed twice
with PBS, fixed in 10% formaldehyde for 1 h, and stained for 10
min with 0.2% (wt/vol) Oil-Red O solution in 60% (vol/vol)
isopropanol. Cells were then washed several times with water,
and excess water was evaporated by placing the stained cultures
at approximately 32 C. For the quantification of the staining,
the Oil-Red O was extracted with 100% isopropanol from the
cells and measured at 500 nm.
Reagents
Dexamethasone (D-4902), 3-isobutyl-1-methylxanthine (I-
5879), insulin (I-9278), Oil-Red O (00625), and merbarone
(M2070) were obtained from Sigma-Aldrich (St. Louis, MO).
Anti-PARP (sc-7150) antibody was purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA), anti-PAR (51-8114KC)
from BD Pharmingen (San Diego, CA), anti-H3 (1791-100)
from Abcam (Cambridge, MA), anti-H3K9me3 (07-442) from
Millipore (Bedford, MA), anti-H3K4me3 (07-473) from Milli-
pore, and antitubulin (T6199) antibody from Sigma-Aldrich.
PJ34 was purchased from Alexis Biochemicals (San Diego, CA)
(ALX-270-289-0000).
Whole-cell extraction
Whole-cell extracts were prepared by lysing the cells for 20
min in radioimmunoprecipitation assay buffer [50 mM Tris (pH
8), 400mMNaCl, 0.5%Nonidet P-40, 1% deoxycholate, 0.1%
sodium dodecyl sulfate, 1 !g/ml pepstatin, 1 !g/ml bestatin, 2
!g/ml leupeptin, 2 mM phenylmethylsulfony lfluoride, 10 mM
"-glycerophosphate, 1 mMNaF, and 1mM dithiothreitol] at 4 C
rotating on the wheels. Lysate was centrifuged for 20 min at 4 C
at 14,000 rpm. Total proteins were loaded on 7.5% sodium
dodecyl sulfate gels and blottedwith anti-PAR, anti-PARP, anti-
PPAR#, and antitubulin antibodies.
In vitro ADP-ribosylation assay
ADP-ribosylation assays were performed as earlier de-
scribed (33). Briefly, 400 nM PARP1 was incubated with 100
nM 32P-NAD! and 200 nM DNA in PARP reaction buffer in
the presence or absence of PJ34 (20 !M) or merbarone (20,
60, or 80 !M).
NAD measurements
For NAD!measurements, 0.5" 10#6 cells of differentiated
or undifferentiated 3T3-L1 cells were pelleted, and total NAD!
was measured using the EnzyChrom NAD!/NADH Assay kit
(E2ND-100) from BioAssay Systems (Hayward, CA) according
to the manufacturers’ instructions.
RNA extraction and real-time PCR analysis
Total RNA from 3T3-L1 cells was extracted using TRIzol
(Invitrogen, Carlsbad, CA) with a deoxyribonuclease step.
Equal amount of RNAwere reverse transcribed using the High-
Capacity cDNAReverse Transcription kit (Applied Biosystems,
Foster City, CA). Real-time PCR was performed using the Ro-
tor-Gene 3000 (Corbett Life Science, now QIAGEN, Valencia,
CA).Cyclophilinwas chosen as the internal control for normal-
ization after screening several candidate genes.
Chromatin immunoprecipitation
ChIP experiments were performed as described earlier (34).
Stable PARP1 knockdown in 3T3-L1 cells
Generation of viruses and transduction of cells was done as
described earlier (35). Briefly, pRDI vector expressing PARP1
shRNA was used to transduce 3T3-L1 cells. The shRNA was
directed against the sequence encoding the catalytic region of
PARP1, which was amplified with the following primers:
5$-GATCCCCAAGAGCGACGCTTATTACTGTTTCAAGA-
GAACAGTAATAAGCGTCGCTCTTTTTTTGGAAA-3$ (sense)
and 5$-AGCTTTTCCAAAAAAAGAGCGACGCTTATTACTG-
TTCTCTTGAAACAGTAATAAGCGTCGCTCTTGGG-3$ (anti-
sense). Transduced cells were selected through puromycin-resis-
tance gene.
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Supplemental Figures 
 
Figure S1. PJ34 inhibits lipid accumulation in 3T3-L1 cells.  
(A) 3T3-L1 pre-adipocytes were subjected to adipocyte differentiation. Total cell extracts 
from the indicated days and PAR formation were analyzed by Western blotting. (B) Oil-
Red O staining of 3T3-L1 cells that are subjected to 7 days of adipocyte differentiation 
protocol in the presence of PJ34. 
 
Figure S2. Effect of PJ34 treatment at day 6 and 7 on PPARJ2-dependent gene 
expression and  Merbarone doe not influence PARP1’s enzymatic activity  
(A) Real-time RT-PCR analysis on day 7 from differentiated 3T3-L1 cells that were 
treated at days 5 and 6 of differentiation with DMSO control or 10µM PJ34. mRNA 
levels were normalized with Cyclophilin. Results are from three independent 
experiments, mean ± SEM. (B) 3T3-L1 pre-adipocytes were subjected to adipocyte 
differentiation during 7 days in the absence or presence of PARP inhibitor PJ34 (10 PM). 
Inhibitor was supplemented daily. Real-time RT-PCR analysis is shown. Presented values 
are not normalized. Results are from 3 independent experiments mean ±SEM. (C) 400nM 
PARP1 was incubated with 100nM 32P-NAD and 200nM DNA in PARP reaction buffer 
in the presence of 20µM PJ34 or 20µM, 60µM and 80µM Merbarone (M). For each 
condition a solvent control was carried out. The mixture was incubated for 10 min at 
30°C. Proteins were separated by SDS-PAGE and ADP-ribosylation was analyzed by 
autoradiography.  
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S3. NAD+ concentration in undifferentiated and differentiated adipocytes 
3T3-L1 pre-adipocytes were subjected to adipocyte differentiation during 7 days. NAD+ 
levels of differentiated or undifferentiated cells were measured. Results show NAD+ 
levels per mg protein. Results are from 3 independent experiments, mean ± SEM. 
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ARTD1 deletion causes increased hepatic lipid
accumulation in mice fed a high-fat diet and impairs
adipocyte function and differentiation
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ABSTRACT ADP-ribosyltransferase Diphtheria toxin-
like 1 [ARTD1; formerly called poly-ADP-ribose poly-
merase 1 (PARP1)] is a chromatin-associated enzyme
involved in regulating metabolic homeostasis. The liver
is at the core of glucose and lipid metabolism and is
significantly affected by obesity and the metabolic
syndrome. Here, we show that when fed a high-fat diet
(HFD), mice lacking ARTD1 developed exacerbated
hepatic steatosis. ARTD1!/! mice had a 19% higher
liver weight than wild-type (WT) animals and exhibited
a significantly increased serum concentration of choles-
terol (38%) and impaired glucose tolerance. In addi-
tion, adipocyte function and size were significantly
reduced in ARTD1!/! mice fed an HFD (7794 "m2 for
WT and 5579 "m2 for ARTD1!/! mice). The signifi-
cantly reduced adipogenic differentiation of adipose-
derived stromal cells (ASCs) isolated from ARTD1!/!
mice (28 vs. 11% Oil red O-positive cells in WT and
ARTD1!/! ASCs, respectively) suggested that impaired
adipogenesis as the underlying cause for this adipose
tissue malfunction. This function of ARTD1 was spe-
cific for adipogenesis, since osteogenic differentiation
was not affected by the ARTD1 deletion. In summary,
we show that ARTD1!/! mice fed an HFD display
impaired adipogenesis and show exacerbated hepatic
steatosis, which can have important implications for
nonalcoholic fatty liver disease.—Erener, S., Mirsaidi,
A., Hesse, M., Tiaden, A. N., Ellingsgaard, H., Kostadi-
nova, R., Donath, M. Y., Richards, P. J., Hottiger,
M. O. ARTD1 deletion causes increased hepatic lipid
accumulation in mice fed a high-fat diet and impairs
adipocyte function and differentiation. FASEB J. 26,
2631–2638 (2012). www.fasebj.org
Key Words: adipogenesis # ADP-ribosylation # liver # PARP-1
Obesity is a complex metabolic disorder character-
ized by an excess of body fat that is closely associated
with other serious health conditions, such as heart
disease and diabetes (1). White adipose tissue (WAT) is
the predominant storage site for excess energy in the
form of fat in adult humans, but also functions as an
important endocrine organ (2, 3). However, it appears
that low-grade chronic inflammation (metaflamma-
tion) in metabolic tissues is the underlying mechanism
leading to the disruption of nutrient and energy me-
tabolism (4, 5).
ADP-ribosyltransferase Diphtheria toxin-like 1 [ARTD1;
formerly called poly-ADP-ribose polymerase 1 (PARP1);
ref. 6] is a chromatin-associated enzyme that modifies
itself and target proteins by transferring the ADP-ribose
moieties from nicotinamide adenine dinucleotide
(NAD!) to specific acceptor residues on target pro-
teins (7). ARTD1 is thus able to regulate protein
function, chromatin compaction, and gene expression
(7, 8) and is subsequently involved in numerous bio-
logical phenomena, such as stress response, inflamma-
tion, and differentiation or cell cycle regulation, as well
as in infectious diseases and cancer (9). Mice lacking
ARTD1 also exhibit metabolic phenotypes, such as
1 Correspondence: Institute of Veterinary Biochemistry and
Molecular Biology, University of Zürich, Winterthurerstrasse
190, Zürich 8057, Switzerland. E-mail: hottiger@vetbio.uzh.ch
doi: 10.1096/fj.11-200212
This article includes supplemental data. Please visit http://
www.fasebj.org to obtain this information.
Abbreviations: aP2, adipocyte protein 2; ARTD, ADP-ri-
bosltransferase Diphtheria toxin-like; ASC, adipocyte-derived
stromal cell; ATGL, adipose triglyceride lipase; CD36, cluster
of differentiation 36; DMEM, Dulbecco’s modified eagle
medium; FBS, fetal bovine serum; FFA, free fatty acid; Glut4,
glucose transporter type 4; GTT, glucose tolerance test; H&E,
hematoxylin and eosin; HFD, high-fat diet; HSL, hormone
sensitive lipase; ITT, insulin tolerance test; NAD!, nicotin-
amide adenine dinucleotide; NAFLD, nonalcoholic fatty liver
disease; ND, normal diet; PAR, poly-ADP-ribose; PPAR",
peroxisome proliferator-activated receptor "; PARP, poly-
ADP-ribose polymerase; PBS, phosphate-buffered saline;
WAT, white adipose tissue; WT, wild type
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alterations in body weight, WAT formation, and the
development of high-fat diet (HFD)-induced obesity,
although these vary depending on the strain back-
ground (10–12). The deletion of ARTD1, a major
NAD!-consuming enzyme, can lead to increased cellu-
lar NAD! levels (10). Consequently, ARTD1 deletion
can activate NAD!-dependent enzymes, such as sir-
tuins, and thereby indirectly induce phenotypes, such
as increased mitochondrial biosynthesis and altered
energy metabolism (10, 13). Furthermore, the enzy-
matic activity of ARTD1 also directly partakes in the
sustained expression of the key regulator of adipocyte
function, peroxisome proliferator-activated receptor "
(PPAR"; ref. 14). In cell culture, ARTD1 modulates
PPAR"-dependent gene expression [such as cluster of
differentiation 36 (CD36) or adipocyte protein 2 (aP2)]
and adipocyte function (14) and may thus also be
involved in adipogenesis in vivo.
To identify and characterize such direct in vivo
functions of ARTD1 in metabolism, we analyzed
ARTD1#/# and wild-type (WT) mice of the C57BL/6
background fed an HFD. Here, we report that deletion
of ARTD1 caused increased hepatic fat accumulation
and dyslipidemia in mice exposed to HFD. These
effects correlated with increased PPAR"2 target gene
expression in liver samples from ARTD1#/#mice fed an
HFD as well as with elevated serum levels of cholesterol,
smaller adipocyte size, and impaired adipocyte differ-
entiation. These results define a novel function for
ARTD1 in the development of hepatic steatosis, as well
as in the modulation of adipocyte differentiation and in
adipose tissue function in vivo. These findings may thus
provide novel insights into the molecular pathways that
govern the onset, development, and progression of
prevalent human diseases such as nonalcoholic fatty
liver disease (NAFLD).
MATERIALS AND METHODS
Animals and animal care
In the ARTD1#/# male C57BL/6 mice used in this study and
obtained from Zhao-Qi Wang (Leibniz Institute for Age
Research–Fritz Lipmann Institute, Jena, Germany), part of
the second exon and second intron of the ARTD1 gene is
replaced with the neomycin resistance gene (15). ARTD1#/#
and WT mice were fed an HFD consisting of 60% of calories
from fat (S3282; Bio-Serv, Frenchtown, NJ, USA) starting at
6–8 wk of age for 14 wk. Control mice were fed a normal diet
(ND) consisting of 4.5% fat. Animals were housed in a
specific pathogen-free facility with a 12-h light-dark cycle and
given free access to food and water. Animal experiments were
performed according to the regulations of the Cantonal
Veterinary Office (Zurich, Switzerland).
Culture and analysis of mouse adipocyte-derived stromal
cells (ASCs)
ASCs were isolated, cultured, and analyzed as described
previously (16). In short, fat pads were removed from male
mice and digested with 0.1% collagenase A (Roche Diagnos-
tics, Rotkreuz, Switzerland). Stromal cells were collected by
centrifugation and cultured in supplemented Dulbecco’s
modified eagle medium (DMEM; low glucose with Glutamax;
Invitrogen AG, Basel, Switzerland), 10% fetal bovine serum
(FBS; Invitrogen), and antibiotics. Supernatant was replaced
after 1 d with fresh complete medium and cells were used
between passage 3 and 4. Total RNA was isolated and puri-
fied using TRIzol reagent (Invitrogen) and reverse tran-
scribed using superscript II (Invitrogen) and random
hexanucleotide primers (Promega AG, Dübendorf, Switzer-
land). mRNA expression analysis was performed with
primers specific for ARTD1 (Mm01321084_m1), PPAR"2
(Mm00440940_m1), aP2 (Mm00445878_m1), and glucose
transporter type 4 (GLUT4; Mm00436615_m1) and by using
the StepOnePlus Real-Time PCR System (Applied Biosys-
tems/Life Technologies, Zug, Switzerland). All values were
normalized to the RPS12 ribosomal RNA (Mm00488728_m1).
Adipogenesis
To assess adipogenesis, ASCs were plated at 10,000 cells/cm2
and incubated in adipogenic medium (DMEM supplemented
with 10% FBS and 1 $M dexamethasone; Sigma-Aldrich,
Buchs, Switzerland), 10 $g/ml insulin (Sigma-Aldrich), 0.1
mM indomethacin (Sigma-Aldrich), and 0.5 mM isobutyl
methylxanthine (IBMX; Sigma-Aldrich). After 2 d, cells were
switched to adipogenic medium without IBMX for up to 14 d.
Triglyceride content was determined using 0.3% Oil Red O
(Sigma-Aldrich), and adipocytes were counted in 30 fields of
view by fluorescence microscopy.
Osteogenesis
ASCs were plated at 5000 cells/cm2 and incubated in %-min-
imum essential medium (%-MEM; Invitrogen), supplemented
with 10% FBS, 50 $M l-ascorbic acid 2-phosphate sesquimag-
nesium salt hydrate (Sigma-Aldrich), 10 mM &-glycerophos-
phate (Sigma-Aldrich), and 5 $M retinoic acid (Sigma-Al-
drich) for up to 14 d with regular changes of medium.
Mineralization in cell colonies was identified using Alizarin
Red S (Sigma-Aldrich).
RNA extraction and real-time PCR analysis from WAT
Mouse tissues were isolated, rinsed in phosphate-buffered
saline (PBS), frozen in liquid nitrogen and stored at #80°C
until extraction. Total RNA was extracted from WAT using
the RNeasy Lipid Tissue Kit (Qiagen, Hombrechtikon, Swit-
zerland) according to the manufacturer’s instructions, with
the inclusion of a DNase digestion step. Total RNA from liver
and also from 3T3-L1 cells was extracted using the Total RNA
isolation mini kit (Macherey Nagel, Oensingen, Switzerland)
with a DNase step. Equal amounts of RNA from 5–8 mice
were pooled and reverse-transcribed using the high-capacity
cDNA reverse transcription kit (Applied Biosystems/Life
Technologies, Zug, Switzerland). Real-time PCR was per-
formed using the Rotor-Gene 3000 (Corbett Life Science,
now Qiagen) and SYBR Green using the primers listed in
Supplemental Table S1. Cyclophilin was chosen as the internal
control for normalization and for the relative quantification
of gene expression.
Whole-cell extraction
Tissues were lysed in RIPA buffer (50 mM Tris, pH 8; 400 mM
NaCl; 0.5% Triton Nonidet P-40; 1% DOC; 0.1% SDS; 1
$g/ml pepstatin; 1 $g/ml bestatin; 2 $g/ml leupeptin; 2 mM
2632 Vol. 26 June 2012 ERENER ET AL.The FASEB Journal ! www.fasebj.org
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PMSF; 10 mM !-glycerophosphate; 1 mM NaF; and 1 mM
DTT), homogenized with a needle and syringe, and rotated
for 20 min at 4°C. Lysate was centrifuged for 20 min at 4°C at
14,000 rpm. Total proteins were loaded on 7.5% SDS gels and
blotted with anti-PAR and anti-tubulin antibodies.
Serum measurements
Serum insulin concentrations were measured with the insulin
ELISA kit (Mercodia Inc., Uppsala, Sweden). Blood glucose
was determined by using the FreeStyle Lite glucometer (Ab-
bott, Baar, Switzerland).
Glucose tolerance tests (GTTs) and insulin tolerance tests
(ITTs)
For the GTT, mice were unfed overnight (14 h); for the ITT,
mice were unfed for 3 h. Glucose (1.2 g/kg body weight) or
human recombinant insulin (HFD: 1.4 U/kg; ND: 0.75 U/kg)
was injected intraperitoneally. Blood glucose concentrations
were determined from tail using the FreeStyle Lite glucom-
eter (Abbott).
Histology and cell-size measurement
Freshly isolated epididymal WAT and liver tissue from mice
fed HFD was fixed in 4% formalin and embedded in paraffin.
Sections were stained with hematoxylin and eosin (H&E) or
Oil Red O. Adipocytes were photographed with a Leica DMR
microscope (Leica Microsystems, Glattbrugg, Switzerland)
and cell morphology and size were analyzed using the Leica
IM 1000 software. Liver photographs were recorded using an
Olympus AH-2 microscope (Olympus, Tokyo, Japan)
equipped with an Axiocam camera (Carl Zeiss, Oberkochen,
Germany).
RESULTS
ARTD1!/! mice fed HFD have increased liver weight
and hepatic lipid deposition
To determine the role of ARTD1 in metabolic disor-
ders, we analyzed 6–8 wk old WT and ARTD1"/" mice
in the C57BL/6J background that were fed ND or HFD.
WT and ARTD1"/" mice fed ND had identical body
weights (Supplemental Fig. S1A). Both WT and
ARTD1"/" mice fed HFD gained significantly more
body weight as compared to those fed ND (identified as
week 0; Fig. 1A). Furthermore, in comparison to
ARTD1"/"mice fed HFD,WTmice were heavier, which
was not attributable to differences in food intake (Sup-
plemental Fig. S1B). A pathological analysis revealed
that the most apparent phenotype of the ARTD1"/"
mice fed HFD was the significantly increased liver
weight (Fig. 1B). Histological examination (H&E and
Oil Red O staining) of liver sections revealed markedly
increased hepatic lipid deposition in ARTD1"/" mice
fed HFD, as compared to the WT controls (Fig. 1C),
while no apparent difference was observed in mice fed
ND (data not shown). H&E staining of skeletal muscle
tissue of WT and ARTD1"/" mice did not reveal any
difference (Fig. 1C).
ARTD1!/! mice fed HFD exhibit altered PPAR"2
target gene expression and dyslipidemia
Hepatic lipid accumulation is often associated with an
ectopic induction of PPAR#2 and PPAR#2-dependent
gene expression in the liver and muscle (17). We
therefore tested whether the increased lipid deposition
in livers of ARTD1"/" mice correlated with alterations
in PPAR#2 target gene expression in the liver. The
expression of PPAR#2 in ARTD1"/" livers was increased
but not significantly different as compared to WT
samples (Fig. 2A). However, the PPAR#2 target genes
aP2 (fatty acid binding protein) and LPL (lipoprotein
lipase) were significantly up-regulated in ARTD1"/"
livers of mice fed HFD. Significantly increased compen-
satory expression was also observed for PPAR$, a key
regulator involved in fatty acid catabolism. Lipin, an-
other highly inducible enzyme that is involved in tri-
glyceride metabolism, was unaffected between the two
genotypes, indicating that not all factors involved in
lipid metabolism were changed in the livers of
ARTD1"/" mice. These results, and in particular the
strongly elevated expression of aP2, revealed that livers
of ARTD1"/" mice fed HFD show gene expression
Figure 1. ARTD1"/" mice fed HFD display decreased weight gain and have reduced adipocyte size. A) Body weight of WT and
ARTD1"/" mice that were fed HFD. HFD feeding started when mice were 6–8 wk old (time point 0; n%8–9 mice/group).
*P & 0.05. B) Liver weight was measured and normalized with body weight (n%8–9 mice/group, means'se). *P & 0.05, 14 wk
after HFD. C) Representative images of Oil Red O-stained (top panels) or H&E-stained (bottom panels) sections of
paraffin-embedded liver tissue from WT or ARTD1"/" mice fed HFD (n%4). H&E-stained skeletal muscle sections are shown as
a control and for comparison (right panel).
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patterns typically associated with adipocytes and adipo-
genesis (17).
The hepatic lipid accumulation observed in ARTD1!/!
mice suggested that the metabolic analytes might be
altered in these animals. We therefore measured the
plasma levels of free fatty acids (FFAs), triglycerides, and
cholesterol. Indeed, ARTD1!/! mice displayed a mar-
ginal elevation in FFA and triglyceride levels as well as
significantly increased cholesterol amounts, which also
hinted at a disturbed lipid homeostasis in ARTD1!/!mice
(Fig. 2B). However, lipolysis was likely not the cause for
these alterations in lipid levels, since neither adipose
triglyceride lipase (ATGL) nor hormone sensitive lipase
(HSL) mRNA levels were significantly affected by the
ARTD1 deletion (Fig. 2C).
ARTD1!/! mice fed HFD exhibit defective glucose
homeostasis
The increased FFA blood concentration and hepatic
lipid accumulation can generate metabolic signals that
impair the metabolization of glucose (18). To deter-
mine whether the hepatic lipid accumulation and dys-
lipidemia in ARTD1!/! mice is accompanied by abnor-
malities in glucose homeostasis, we performed GTTs in
WT and ARTD1!/! mice fed HFD. Mice were injected
with 1.2 g glucose/kg body weight, and glucose levels
were quantified over a period of 2 h. Overall,
ARTD1!/!mice had an 18% increased glucose content
(area under curve) and required more time to clear the
injected glucose, although the basal glucose levels were
not significantly altered (Fig. 3A, B). Since this analysis
was performed with mice that experienced 14 h of food
withdrawal, the differences betweenWT and ARTD1!/!
mice may be underestimated (19). To explore the
potential mechanism causing impaired glucose toler-
ance in ARTD1!/! mice, we examined aspects of insu-
lin secretion in mice with and without ARTD1. A
significant increase in plasma insulin was observed in
ARTD1!/! mice as compared to WT mice following an
i.p. glucose injection (Fig. 3C), thus indicating that
"-cell function is unlikely to be impaired in
ARTD1!/! mice. This insulin burst, which was not
observed in WT mice, may hide elevated glucose
levels in the ARTD1!/! mice at earlier time points.
We next asked whether insulin sensitivity contributes
to this phenotype. To assess whole-body insulin sen-
sitivity, ITTs were performed in mice after 12 wk of
exposure to HFD. Mice were injected with 1.4 U
insulin/kg body weight, and glucose levels were
determined during 90 min. Serum glucose levels of
ARTD1!/! mice were 20% higher as compared to the
WT control (area under curve), which is suggestive of
a tendency toward insulin resistance, but this effect
was not significant (Fig. 3D).
Comparable analysis with animals fed the ND re-
vealed that glucose levels and response to GTTs and
ITTs did not significantly change between the two
genotypes (Supplemental Fig. S1C–E). Furthermore,
insulin-stimulated AKT phosphorylation in muscle and
WAT tissue from WT and ARTD1!/! mice fed ND was
Figure 2. ARTD1!/! mice fed HFD exhibit altered PPAR#2 target gene expression and dyslipidemia. A) Real-time RT-PCR
analysis of PPAR#2 and PPAR#2 target genes in liver tissue obtained from WT and ARTD1!/! mice that were fed HFD (RNA
of 7 mice pooled, means$sd of technical duplicates, 14 wk after HFD). B) Serum free fatty acid (FFA), triglyceride, and
cholesterol levels were measured from independent samples of 5 WT and 4 ARTD1!/! mice. C) Real-time RT-PCR analysis of
ATGL and HSL expression in WAT of WT and ARTD1!/! mice (RNA of 5–6 mice pooled, technical replicates, means$sd).
Figure 3. ARTD1!/! mice exhibit deteriorated glucose homeostasis. A) Serum glucose levels were measured from WT and
ARTD1!/! mice. B) GTT: mice were injected with glucose (1.2 g/kg body weight), and glucose levels were quantified over a
period of 2 h. C) Serum insulin levels during the GTT shown in B. D) ITT: mice were injected with insulin (1.4 U/kg body
weight), and glucose levels were determined over a period of 90 min. Values are means $ se, n % 5–6 mice/group. *P & 0.05,
12 wk after HFD.
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also comparable (Supplemental Fig. S1F) suggesting
that ARTD1 does not have a direct role in glucose
homeostasis and insulin signaling under ND, but that
the changes observed with HFD were rather the conse-
quence of dyslipidemia and excessive lipid accumula-
tion in the liver.
Adipocyte size and poly-ADP-ribose (PAR) formation
in ARTD1!/! mice
We have recently reported that ARTD1 regulates adi-
pogenesis in vitro (14), and PPAR! deletion in mouse
adipose tissue was shown to cause increased lipid
deposition in the livers (20). Our results on hepatic
lipid accumulation and the dyslipidemic phenotype in
ARTD1"/" mice fed HFD encouraged us to investigate
the role of ARTD1 on adipocyte and WAT function in
vivo. We therefore analyzed WAT from WT and
ARTD1"/"mice. Surprisingly, neither the expression of
PPAR!2 or its target genes aP2 and CD36 nor the
inflammatory genes IL-1#, IL-13ra, and MCP1 differed
between the WT and ARTD1"/" WAT samples from
mice fed HFD (Fig. 4A and Supplemental Fig. S2).
However, ARTD1"/" WAT tissue from mice fed HFD
expressed less IL-6, which is a main regulator of inflam-
mation. In addition, relative mRNA levels of the inflam-
matory genes IL-10 and IL-12 and of the macrophage
specific genes Pu.1 and MPEG 1 were also reduced,
while SAA3 transcription was elevated. These results
showed that a subset of the inflammatory genes was
affected. Moreover, histological analysis of epididymal
WAT from ARTD1"/" mice revealed a profound
change in adipose tissue morphology, as evidenced by
the significant reduction in adipocyte size (Fig. 4B, C).
These results suggest that altered adipose tissue mor-
phology likely impaired the storage of excess lipids in
ARTD1"/" mice fed HFD and thus caused a patholog-
ical lipid accumulation in the liver. This significant
effect of ARTD1 deficiency on lipid metabolism and on
the size of adipocytes from ARTD1"/" mice fed HFD
suggests a fundamental role for ARTD1 in adipocyte
function. Since we have recently shown that PAR for-
mation is strongly induced in 3T3-L1 cells after 7 d of
adipogenic induction (14), we investigated whether
PAR was also formed in mature adipocytes in vivo. We
could not detect PAR formation in WAT of WT mice
that were fed ND (data not shown), but a distinct PAR
signal was observed in the WAT extracts of WT mice
(but not in the WAT of ARTD1"/" mice) that were
maintained on HFD (Fig. 4D), suggesting that high
energy diet (nutrient availability) induced ADP-ribosy-
lation in WAT in vivo and in an ARTD1-dependent
manner.
Adipogenic gene expression in differentiating aASCs
is dependent on ARTD1
The in vivo results obtained from the studies with
ARTD1"/" mice suggested that ARTD1 and PAR for-
mation are centrally involved in adipose tissue activities.
In addition, ARTD1 and PAR formation have been
implicated in chromatin regulation (21) and were
shown to affect PPAR!2-dependent gene expression
and adipocyte function in differentiating 3T3-L1 cells
(14, 21). We therefore hypothesized that ARTD1 may
also affect the differentiation and development of
functional adipocytes in vivo.
We tested this hypothesis by using ASCs, which can
be easily isolated and expanded and have the ability to
differentiate into several types of mesenchymal tissue.
Differentiating ASCs are an established experimental
system to study adipocyte differentiation (22). To study
the role of ARTD1 and poly-ADP-ribosylation in adipo-
genesis, we compared ASCs from ARTD1"/" and from
WT mice. In uninduced ASCs from WT mice, ARTD1
expression levels were high and increased further at d
10 after the induction of adipogenesis (Fig. 5A). Tran-
scripts of the adipogenesis marker genes PPAR!2, aP2,
and GLUT4 were not detectable prior to the induction
of adipogenesis but increased significantly on adipo-
genic induction in WT mice (Fig. 5B–D). In contrast,
PPAR!2, aP2, and GLUT4 expression remained at sig-
nificantly lower levels in ASCs from ARTD1"/" mice
throughout adipogenesis (Fig. 5B–D). The marked
Figure 4. Adipocyte size and PAR formation in ARTD1"/" mice. A) Real-time RT-PCR analysis in total cell extracts from
epididymal WAT of WT and ARTD1"/" mice that were fed HFD. mRNA levels were normalized with cyclophilin A. Results are
means of 5–6 pooled mice, means $ sd of technical replicates. ns, not significant. *P % 0.05; **P % 0.01; ***P % 0.0001. B)
Whisker plot of adipocyte area from evaluation of 450 adipocytes from 4–5 independent mice. ***P % 0.0001 comparing mean
adipocyte area. C) Representative images of H&E-stained epididymal adipose tissue from WT and ARTD1"/" mice. D) PAR
detection in total cell extracts from epididymal WAT ofWT and ARTD1"/"mice that were fed HFD. All panels: 14 wk after HFD.
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effect of ARTD1 deletion on adipogenic gene expres-
sion suggests that ARTD1 is a major regulator of
normal ASC differentiation.
Functional characterization of adipogenic ASCs
isolated from ARTD1!/! mice
After 10 d of adipogenic differentiation, Oil Red O
staining revealed a significantly higher percentage of
mature adipocytes in ASC cultures isolated from WT
mice as compared to ARTD1!/! mice (Fig. 6A). To
further study the link between ARTD1 and adipogene-
sis, we assessed ASC differentiation in the presence of
the three PARP inhibitors (PJ34, olaparib, and nicotin-
amide) by Oil Red O staining (Fig. 6B–D). All three
compounds significantly reduced the percentage of Oil
Red O-positive cells in a concentration-dependent man-
ner. Interestingly, the detrimental effect of ARTD1 loss
of function on ASC adipogenesis was much less appar-
ent in ASCs undergoing osteogenesis, thus suggestive of
a lineage-specific role for ARTD1 in mesenchymal stem
cell differentiation (Supplemental Fig. S3). These re-
sults are in agreement with the strong and specific
influence of the ARTD1 deletion on PPAR"2-depen-
dent gene expression in adipose tissue and thus further
highlight the importance of ADP-ribosylation in adipo-
genesis.
Taken together, these results demonstrate that
ARTD1!/! deficiency in mice affects adipocyte func-
tion in vivo, and lipid deposition in the liver. This
correlates with the up-regulated expression of hepatic
PPAR"2 and its target genes involved in fatty acid
metabolism in ARTD1!/! mice. The effect of ARTD1
and PAR formation on the adipogenic differentiation
process may represent the underlying cause for the in
vivo effects on WAT function and lipid deposition in
ARTD1!/! mice.
DISCUSSION
In the present study, ARTD1!/! mice of the C57BL/6
background were fed HFD, and adipocyte and WAT
function were analyzed. Several independent groups
have previously reported significant differences in the
body weight of adult WT and ARTD1!/! mice from
various backgrounds (15, 23). While we and others (10)
have observed a decreased body weight in C57BL/6
ARTD1!/! mice fed HFD, ARTD1!/! mice of the
Figure 5. Adipogenesis is impaired in ASCs from ARTD1!/! mice. Expression levels of ARTD1 (A) PPAR"2 (B), aP2 (C), and
GLUT4 (D) were evaluated by qRT-PCR over 0, 5, and 10 d of adipogenic differentiation. Expression value of each gene was
normalized to the amount of ribosomal protein S12 (RPS12) RNA in order to calculate relative amounts of mRNA. *P # 0.05,
**P # 0.01.
Figure 6. Triglyceride accumulation is decreased in adipo-
genic ASCs from ARTD1!/! mice. A) Representative fluores-
cent images of ASCs stained with Oil Red O (red) and
Hoechst 33342 nuclear stain (blue). Scale bars $ 150 %m.
Percentage of cells demonstrating triglyceride accumulation
was quantified in ASCs at d 10. B–D) ASCs fromWTmice were
induced to adipogenic differentiation in the presence of the
ARTD1 inhibitors PJ34 (B), olaparib (C), and nicotin-
amide (D), and the percentage of cells demonstrating triglycer-
ide accumulation was quantified at d 10. All differentiation
studies were carried out using ASCs at passage 3 to 4 and were
performed in triplicate. *P # 0.05, **P # 0.01, ***P # 0.01.
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SV129 background have been shown to be more sus-
ceptible to HFD-induced obesity (11). However, mice
of the C57BL/6 background are readily susceptible to
diet-induced obesity, irrespective of the presence or
absence of ARTD1 (12). Our findings of lower body
weight, increased liver weight, smaller adipocytes, ele-
vated serum cholesterol levels, and impaired glucose
tolerance in ARTD1!/! mice suggest that lipid alloca-
tion is impaired. These results differ from recently
published observations with ARTD1!/! mice of the
same strain background (10), although hepatic lipid
accumulation was not assessed in this study. However, it
should be noted that the two C57BL/6 ARTD1!/!
mouse strains were created independently by targeting
different ARTD1 exons (15, 23), and as such, have given
rise to certain age-related disparities, as evidenced by
alterations in telomere lengths (24, 25). Whether such
differences also account for the contradicting effects of
the ARTD1 deletion on lipid metabolism remains to be
determined. In addition, the metabolic differences
between the two studies using C57BL/6 ARTD1!/!
mice might also be due to the fact that we started HFD
feeding earlier (when the mice were 6–8 wk old),
performed our analysis later (after 12 wk of HFD
feeding) and used an HFD preparation from a different
supplier with slightly different composition (10).
In the present study, PAR formation was only ob-
served inWTmice and on HFD feeding. The absence of
PAR formation in the WAT of ARTD1!/! animals
indicated that PAR formation in WAT was dependent
on nutrient availability and on ARTD1. Alterations in
PAR formation due to ARTD1 deletion could poten-
tially change NAD" metabolism in these animals and
thereby cause the activation of sirtuin 1 (SIRT1; ref.
10). Altered sirtuin activity may, in turn, affect adi-
pocyte gene expression and function, metabolism, or
number of mitochondria, for example, through the
deacetylation of Forkhead box protein O1 (FOXO1;
refs. 10, 26–28). Such indirect effects cannot be ex-
cluded, but our results describing the effects of ARTD1
deletion on ASC adipogenesis also point to a direct
effect of ARTD1 and ADP-ribosylation. These findings
are in agreement with our earlier in vitro observation,
where ARTD1 activity and ADP-ribosylation were in-
duced at d 7 during adipogenesis and crucial for
the sustained expression of PPAR#2 and CCAAT/
enhancer-binding protein $ (C/EBP-$), but not for the
upstream regulator C/EBP-% (14). In the current study,
ASCs from ARTD1!/! mice differentiated less effi-
ciently into mature adipocytes but were capable of
undergoing normal osteogenesis, thus confirming that
ARTD1 plays a lineage-specific role in ASC differentia-
tion. Further studies are needed to confirm the involve-
ment of PAR formation in adipogenesis and also its role
in the regulation of PPAR#2-dependent gene expres-
sion in WAT. The fact that three of the analyzed
inflammatory genes (IL-6, IL-10, and IL-12) were af-
fected by the ARTD1 deletion suggests a limited and
specific effect on only a subset of the genes expressed in
WAT in vivo. Interestingly, two macrophage-specific
genes (Pu.1 and MPEG 1) exhibited reduced mRNA
levels, alluding to a possible involvement of ARTD1 in
macrophage differentiation.
The results presented here point to a direct and
specific involvement of ARTD1 in adipogenesis in vivo.
However, other genes or compensatory mechanisms
seem to assure WAT formation in the absence of
ARTD1. Apart from this, our results suggest that
ARTD1 is required for efficient adipogenesis and that
ARTD1 ablation limits lipid storage in adipocytes, re-
stricts adipocyte size, and causes hepatic lipid deposi-
tion. It therefore appears that ARTD1 may regulate
adipocyte turnover and thereby indirectly affect adi-
pocyte number and the response to different nutri-
tional schemes. It will be interesting to investigate the
metabolism and the long-term effect of HFD on
ARTD1!/! mice. ARTD1 deficient mice may thus be-
come a useful model to study how adipocyte differen-
tiation and function affect pathological responses to
HFD and lead to diet-induced obesity.
Although the storage of excess energy in the form of
triglycerides and the release of FFAs is the principal
function of adipocytes (29), the liver is the organ of fatty
acid uptake, synthesis, and circulation and can therefore
be considered a hub of fatty acid metabolism (30). In
humans, components of the metabolic syndrome, such as
obesity, insulin resistance or dyslipidemia, are associated
with fatty liver syndrome, which is one characteristic of
NAFLD (31, 32). One consequence of NAFLD is an
excessive release of FFAs into the bloodstream, which
exacerbates peripheral insulin resistance. Our findings of
significantly increased hepatic lipid accumulation, ele-
vated serum cholesterol levels, and impaired glucose
tolerance in ARTD1!/! mice, despite the unaffected
insulin response, suggests that other lipid mediators or
related mechanisms, such as inflammation, may be re-
quired for the development insulin resistance. Alterna-
tively, it can be speculated that the hepatic insulin resis-
tance is compensated for during the whole-body insulin
resistance test. To explore insulin sensitivity more specif-
ically at the level of the liver, hyperinsulinemic-euglycemic
clamp studies could be employed, since the majority of
endogenously produced glucose comes from hepatocytes.
Currently, it is also not clear whether elevated cholesterol
levels are only a consequence of the changes in WAT or
whether they are also caused and exacerbated by the
ARTD1 deficiency in liver tissue, which might affect other
metabolic processes. Further studies using conditional
knockout mice with reduced expression of ARTD1 either
in WAT or liver would certainly provide additional in-
sights into this interdependency.
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Suppl. Figure S1. ARTD1 -/- mice on ND exhibit reduced expression of adipogenic 
gene markers in WAT. (A-E) ARTD1 -/- mice display comparable sensitivity with WT mice to 
GTT and ITTs. (A) Body weight (B) Food intake (C) Starving glucose levels of WT and ARTD1 -
/- mice. n=6 mice per group, mean ±SE. (D) Glucose tolerance test (GTT) measured after 14 h 
fasting WT and ARTD1 -/- mice. 6 weeks old mice were injected 0.75 g glucose per kg body 
weight. n = 5 mice per group, mean ±SE. (E) Insulin tolerance test (ITT) measured after 3 hr 
fasting WT and ARTD1 -/- mice. Mice were injected 0.75 U insulin per kg body weight n = 5 
mice per group, mean ±SE. (F) Western blot analysis of phosphorylated Akt (p-Akt) from 
muscle and WAT of insulin (0.75 U/kg, 10 min) injected WT and ARTD1 -/- mice (14 h fast). 
 
Suppl. Figure S2. PPAR! and PPAR! - dependent gene expression in WAT from 
ARTD1 -/- mice on HFD. Real-time RT-PCR analysis in total cell extracts from epididymal 
WAT of WT and ARTD1 -/- mice that were fed with HFD. mRNA levels were normalized with 
Cyclophilin A. Results represent mean ±SD of technical replicates. 
 
Suppl. Figure S3. Osteogenic differentiation of ASCs is not adversely affected by 
ARTD1 deletion. Analysis of osteogenic differentiation in ASCs isolated from wild type (WT) 
and ARTD1-/- mice. (A) The expression level of osteopontin (Spp1) was evaluated by qRT-PCR 
over 0, 3, 7 and 14 days of osteogenic differentiation. The expression value of each gene was 
normalized to the amount of ribosomal protein S12 (RPS12) RNA in order to calculate relative 
amounts of mRNA. (B) Mineral deposition was identified in mouse ASCs by Alizarin red S 
staining (red) at various stages during osteogenic differentiation. (C) The effect of ARTD1 
inhibition on the osteogenic differentiation of ASCs isolated from WT mice was evaluated after 
14 days using Alizarin red S staining. *P < 0.05, **P < 0.01. 
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Supplemental table S1. Primers used for real-time RT-PCR analyses.  
The sequences of forward (F) and reverse (R) primers used for PCR are given in 5`-3`direction. 
Gene  Sequence (F, R; 5`-3`) 
aP2 F: ATGGGTGAAACTCTGGGAGATTCT 
R: CTTGGAGCTTCAGGTCATATTTGTA 
Arginase 1 F: CAGAAGAATGGAAGAGTCAG 
R: CAGATATGCAGGGAGTCACC 
ATGL F: TGTGGCCTCATTCCTCCTAC 
R: TCGTGGATGTTGGTGGAGCT 
CD36 F: ACAACAGGGTTTCAGCAGAAAGAGG 
R: GGTCTCTGACACCTGAGCCAAATG 
Cyclophilin A F: TCACCATTTCCGACTGTGGA 
R: AATGCCCGCAAGTCAAAAGA 
HSL F: GCTGGGCTGTCAAGCACTGT 
R: GTAACTGGGTAGGCTGCCAT 
IL-10 F: GCTCTTACTGACTGGCATGAG 
R: CGCAGCTCTAGGAGCATGTG 
IL-12 F: GAAGTTCAACATCAAGAGCAGTAG 
R: AGGGAGAAGTAGGAATGGGG 
IL-13ra F: TGCTGCTACTGTGGACCGCCA 
R: CCTTCAGGAGGACTCCACGTCCA 
IL-1! F: AAGGAGAACCAAGCAACGACAAAA 
R: TGGGGAACTCTGCAGACTCAAACT 
IL-6 F: CTGCAAGAGACTTCCATCCAGTT 
R: GAAGTAGGGAAGGCCGTGG 
IP-10 F: GCACGAACTTAACCACCATCTTCC 
R: CTACCCATTGATACATACTTGATGACAC 
Lipin F: AGCGCCAAAGAATAACCTGG 
R: TGAAGACTCGCTGTGAATGG 
LPL F: AGGACCCCTGAAGACAC 
R: GGCACCCAACTCTCATA 
MCP-1 F: TTAAAAACCTGGATCGAACCAA 
R: GCATTAGCTTCAGATTTACGGGT 
MPEG-1 F: GTGAAACAAAAGCCAGACAGAGCCT 
R: TCATGGCGCAGATGGTTTTGGC 
PPAR" F: CGGGAAAGACCAGCAACAAC 
R: TGGCAGCAGTGGAAGAATCG 
PPAR#2 F: ATGGGTGAAACTCTGGGAGATTCT 
R: CTTGGAGCTTCAGGTCATATTTGTA 
Pu.1 F: GATCCGCCTTGATCCCCACCG 
R: TCTCCATCGCTGCCCACGAA 
SAA3 F: TGCCATCATTCTTTGCATCTTGA 
R: CCGTGAACTTCTGAACAGCCT 
aP2 Mm00445878_m1 
ARTD1 Mm01321084_m1 
GLUT4 Mm00436615_m1 
PPAR#2 Mm00440940_m1 
RPS12 Mm00488728_m1 
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ABSTRACT: Inhibiting ADP-ribosyl transferases with PARP-inhibitors is consid-
ered a promising strategy for the treatment of many cancers and ischemia, but most
of the cellular targets are poorly characterized. Here, we describe an inhibitor of
ADP-ribosyltransferase-3/poly(ADP-ribose) polymerase-3 (ARTD3), a regulator of
DNA repair and mitotic progression. In vitro proﬁling against 12 members of the
enzyme family suggests selectivity for ARTD3, and crystal structures illustrate the
molecular basis for inhibitor selectivity. The compound is active in cells, where it
elicits ARTD3-speciﬁc eﬀects at submicromolar concentration. Our results show
that by targeting the nicotinamide binding site, selective inhibition can be achieved
among the closest relatives of the validated clinical target, ADP-ribosyltransferase-1/
poly(ADP-ribose) polymerase-1.
The 17 human ADP-ribosyltransferases with diphtheriatoxin homology (ARTD) catalyze substrate protein ADP-
ribosylation to regulate multiple processes including chromatin
remodeling, transcription, DNA repair, and protein degrada-
tion. Poly(ADP-ribose) polymerase-1 (ARTD1/PARP1) is a
pivotal regulator of DNA base excision repair. As such, it is a
target for cancer and ischemia drug development, as its
inhibition enhances DNA damage during cytotoxic chemo- or
radiotherapy treatment for cancer and reduces ARTD1
overactivation due to ischemia, respectively.1−3 However,
selective inhibitors of individual ARTD family members are
not available, and new inhibitors are generally proﬁled against a
limited subset of ARTD enzymes. This makes evaluation of the
clinical beneﬁts of broad range vs. selective inhibition
impossible. This also hampers research into ADP-ribosylation
dependent signaling mechanisms, where selective inhibitors
would be a valuable complement to genetic methods. Thus,
there is a critical need for selective inhibitors of ADP-
ribosyltransferases, both for probing the functions of individual
ARTD enzymes and for evaluating their potential as therapeutic
targets.
To address this need, we recently proﬁled a focused library of
185 compounds for their ability to bind to the active sites of 13
human ARTDs.4 We found that 3-(4-oxo-3,4-dihydroquinazo-
lin-2-yl)-N-[1-pyridin-2-yl)ethyl]propanamide (STO1131; Fig-
ure 1a) preferentially bound ARTD3/PARP3,5 a family
member that is similar to ARTD1 in the active site6 and also
functions in DNA repair.7−11 To further investigate the
STO1131−ARTD3 interaction and to improve the qualities
of the compound as a selective ARTD3 inhibitor, we performed
diﬀerential scanning ﬂuorimetry during thermal unfolding,
melting temperature (Tm) shift assays. The results conﬁrmed
that STO1131 signiﬁcantly stabilized ARTD3 and that it only
slightly stabilized the closely related homologues ARTD1 and
ARTD2/PARP2 (Figure 1b and Supporting Information Table
1). The individual enantiomers ME0354 and ME0355 of the
racemic STO1131 were prepared (Figure 1c, the Supporting
Information text, and Supporting Information Figures 1 and 2).
ME0354 had a moderate eﬀect (ΔTm 4.8 °C) whereas ME0355
displayed strong thermal stabilization of ARTD3 (ΔTm 9.7 °C;
Table 1). Next, we established an in vitro activity assay in which
histone protein H1.0 modiﬁcation by ARTD3 was measured
(Supporting Information Figure 3) and conﬁrmed that
ME0355 inhibited ARTD3 transferase activity (IC50 1.3 μM)
while ME0354 had only weak inhibitory activity (Table 1).
In order to understand these interactions at a molecular level,
we determined crystal structures of the transferase domain of
ARTD3 in complex with these compounds. When crystals were
grown in presence of the racemic STO1131, only one
enantiomer was found in the active site, namely, ME0355.
Crystallization of ARTD3 in the presence of ME0355 resulted
in an identical structure (Figure 2a and b and Supplementary
Received: March 24, 2013
Accepted: June 6, 2013
Published: June 6, 2013
Letters
pubs.acs.org/acschemicalbiology
© 2013 American Chemical Society 1698 dx.doi.org/10.1021/cb4002014 | ACS Chem. Biol. 2013, 8, 1698−1703
Results 
 62 
 
Table 2). This was consistent with the inability of ME0354 to
stabilize and inhibit ARTD3.
The 4-oxo-dihydroquinazolinyl moiety anchors ME0355 in
the nicotinamide binding cleft of the ARTD3 active site.
Therefore, the anchoring moiety was not modiﬁed in eﬀort to
synthesize close analogs with improved binding aﬃnity and
selectivity. Two analogs, ME0327 and ME0328, which contain
a phenyl group instead of the 2-pyridinyl moiety, were
synthesized (Figure 1c, Supporting Information, and Support-
ing Information Figures 4 and 5). In the histone H1 ADP-
ribosylation assay, ME0327 (ΔTm 6.0 °C, IC50 ∼15 μM),
similar to ME0354, was a weak inhibitor of ARTD3 activity. In
contrast, ME0328 (ΔTm 8.5 °C) inhibited ARTD3 with an IC50
of 0.89 μM (Figure 3a and Table 1), which was a slight
improvement in IC50 over ME0355.
Crystal structures of ARTD3 compound complexes explain
the diﬀerential potencies of the respective enantiomers (Figure
2b and c): whereas the carbonyl oxygens in the linker amides of
ME0328 and ME0355 form water mediated hydrogen bonds
with the Asn387 side chain, the corresponding carbonyl oxygen
in the ARTD3-ME0354 complex (and, thus, the ARTD3-
ME0327 complex) is rotated away from Asn387. The diﬀerent
conformations of the enantiomers also aﬀect the angles
between the distal 2-pyridinyls and phenyls of ME0354/
ME0355 and ME0327/ME0328, respectively, and the hydro-
phobic side chains Leu287, Val288 and Val390 in the α-helical
regulatory domain.
Next, the selectivity of ME0328 for ARTD3 over the closest
ARTD3 homologues was investigated. To obtain a comparable
measure for the potency of ME0328, we established ADP-
ribosyltransferase activity assays for 11 ARTD enzymes. The
results show that ME0328 selectively inhibits ARTD3 (IC50
0.89 μM, Figure 3a), with weaker activity against ARTD1 and
ARTD2 (IC50 6.3 and 10.8 μM, respectively), and no signiﬁcant
activity (IC50 >30 μM) against any other ARTD enzyme for
which we could measure transferase activity (Figure 3b, Table
1, and Supporting Information Table 3).
The crystal structures of ARTD3 and ARTD1, each in
complex with ME0328, illustrate the structural basis for
selective ARTD3 inhibition (Figure 2). In ARTD3, ME0328
is clearly visible in the electron density, stretching from the
nicotinamide anchoring pocket to the amino-terminal end of
the donor loop and making contacts with the α-helical
regulatory domain, similar as ME0355. In contrast, in
ARTD1, density was only observed for the 4-oxo-dihydroqui-
nazolinyl moiety and the remainder of the compound could not
be modeled (Figure 2e); a similar observation was made for the
complex of ARTD1 with ME0355 (results not shown). The
underlying reason is likely the higher polarity of the region as
compared to ARTD3, dominated by the ARTD1 side chains
Asp766, Asn767, and Asn868 near the ME0328 phenyl group.
This is consistent with the lower potency of the compounds as
ARTD1 inhibitors.
Finally, we investigated whether ME0328 could inhibit
ARTD3 in cells. Depletion of ARTD3 by RNA interference
results in a delay of DNA repair, which can be quantiﬁed by
measuring the retention of γH2AX protein containing foci in
cells after induced DNA damage.9,10 The retention of γH2AX
foci in human alveolar basal epithelial (A549) cells was
measured after preincubation for 1 h with ME0328 or
ME0355 (10 μM), followed by γ-irradiation (2 Gy). Both
compounds resulted in a signiﬁcant delay of γH2AX-foci
resolution, showing that both compounds were able to aﬀect
ARTD3 in cells (Figure 3c). In A549 cells a concentration
dependent delay of γH2AX-foci resolution was observed 4 h
after irradiation (Figure 3d). The eﬀects were signiﬁcant, even
at concentrations below 1 μM. γH2AX foci retention upon
ARTD3 inhibitor treatment was also observed in primary
human fetal lung ﬁbroblast (MRC5) cells. Importantly, these
eﬀects were speciﬁc for the two compounds that inhibited
Figure 1. 4-Oxo-3H-quinazolin-2-yl derivatives bind and stabilize a subset of the 17 human PARP-family ADP-ribosyltransferases. (a) Chemical
structure of the racemic compound STO1131, a recently identiﬁed ARTD binder.4 (b) In Tm shift assays, STO1131 strongly stabilized ARTD3, and
displayed weak stabilization of ARTD1 and ARTD2 (see Supporting Information Table 1 for details). N.d., not determined. (c) Chemical structures
of ME0354 and ME0355, the individual enantiomers of STO1131, as well as the two analogs ME0327 and ME0328.
Table 1. Compound Eﬀects on ARTD3/PARP3 Thermal
Stability and Enzymatic Activity In Vitro
ARTD3/PARP3 ARTD1/PARP1
compd. Tm shift (°C)
a IC50 (μM)
b Tm shift (°C)
a IC50 (μM)
b
STO1131 8.5 ± 0.2 6.0 ± 2.2 2.0 ± 0.1 n.d.c
ME0354 4.8 ± 0.2 >100 2.4 ± 0.1 0.9 ± 0.1
ME0355 9.7 ± 0.4 1.3 ± 0.2 2.0 ± 0.2 9.1 ± 2.6
ME0327 6.0 ± 0.5 15.3 ± 10.0 3.1 ± 0.03 1.0 ± 0.1
ME0328 8.5 ± 0.6 0.89 ± 0.28 1.8 ± 0.1 6.3 ± 0.6
aTm shift data: Values represent means ± SD of three independent
experiments bIC50 data: Values represent means ± SE of the ﬁtted
parameter (based on duplicate or triplicate experiments, each using
three replicates). cn.d., not determined.
ACS Chemical Biology Letters
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ARTD3 catalytic activity in vitro; their enantiomers, which lack
ARTD3 inhibitory activity, did not elicit γH2AX-foci retention
(Figure 3e). Thus, ME0327 and ME0354, which diﬀer from
ME0328 and ME0355, respectively, only in the stereochemistry
of a single methyl group, fail to inhibit ARTD3 in biochemical
and cellular assays and can serve as negative controls in the
study of ARTD3 functions.
In silico and in vitro physicochemical and metabolic proﬁling
indicated that ME0328 is soluble, cell permeable, and
metabolically stable in human liver microsomes and rat
hepatocytes (Supporting Information Table 4). Cell prolifer-
ation assays conducted with nonirradiated human A549 and
mouse MRC5 cells cultured in the presence of ME0328 or
ME0355 (10 μM) did not reveal any signs of compound
toxicity after 72 h; similar assays conducted with U2OS, 3T3,
and Hek293T cells cultured in the presence of compounds (50
μM) did not indicate compound toxicity after 96 h. Control
experiments using mouse 3T3 and MRC5 cells showed that
neither ME0328 nor ME0355 (20 μM) aﬀected ARTD1/
PARP1 activity after H2O2-induced DNA damage (Supporting
Information Figure 6). Database searches on similarity and
substructures using ME0328/ME0355 did not yield any hits
that imply oﬀ-target biological eﬀects (Supporting Information
Table 5).
This is the ﬁrst report of a nicotinamide pocket anchored
PARP inhibitor with documented selectivity over a wide range
of ARTD enzyme family members. Recently, selective
inhibition of the tankyrases (ARTD5 and ARTD6) has been
achieved by targeting compounds at the putative binding site
for the NAD+ adenine moiety, a site that is poorly conserved in
other PARP-family members.12 Our results are in support of
development of selective PARP inhibitors using nicotinamide
mimetics, possibly based on existing compounds.
In summary, we describe a cell-permeable, selective inhibitor
of ARTD3/PARP3; this compound inhibits ARTD3 ADP-
ribosyltransferase activity and displays >7-fold selectivity over
ARTD1 and its nearest homologues. The cellular eﬀects of
ME0328 are likely to be ARTD3 speciﬁc based on several
Figure 2. Structural basis of ARTD3 inhibition by ME0328 and related compounds. (a) Overview of ARTD3 in the ARTD3−ME0355 crystal
complex (PDB entry 4GV0). The α-helical regulatory domain (αreg) is shown in a darker shade. The donor loop is shown in pink, and the bound
inhibitor is shown in orange. The Tyr425 side chain is shown for orientation. (b) Close-up of the active site in the ARTD3−ME0355 complex.
Notable interactions outside the nicotinamide pocket are the hydrogen bond with the Asn387 side chain mediated by water (hydrogen bonding
distances indicated in Ångstrom), and hydrophobic interactions with side chains in the α-helical regulatory domain. (c) In the ARTD3−ME0354
complex (4GV2), the weak inhibitor does not form a hydrogen bond with Asn387. (d) Crystal structure, at 1.80 Å resolution, of ARTD3 in complex
with ME0328 (4GV4). The quinazolinyl moiety anchors the compound in the nicotinamide binding pocket, while the elongated tail of the
compound makes extensive interactions with side chains lining the active site. The electron density for the ligand, rendered at 1.5 σ, is indicated as
mesh. In ARTD3−ME0328, the conformation of the inhibitor is similar to that of ME0355 (panel b), but the proximity of a phenyl (as compared to
2-pyridinyl) to the hydrophobic environment around Val288 might explain its slightly higher potency over ME0355. (e) Superposition of the
ARTD3−ME0328 complex (chocolate; compound in gray) with the ARTD1−ME0328 complex (cyan; compound in cyan; 4GV7) to illustrate the
overall structural conservation in the active sites and the diﬀerent environments (hydrophobic in ARTD3 vs polar in ARTD1) contributed by side
chains in the α-helical regulatory domain. Side chain labels and hydrogen bonding distances in this panel refer to ARTD3. (f) In the ARTD1−
ME0328 complex, only partial electron density was observed for the ligand (shown as mesh, rendered at 1 σ), consistent with low potency of
ME0328 against ARTD1. A section of the donor loop was omitted for clarity.
ACS Chemical Biology Letters
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observations: (i) Neither ME0328 nor ME0355 inhibited
ARTD1 (Supporting Information Figure 6). (ii) The
enantiomers ME0327 and ME0354, which inhibit ARTD1
but not ARTD3 (Table 1), did not elicit γH2AX-foci retention
in cells after γ-irradiation (Figure 3). (iii) Depletion of ARTD1
by RNA interference did not result in a delay of γH2AX foci
resolution after DNA damage.9 Given these results, we expect
that ME0328 will be useful for research into the speciﬁc
functions of ARTD3 vis-a-̀vis ARTD1 and ARTD2, which is
important for understanding the cellular functions of ADP-
ribosylation, the basic mechanisms of DNA repair, and, in the
long term, PARP-inhibitor based therapeutics development.
■ METHODS
Molecular Cloning, Protein Expression, and Protein Puriﬁ-
cation. Molecular cloning and protein production was carried out as
described before.4 Brieﬂy, the sequences encoding residues
ARTD1654−1013, ARTD2186−530, full-length ARTD3, ARTD3178−532,
ARTD4241−600, ARTD51017−1325, ARTD6952−1166, ARTD7459−656,
ARTD81611−1810, ARTD12480−688, ARTD151−274, and full-length
histone H1.0 were inserted into pNIC28-Bsa4, and ARTD10809−1017
was inserted into pNIC28-CH, by ligation independent cloning.13
Proteins were puriﬁed by immobilized metal aﬃnity followed by size
exclusion chromatography, concentrated by ultraﬁltration, ﬂash frozen
in aliquots, and stored at −80 °C. Protein masses were veriﬁed by
time-of-ﬂight mass spectrometry. Full-length ARTD1 (cat. no. 11040-
H08B) was purchased from Sino Biological Inc.
Biophysical and Enzymatic Assays. Tm-shift assays of
compound stabilization of ARTD catalytic domain fragments was
carried out by diﬀerential scanning ﬂuorimetry as described.4 Reported
values represent means ± SD of two to ﬁve independent experiments.
Protein ADP-ribosylation was measured using hexahistidine-tagged
ARTD proteins and recombinant histone proteins captured on 96-well
Ni2+-chelating plates (5-PRIME).14,15 ADP-ribosylation reactions were
initiated by addition of NAD+ (2% biotinylated; Nordic BioSite), and
modiﬁed reaction products were detected by chemiluminescence. Km
values were estimated using plots of initial rates vs. NAD+
concentrations and linear curve ﬁtting with GraphPad Prism
(GraphPad Software). All compounds were dissolved in dimethyl
sulfoxide (DMSO) to a stock concentration of 50 mM. Experiments to
determine IC50 values were conducted with compound concentrations
in the range between 10 nM and 450 μM with a DMSO concentration
of 1% (v/v). Measurements were carried out at an NAD+
concentration below Km for each transferase. IC50 values were
estimated using curve ﬁtting with GraphPad Prism. Reported values
represent means ± SE of the ﬁts of the curves based on duplicate or
triplicate experiments, each determined based on three replicates.
Protein Crystallization. Crystals of the ARTD3 complexes with
compounds ME0328, ME0354, and ME0355 were obtained by the
sitting drop vapor diﬀusion method in 96-well plates (Corning) by
mixing 2 μL of protein (12 mg mL−1) including 1−2 mM compound
dissolved in dimethyl sulfoxide (DMSO) and 0.7 μL of reservoir
solution containing 1.7−2.0 M DL-malic acid, 0.1 M bis-tris-propane
pH 7.0, and 0.3 μL of crystal seed solution. The crystal seed solution
Figure 3. ME0328 is a potent and selective inhibitor of ARTD3/
PARP3 that is active in cells. (a) In in vitro histone H1 modiﬁcation
assay, ME0328 inhibits the transferase activity of ARTD3 with an IC50
of 0.89 ± 0.28 μM. (b) In vitro IC50-values for ME0328 against 11
human PARP-family ADP-ribose transferases illustrated as circles in
the dendrogram, as indicated (see Supporting Information Table 3 for
details). (c) In human A549 cells, ME0328 and ME0355 (at 10 μM)
delay the resolution of γH2AX-containing foci that serve as markers
for DNA double strand break repair following γ-irradiation (2 Gy).
These compounds cause eﬀects similar to those of ARTD3 depletion
Figure 3. continued
by RNA interference.9,10 (d) Treatment of A549 cells with ME0238 at
varying concentrations resulted in a concentration dependent
retention of γH2AX-containing foci. (e) After γ-irradiation, foci
retention could be observed only in response to treatment with
ME0328 or ME0355, but not with their respective enantiomers
ME0327 and ME0354, which also did not inhibit ARTD3 enzymatic
activity in vitro. Data from two (panel c) and three biological replicates
(panels d and e) were analyzed, and statistical signiﬁcance was
evaluated using a two-tailed t-test (*p < 0.01; **p < 0.001) using
DMSO treatment as control.
ACS Chemical Biology Letters
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was prepared by crushing needle crystals of ARTD3 and mixing with
reservoir solution. The plates were incubated at 20 °C and crystals
appeared within a few days. After two weeks, crystals were brieﬂy
transferred to a cryo solution consisting of 1.7−2.0 M DL-malic acid,
0.1 M bis-tris-propane pH 7.0, 20−25% (w/v) glycerol, 0.2 M sodium
chloride, and 1−2 mM compound and then cooled in liquid nitrogen.
Crystals of the ARTD1−ME0328 complex were obtained by the
sitting-drop vapor diﬀusion method in 96-well plates (Corning) by
mixing 0.3 μL of protein at a concentration of 50 mg mL−1 including 1
mM compound dissolved in dimethyl sulfoxide (DMSO) and 0.4 μL
of reservoir solution containing 20% PEG3350, 0.2 M potassium
thiocyanate, 0.1 M bis-tris-propane pH 7.5. The plates were incubated
at 4 °C, and crystals appeared after 1 day. The crystals were brieﬂy
transferred to a cryo solution consisting of 20% PEG3350, 0.2 M
potassium thiocyanate, 0.1 M bis-tris-propane pH 7.5, 20% glycerol,
0.2 M sodium chloride, 1.2 mM ME0328, then cooled in liquid
nitrogen.
Diﬀraction Data Collection, Processing and Reﬁnement.
Diﬀraction data were collected on cryo-cooled crystals at the
synchroton beamlines I04 at Diamond Light Source (Didcot, United
Kingdom), ID14.4 at ESRF (Grenoble, France), and BL14.1 at BESSY
(Berlin, Germany). Data were indexed and integrated using the XDS
package16 or the AutoProc toolbox.17 Model building was done with
Coot18 and reﬁnement with Refmac519 (ARTD3) or Buster20
(ARTD1). The reﬁnement progress was monitored by decreasing R
and Rfree values.
Cellular Assay of γH2AX-Foci Resolution. Prior to experiments,
compound cytotoxicity in A549 and MRC5 cells was evaluated using
WST-1 assays (Roche Bioscience). A549 cells were cultured in
Dulbecco’s Modiﬁed Eagle’s Medium supplemented with 10% fetal
calf serum (FCS), penicillin, and streptomycin. MRC5 cells were
cultured in Minimal Essential Medium supplemented with 10% FCS,
penicillin, streptomycin, and L-glutamine. Both cell lines were
maintained in a humidiﬁed incubator at 37 °C and 5% CO2.
Irradiation was done using a Pantak Seifert X-ray system operating at
120 kV and 19 mA at a dose rate of 3.11 Gy/min (total of 2 Gy).
Olaparib (AstraZeneca), ME0327, ME0328, ME0354, and ME0355
were dissolved in DMSO at a stock concentration of 10 mM.
Compounds were added 1 h prior to irradiation and maintained for
the duration of the experiment. Cells were ﬁxed in ice-cold methanol
and blocked in PBS buﬀer containing 10% bovine serum albumin.
Cells were subsequently treated with an antibody against γH2AX
(Millipore 05-636) and analyzed using a Leica DMI 6000B
microscope. Foci were quantiﬁed using Imaris software (Bitplane)
7.4.0. All values are represented as means ± s.e.m. Two tailed
Student’s t-tests were performed using GraphPad Prism.
Synthetic Strategy. The synthetic route to compounds ME0327,
ME0328, ME0354, and ME0355 and analytical data (NMR spectros-
copy, HRMS, optical rotation measurements, and chiral HPLC) are
presented in the Supporting Information.
■ ASSOCIATED CONTENT
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Tables and ﬁgures describing crystallographic data, additional
selectivity proﬁling, cellular compound eﬀects, physicochemical
stability proﬁling, results of similarity searches, proof of
compound purity, additional materials and methods (chemical
procedures). This material is available free of charge via the
Internet at http://pubs.acs.org.
Accession Codes
The atomic coordinates and structure factors of ARTD3 in
complex with inhibitors have been deposited in the Protein
Data Bank with accession codes 4GV4 (ARTD3-ME0328),
4GV2 (ARTD3-ME0354), and 4GV0 (ARTD3-ME0355). The
crystal structure of ARTD1 in complex with ME0328 has been
deposited with accession code 4GV7.
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Supplementary Figure 6. ME0328 and ME0355 have no effect on ARTD1/PARP1 activity in 
cells after H2O2-induced DNA damage.  MRC5 or 3T3 cells were pretreated for 1 hour with 
either Olaparib or ME0328 or ME0355 ȝ0prior to H2O2 treatment (1 mM for 10 minutes). 
Cells were fixed (methanol/acetic acid) and stained with anti-PAR 10H antibody followed by 
Cy3-coupled anti-mouse antibody. Cells were co-stained with DAPI to visualize nuclei. 
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Abstract 
Adipogenesis is accompanied by a dynamic modulation of the chromatin landscape 
induced by the transcription factor PPARγ. Binding of a ligand to PPARγ induces the 
exchange of co-repressors with co-activators. How PPARγ-dependent gene 
expression is maintained remains elusive, since ligands are stored in vacuoles 
throughout adipogenesis. ADP-ribosyltransferase D-type 1 (ARTD1; PARP1) is a 
chromatin-associated enzyme that synthesizes poly-ADP-ribose (PAR). Here, we 
show that on a high-fed diet, a pan-PARP inhibitor reduces white adipose tissue and 
cell size in mice. PARP inhibition also hampered PPARγ-dependent gene expression 
in vitro, whereas inhibition of PAR degradation stimulated gene expression. ChIP 
experiments confirmed that ARTD1 and PPARγ are both recruited to PPARγ target 
genes in a PAR-dependent manner. PPARγ ligand enhanced the PPARγ/ARTD1 
interaction and induced ARTD1-dependent PAR formation, which was important for 
the co-repressor NCoR/co-activator p300 exchange at PPARγ target genes. Our study 
shows that ARTD1 promotes adipogenesis by fascilitating ligand-induced PPARγ co-
factor exchange. 
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Introduction 
Adipocyte formation relies on the adipogenic differentiation of multipotent 
mesenchymal stromal cells (MSCs), resulting in lipid-laden cells which have the 
capacity to influence numerous biological processes, including signaling and immune 
functions (Church et al., 2012). The underlying mechanism of adipogenesis is a broad 
reorganization of the transcriptional landscape due to large-scale chromatin changes 
(Siersbaek et al., 2011). Instrumental in this step-wise reorganization is the 
transcription factor peroxisome proliferator-activated receptor gamma (PPARγ) 
(Heikkinen et al., 2007; Tontonoz and Spiegelman, 2008) and in particular the 
adipocyte-specific isoform PPARγ2 (Fajas et al., 1997; Vidal-Puig et al., 1996).  
PPARγ is a nuclear receptor of the PPAR family, which functions as an obligate 
heterodimer with RXRs (Chawla et al., 2001; Escher et al., 2001; Kliewer et al., 1992; 
Siersbaek et al., 2010). Like many nuclear receptors, PPARγ contains a N-terminal, 
non-conserved A/B domain, a DNA-binding domain (DBD), and the C-terminal 
ligand-binding domain (LBD). The C-terminal domain is required for the hetero-
dimerization with RXRs, ligand-binding is conveyed by the LBD, which harbors 
multiple hydrophobic residues and is important for ligand-dependent interactions with 
cofactors (Gampe et al., 2000; Kallenberger et al., 2003). Binding of a ligand to 
PPARγ triggers a conformational switch that exposes a surface that can interact with 
LXXLL-containing co-activators. Prior to the activation of PPARγ by its ligands, 
PPARγ is bound to co-repressors that suppress transcription of target genes and are 
dislodged upon ligand binding (Yu et al., 2005). PPARγ is induced during the 
differentiation of adipocytes and is highly expressed in white and brown adipose 
tissue (WAT/BAT) (Tontonoz et al., 1994). A series of transcription factors, in 
particular CCAAT/enhancer-binding proteins β and δ (C/EBP-β and C/EBP-δ, 
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respectively), establish transcription factor hotspots and regulate PPARγ2 as well as 
C/EBP-α (Siersbaek et al., 2011; Tontonoz and Spiegelman, 2008). Together with 
C/EBP-α, PPARγ2 determines adipocyte function and transcriptionally co-regulates 
target genes such as adipocyte protein 2 (aP2), cluster of differentiation 36 (CD36) 
and Adiponectin (Lefterova et al., 2008; Rosen et al., 2002; Saladin et al., 1999). In 
previously published work, we have shown that the regulation of PPARγ2-dependent 
gene expression and adipocyte function depends on the formation of poly-ADP-ribose 
(PAR) (Erener et al., 2012a; Erener et al., 2012b). The activity of ARTD1, the best-
studied ADP-ribosyltransferase so far, is strongly activated during adipogenesis and is 
absolutely required for adipogenesis (Erener et al., 2012a). Furthermore, PAR 
formation increases the recruitment of ARTD1 to PPARγ2 target gene promoters. 
However, the molecular mechanism that leads to PAR-dependent regulation of 
PPARγ2 target gene expression remains unknown. 
PAR is synthesized by proteins belonging to the family of ADP-ribosyltransferases 
(ARTs), which transfer the ADP-ribose moiety of nicotinamide dinucleotide (NAD+) 
to acceptor proteins. This reaction leads to either mono- or poly-ADP-ribosylation of 
specific residues in the acceptor protein. The family of ADP-ribosyltransferase 
Diphteria toxin like proteins (ARTD) is currently comprised of eighteen human 
members (ARTD1-18, of which ARTD1 represents the initially characterized PARP 
protein) that all function in different cellular compartments and are structurally 
similar to the bacterial Diphteria toxin (Hottiger et al., 2010). The most abundant and 
best-studied member is the chromatin-associated ARTD1 (PARP1), which has been 
implicated in a plethora of important cellular and biological processes. Thus, ARTD1-
dependent poly-ADP-ribosylation has been implicated in the regulation of chromatin 
compaction, the recruitment of proteins to chromatin, the regulation of enzymatic 
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activities and was described to be involved in biological processes such as stress 
signaling, cell death, inflammation, as well as differentiation (Hassa and Hottiger, 
2008). Furthermore, defects in ADP-ribosylation or in function of ARTs have been 
linked to diseases such as chronic inflammation, neurodegenerative disorders, 
cardiovascular diseases and cancer (Graziani and Szabo, 2005). In this report we aim 
to elucidate the molecular function of ARTD1 and of poly-ADP-ribosylation during 
adipogenesis and in particular, in the regulation of PPARγ2. 
The results presented here indicate that PPARγ-dependent gene expression during 
adipogenesis in vitro and in vivo depends on PAR formation. According to our 
findings, this regulatory function of poly-ADP-ribosylation is brought about by 
complex formation between ARTD1 and PPARγ at the promoter regions of target 
genes and involves the exchange of transcriptional co-repressors such as NCoR with 
activators such as p300. The lack of co-factor exchange in the presence of PARP 
inhibitors could be overcome by treating the cells with an excess of PPARγ ligand. In 
summary, our work elucidates the molecular mechanism by which ADP-ribosylation 
promotes adipogenesis.   
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Results 
PARP inhibitor treatment reduces body weight, white adipose tissue content and 
cell size in mice fed with high fat diet 
Earlier studies have implicated ADP-ribosylation and in particular ARTD1 in 
adipogenesis and adipocyte function (Bai and Canto, 2012; Bai et al., 2007; Erener et 
al., 2012a; Erener et al., 2012b). Based on these results, we hypothesized that the 
inhibition of poly-ADP-ribosylation may have beneficial effects on the onset and 
development of obesity. In order to test this hypothesis, we treated male chow and 
HFD-fed C57BL/6J (WT) mice with for 18 weeks with a pan-PARP inhibitor. To 
confirm that PARP inhibitor treatment reduced PAR formation, we measured total 
ARTD activity in adipose tissue. As expected, total ARTD activity was significantly 
reduced by 35% in mice treated with PARP inhibitor (Figure S1A). Overall, vehicle-
treated mice on the HFD presented with significant higher bodyweight compared to 
equivalently fed PARP inhibitor-treated animals (Figure 1A, B), although their food 
intake was equal (Figure S1B). In addition, HFD caused a marked increase in the 
amount of subcutaneous (Sc) fat, while only minor increases were observed in the 
epididymal (Epi), perirenal (Peri) white adipose tissue (WAT), and the brown adipose 
tissue (BAT) (Figure 1C, D). However, the increase in HFD-mediated ScWAT 
observed in PARP inhibitor-treated mice was found to be significantly lower as 
compared to vehicle-treated mice, while no significant differences were seen between 
EpiWAT, PeriWAT or BAT (Figure 1D). In order to test if this PARP inhibitor effect 
on WAT also manifested itself in the epiWAT adipocyte morphology, as it observed 
in ARTD1-/- mice (Erener et al., 2012b), epiWAT was isolated, fixed, stained and 
subjected to quantitative microscopic analysis. Adipocytes from PARP inhibitor-
treated mice were significantly smaller than corresponding cells from WAT of the 
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vehicle-treated control animals (Figure 1E). To test if the smaller adipocyte size 
correlated with adipogenic gene expression, a quantitative RT-PCR analysis was 
performed. In agreement with earlier studies (Erener et al., 2012b) and the reduced 
bodyweight gain as well as the reduced expansion of the Sc fat pad after HFD and 
PARP inhibitor treatment (Figure 1A-E), the expression of the key adipogenesis 
regulator PPARγ2 was significantly reduced (Figure 1F). The expression of other 
adipogenic markers including aP2, CD36 and Adiponectin were also found to be 
down-regulated in WAT from PARP inhibitor-treated mice, although statistical 
significance was not reached (Figure S1C). 
In summary, these results show that HFD-induced hypertrophy and obesity in mice is 
dependent on ADP-ribosylation. 
  
PAR formation is required for PPARγ-dependent gene expression 
In order to study the mechanistic details of how ADP-ribosylation impacts on 
adipogenesis (Erener et al., 2012a), we characterized adipocyte differentiation in 3T3-
L1 pre-adipocyte cultures in the presence or absence of different inhibitors. 
Adipogenesis was induced in 3T3-L1 cells following the addition of insulin, 3-
isobutyl-1-methylxanthine (IBMX) and dexamethasone (Ntambi and Young-Cheul, 
2000), upon which they consistently formed lipid-laden adipocytes (Figure 2A).  
In line with our earlier studies (Erener et al., 2012a), where we used PJ34 as PARP 
inhibitor, the presence of the more specific PARP inhibitor ABT888 during the first 
seven days of adipogenesis strongly affected the expression of PPARγ2 itself and its 
target genes aP2, CD36 and Adiponectin (Figure 2B, S2A). The effect of PARP 
inhibitors on PPARγ2 itself can be explained by previous results (Erener et al., 
2012a), which showed that PARP inhibition does not inhibit initial PPARγ2 
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expression but rather inhibits the regulatory feedback loop of C/EBPα and PPARγ 
expression (Saladin et al., 1999). To confirm that the effect of PARP inhibitors was 
indeed due to the lack of PAR, we also performed the reverse experiment by 
inhibiting PAR degradation with the PARG inhibitor RBPI-3, which enhanced PAR 
formation (Figure S2B). In agreement with the hypothesis, RBPI-3 caused a 
significant increase in the transcription of PPARγ2, aP2, CD36 or Adiponectin 
(Figure 2C). Similarly, the inhibition of nicotinamide phosphoribosyl transferase 
(NAMPT) by FK866, which decreases cellular NAD+ levels and thus interferes with 
PAR formation, strongly reduced PPARγ-dependent gene expression and PPARγ 
protein levels (Figures S2C, S2D). Finally, mouse embryonic fibroblasts (MEFs) 
lacking ARTD1 exhibited significantly reduced PAR formation and reduced PPARγ-
dependent gene expression (Figures S2E, S2F). To exclude potential effects on early 
differentiation events (e.g., mitotic clonal expansion), we also treated 3T3-L1 cells 
with PARP inhibitor only during late stages of adipocyte differentiation, from day 7 
to day 21. As expected, the PARP inhibitor significantly reduced expression of the 
PPARγ-dependent genes aP2, CD36 and Adiponectin (Figure 2D). Based on these 
findings, we conclude that PAR formation is required for the expression of PPARγ 
and PPARγ-dependent genes during the differentiation of 3T3-L1 cells to functional, 
lipid-laden adipocytes.  
 
The ligand-dependent interaction between PPARγ and ARTD1 at target genes 
induces PAR 
ARTD1 is the main intracellular ADP-ribosyltransferase and generally responsible for 
about 90% of the cellular PAR formation under normal conditions (Shieh et al., 
1998). The stimulation of PPARγ-dependent gene expression upon PARG inhibitor 
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treatment thus hints at a role for ARTD1 and PAR in regulating the promoter activity 
of PPARγ target genes. We first assessed the interaction of ARTD1 with PPARγ by 
immunoprecipitation (IP) experiments of PPARγ from nuclear extracts of 3T3-L1 
cells on day 7 of differentiation. The results show that PARylated ARTD1 was co-
precipitated using an anti-PPARγ antibody (Figure 3A). Chromatin-IP (ChIP) 
experiments with anti-ARTD1 antibodies confirmed the PAR-dependent recruitment 
of ARTD1 at the PPREs of PPARγ-dependent genes (Figure S3A). To further 
confirm this interaction and to analyze whether ARTD1 and PPARγ interact at the 
promoter region of the respective target genes, re-ChIP experiments were performed. 
Chromatin taken from 3T3-L1 cells 7 days after differentiation induction was first 
precipitated with an anti-ARTD1 antibody and then with an anti-PPARγ antibody, 
and the presence of aP2 and CD36 promoter sequences, corresponding to the PPARγ 
response elements (PPREs), were subsequently analyzed by quantitative real-time 
PCR (qRT-PCR). Both, aP2 and CD36 PPREs were enriched by the re-ChIP 
treatment (Figure 3B). In contrast, the negative control gene keratin 19 (K19) was not 
enriched. These results indicate a direct interaction of ARTD1 with PPARγ at the 
PPREs of at least a subset of PPARγ target genes.  
Nuclear receptors such as PPARs are activated and undergo a conformational switch 
upon ligand binding (Gampe et al., 2000; Gelman et al., 1999; Kallenberger et al., 
2003). It was thus hypothesized that the PPARγ ligand may be involved in the 
ARTD1-dependent regulation of PPARγ itself and thereby affects the interaction 
between these two proteins. We therefore performed ChIP experiments with lysates 
from Rosiglitazone pre-treated 3T3-L1 cells at day 7 days of differentiation. In 
Rosiglitazone pre-treated cells, ARTD1 was more tightly associated with the PPREs 
of the PPARγ-dependent genes aP2, CD36 and Adiponectin (Figure 3C) compared to 
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cells that were not treated with Rosiglitazone, suggesting a ligand-induced interaction 
of ARTD1 with PPARγ at the PPREs of these genes. Similarly, ChIP of PAR with the 
10H anti-PAR antibody revealed the association of PAR with the PPREs of PPARγ 
target genes (Figure S3B). To further confirm the interaction between ARTD1 and 
PPARγ in the presence of the PPARγ ligand Rosiglitazone, pull-down experiments 
with recombinant, GST-tagged PPARγ2 and recombinant ARTD1 were performed in 
the presence or absence of Rosiglitazone. The presence of Rosiglitazone enhanced the 
affinity of ARTD1 for PPARγ2 (Figure 3D). Interestingly, Rosiglitazone treatment 
not only stimulated ARTD1-PPARγ2 interaction, but also enhanced PAR formation 
in 3T3-L1 cells at day 7 of differentiation (Figure 3E). In contrast, HEK 293T cells, 
which do not express PPARγ, only showed weak PAR formation that was not 
stimulated by Rosiglitazone (Figure S3C), suggesting that the presence of PPARγ is 
required for PAR formation induced by Rosiglitazone.  
Since we have recently shown, that PAR formation during adipogenesis depends on 
topoisomerase II (TopoII) (Erener et al., 2012a), we also tested whether 
Rosiglitazone-induced PAR formation depended on TopoII. Indeed, the TopoII 
inhibitor Merbarone effectively attenuated Rosiglitazone-induced PAR formation 
(Figure 3F) and ChIP experiments revealed the enrichment of TopoII at the PPREs of 
the PPARγ-dependent genes aP2 and CD36, while no significant enrichment at the 
control gene K19 was observed (Figure 3G). Finally, the co-localization of TopoII 
and ARTD1 in 3T3-L1 cells (day 7 of adipogenesis) was confirmed by 
immunofluorescence confocal microscopy (Figure 3H). 
In summary, these experiments suggest that ARTD1 and PPARγ interact at the 
PPREs of target genes in a ligand-dependent manner, which leads to TopoII-
dependent PAR formation at PPARγ-dependent genes. 
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H2O2-induced PAR formation causes upregulation of PPARγ-dependent gene 
expression 
So far, our results have shown that PPARγ ligand Rosiglitazone favours the 
interaction of ARTD1 with PPARγ at the PPREs of target genes and leads to PAR 
formation during adipogenesis. We therefore tested if PAR formation could induce 
markers of adipogenesis independent of Rosiglitazone and the classical differentiation 
protocol. PPARγ and HA-tagged ARTD1 were overexpressed in HEK293T cells and 
H2O2 treatment was used to induce PAR formation (data not shown). An IP with anti-
HA antibody precipitated PPARγ2, but only if the cells were treated with H2O2 
(Figure 4A). Similarly, IP of PPARγ2 precipitated poly-ADP-ribosylated ARTD1 
only when PPARγ2-overexpressing HEK293T cells had been exposed to H2O2 
(Figure 4B). This result confirms that the induction of PAR formation alone is 
sufficient to stabilize the interaction between ARTD1 and PPARγ. Next, we tested if 
H2O2 also induces adipogenic gene expression in undifferentiated 3T3-L1 cells that 
overexpress PPARγ2. For these experiments, PPARγ-dependent gene expression was 
assessed with a reporter construct following exposure to H2O2, and other additional 
experimental conditions (PARP inhibition, overexpression of wild-type (WT) 
ARTD1, two enzymatic inactive ARTD1 mutants, or PARG inhibition). 
Rosiglitazone treatment induced PPARγ-dependent gene expression confirming that 
this reporter construct permits the detection of PPARγ-dependent gene expression in 
these cells and under these experimental conditions (Figure S4A). H2O2 treatment led 
to increased Luciferase activity, which was comparable to the effect induced by 
Rosiglitazone (Figure 4C, S4A). Co-treatment with the PARP inhibitor abolished this 
stimulation, indicating that ADP-ribose polymers are indeed responsible for the 
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observed effect. Since overexpression of WT ARTD1 strongly enhanced the RLU 
Firefly/Renilla signal, while neither the E988K nor the Y907A C908Y enzymatically 
inactive mutant conferred this effect, PPARγ-dependent gene expression was 
mediated by ARTD1-dependent PAR formation under these experimental conditions 
(Figure 4D). Co-treating the cells with PARG inhibitor increased the response to 
H2O2 as compared to an inactive control substance (Figure 4E). A similar result was 
observed in HEK 293T cells overexpressing PPARγ and either one of the ARTD1 
mutants (Figure S4B).  
 
Excess of PPARγ ligand functionally replaces PAR 
To confirm the results obtained with the Luciferase reporter assay, the effect of PAR 
formation on PPARγ-dependent gene expression was studied in the 3T3-L1 cells. At 
day 3 of differentiation we treated cells with H2O2, in the presence or absence of 
PARP inhibitor. Two hours after treatment with H2O2, which coincides with PAR 
formation, the expression of aP2, CD36 and Adiponectin was analyzed by qRT-PCR. 
H2O2 treatment led to increased expression of Adiponectin (AdipoQ) in PPARγ-
overexpressing 3T3-L1 cells, which was inhibited by PARP inhibitor (Figure 4F). Not 
all PPARγ target genes (e.g aP2) were induced upon H2O2 stimulation (Figure 4F). 
These results thus demonstrate that the induction of PAR formation by H2O2 alone is 
sufficient to activate the expression of at least a subset of PPARγ-dependent genes. 
Finally, we assessed whether the PPARγ ligand Rosiglitazone could functionally 
replace PAR. We therefore treated differentiating 3T3-L1 cells with PARP inhibitor 
and supplemented with an excess of Rosiglitazone to compensate for the lack of PAR. 
Indeed, the Rosiglitazone excess compensated for the effect of PARP inhibitor 
treatment and robustly induced the expression of aP2, CD36, Adiponectin and 
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PPARγ2 (Figure 4G). As expected, Rosiglitazone induced the expression of all 
PPARγ-target genes whereas the activation of ARTD1 as shown in Figure 4F was 
more selective and only induced the expression of a subset of genes. 
In summary, these experiments show that PAR formation is able to induce PPARγ-
dependent gene expression independent of the presence of PPARγ ligands.  
 
PAR formation controls PPARγ-dependent gene expression by facilitating ligand 
induced co-factor exchange 
The function of DNA-binding transcription factors is regulated by the dynamic 
exchange of co-activator and co-repressor complexes at the promoters of the target 
genes (Rosenfeld et al., 2006). Two of the most important regulators of PPARγ 
functions are the co-activator complex p300 and the nuclear receptor co-repressor 
1(NCoR-1) (Lee et al., 2001). We therefore analyzed if these co-factors also interact 
with ARTD1 and PPARγ in the presence of PPARγ ligands. 
GST pull-down experiments with ARTD1, p300 and PPARγ revealed complex 
formation in the presence of Rosiglitazone, which was further increased in the 
presence of ADP-ribosylated ARTD1 (Figure 5A). This result suggests a direct 
interaction of the PPARγ co-activator p300 with ARTD1 and PPARγ. Next, we tested 
if H2O2-stimulated PAR formation could also induce this complex formation in 
HEK293T cells. PPARγ, ARTD1 and p300 were overexpressed in H2O2-stimulated 
HEK293T cells, and nuclear extracts were prepared. IP of p300 co-precipitated 
ARTD1 and PPARγ, and in both cases, more protein was co-precipitated in the H2O2-
treated samples (Figure 5B). Furthermore, we analyzed if the localization of p300 co-
activator to the PPARγ-dependent genes was dependent on PAR formation. In 3T3-
L1 cells differentiated for 7 days, the binding of p300 to the PRRE of aP2 and 
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Adiponectin was significantly reduced upon PARP inhibitor treatment (Figure 5C). 
This suggests that the reduction of p300  at the PPRE translates into reduced 
expression of the corresponding gene. The PPARγ-dependent gene CD36 showed the 
same trend. Importantly, p300 was not enriched at the PRRE of the PPARγ-
independent control gene K19. Interestingly, and in agreement with the respective co-
activator and -repressor functions, occupancy of the co-repressor NCoR-1 exhibited 
the opposite behavior and was increased at the PRREs of PPARγ-dependent genes 
upon PARP inhibiton (Figure 5D). A similar result was obtained with cells that were 
treated with PARP inhibitor from day 5 to 8 of differentiation (Figure S5A). These 
findings thus confirm that maintainance of PAR formation is a regulatory requirement 
for PPARγ-dependent gene expression throughout the differentiation process.  
Our findings thus provide evidence that inhibitoion of PARP at the latter stages of 
adipogenesis allows PPARγ recruitment to its target genes, but that the co-recruitment 
of the NCoR-1 repressor inhibits the expression of the target genes. In contrast, the 
presence of PAR favours the recruitment of p300 and subsequently allows 
progressive PPARγ-dependent gene expression. Taken together, our findings indicate 
that PAR formation favours co-activator recruitment and enhances transcription from 
the promoter of specific genes during adipogenesis.  
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Discussion  
Adipogenesis is driven by changes in gene transcription, being reliant on the 
reprogramming of the cellular transcription profiles through the activation of specific 
transcription factors (Rosen et al., 2000). Transcription factors that determine the 
early phase of adipogenesis such as Stat5a, C/EBP-β, and C/EBP-δ, are also 
responsible for mediating PPARγ activity (Siersbaek et al., 2011). C/EBP-β is 
required for the establishment of so-called transcription factor ‘hotspots’, but not 
sufficient for the maintenance of PPARγ-dependent gene expression. The activation 
of transcription not only depends on the presence of the correct transcription factor, 
but also on a permissive chromatin structure (Siersbaek et al., 2011). Transcriptional 
cofactors regulate chromatin compaction and recruit elements of the transcription 
machinery. During the course of adipogenesis, co-repressors, which maintain a 
condensed and closed chromatin state, are replaced by co-activators, which induce 
relaxation of the chromatin, thereby rendering the DNA accessible to transcription 
factors (Rosen et al., 2000; Siersbaek et al., 2011).  
We have previously shown that ADP-ribosylation, and in particular that mediated 
by ARTD1, plays an important role in adipogenesis and adipocyte function (Erener et 
al., 2012a; Erener et al., 2012b). We have shown that ARTD1 activity is required for 
normal differentiation of 3T3-L1 cells and is likely dependent on the formation of 
transient, site-specific double strand DNA breaks at promoters of PPARγ-dependent 
genes (Erener et al., 2012a). These findings were further corrobated by in vivo studies 
showing that the presence of ARTD1 permits efficient adipogenesis, whereas lack of 
ARTD1 limits adipocyte function, adipocyte size, and lipid metabolism in the liver 
(Erener et al., 2012b). Although these studies have established a role for ARTD1 in 
adipogenesis and adipocyte turnover, the molecular mechanism by which ARTD1 or 
Results 
 86 
of ADP-ribosylation in general co-regulate these processes have not yet been 
described.  
In the work presented here, we build up on these earlier studies and show that ADP-
ribosylation is an important mediator of WAT formation and PPARγ2 expression in 
mice subjected to HFD. Furthermore, our work demonstrates that PAR formation also 
influences adipogenic gene expression in cell culture and that ARTD1 and PPARγ 
interact at the promoters of PPARγ target genes, including aP2 and CD36, in a PAR-
dependent manner. Most importantly, PAR formation was necessary to induce an 
exchange of the NCoR1 co-repressor with the p300 co-activator at PPARγ target gene 
promoters. Treating cells with an excess of PPARγ ligand could overcome the lack of 
co-factor exchange in the presence of PARP inhibitors. This study thus defines PAR-
induced co-factor exchange in the later phase of adipogenesis as the mechanism by 
which PAR formation regulates and maintains PPARγ2-dependent gene expression. 
Our own in vitro results (data not shown) indicate that this regulation is not mediated 
by PARylation of PPARγ itself, suggesting that it is mainly the auto-modification of 
ARTD1 or the ADP-ribosylation of yet unknown acceptor proteins, that is responsible 
for the ARTD1-dependent regulation of adipogenesis. 
PPARγ is a ligand-dependent transcription factor, but the identity of the 
physiological ligands remains controversial and is under active investigation. During 
adipogenesis, 3T3-L1 cells synthesize a PPARγ-activating substance, but its identity 
remains elusive (Tzameli et al., 2004). Polyunsaturated fatty acids and related 
molecules can activate PPARγ in micromolar concentrations (Forman et al., 1997; 
Keller et al., 1993; Kliewer et al., 1997; Krey et al., 1997), but it is not yet known if 
the concentration inside the cell and in proximity to the receptor is sufficient to 
activate PPARγ or not (Houseknecht et al., 2002). These fatty acids are stored in the 
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form of triglycerides in lipid droplets (Ducharme and Bickel, 2008). It is currently 
unclear if fatty acids can activate PPARs before being incorporated into lipid droplets, 
if rehydrolysis of the triglycerides is required, or if PPARs can be maintained in an 
activated state by other co-factors (Haemmerle et al., 2011).  
Here, we have demonstrated that the increased presence of PAR activates PPARγ-
dependent gene expression and showed direct binding and interaction of auto-
modified ARTD1 with PPARγ. However, the PPARγ ligand Rosiglitazone did not 
compete, but rather stimulated the interaction of modified ARTD1 with PPARγ, thus 
excluding PAR as a classical PPARγ ligand. These results thus define poly-ADP-
ribosylated ARTD1 as a new modulator of PPARγ acitivity. PPARγ antagonists 
exhibit gene-silencing activity due to their ability to promote the recruitment of co-
repressors and the subsequent formation of a condensed chromatin state (Bourguet et 
al., 2000). Co-repressors, such as SMRT and NCOR-1, are dislodged from PPARγ 
upon ligand binding and their inhibition has the potential to increase the expression of 
PPARγ target genes (Li et al., 2011; Yu et al., 2005). In contrast, agonists favor the 
formation of co-activator complexes which can acetylate histones and thereby induce 
chromatin de-condensation and transcriptional initiation (Bourguet et al., 2000). An 
important component of such co-activator complexes are the acetyltransferases 
p300/CBP, which interact with the N-terminus of PPARγ2 independently of the 
ligand, whereas binding to the C-terminus is ligand-dependent (Gelman et al., 1999). 
Based on our results, we postulate that ARTD1 represents a new member of PPARγ2 
co-activator complexes that helps maintain PPARγ2-dependent gene expression 
throughout adipogenesis. Recently, selective activation of PPARγ-target genes by 
certain PPARγ modulators has been reported (Choi et al., 2010; Houtkooper and 
Auwerx, 2010; Ohno et al., 2012; Rocchi et al., 2001). Similarly to these reports, we 
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observed increased expression upon H2O2 treatment only for a subset of PPARγ-
target genes. Hence, it could be speculated that PAR formation influences PPARγ in a 
similar way as a modulating ligand.  
In the experimental system of adipogenesis studied here, PAR formation favored 
p300 binding to PPREs and thereby ensured continuous expression of PPARγ target 
genes. This is consistent with the model of PAR as a platform for the recruitment and 
binding of chromatin remodeling components and elements of the transcription 
machinery (Tulin and Spradling, 2003). Different nuclear receptors and transcription 
factors have been linked to TopoII- and ARTD1-dependent activation of gene 
expression, supporting the idea that this might be a general regulatory mechanism for 
different nuclear receptors involved in the regulation of various cellular processes (Ju 
et al., 2006; Ju and Rosenfeld, 2006; Ju et al., 2004). 
PPARγ is also expressed in cells of the immune system, such as macrophages, 
where it can act as a repressor for inflammatory gene expression through a process 
called transrepression. It is an intriguing possibility that PAR formation may also be 
involved in this process as well. Recently, a role for NCoR in systemic insulin 
resistance upon HFD-induced obesity has been described (Li et al., 2013), raising the 
question as to whether PAR formation might be important for the cofactor recruitment 
and thus for the development of insulin resistance in this context. 
An interesting and unexpected result of this study was the strong effect of PARP 
inhibition on ScWAT formation in mice exposed to HFD. Since ScWAT is a potential 
target for therapies aimed at treating metabolic syndrome (Rodriguez et al., 2007), 
PARP inhibitors may open up new treatment options for patients suffering from this 
disorder. Due to their high level of tolerance and anti-inflammatory effects, PARP 
inhibitors are considered to be promising therapeutic compounds (Giansanti et al., 
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2010; Haddad et al., 2006; Hutchinson, 2010). Also, it might be beneficial that PAR 
has an atypical ligand function and thereby activates only a subset of genes, since this 
allows for more selective treatment. Previous studies showed hepatic steatosis in 
ARTD1-/- mice fed with HFD (Erener et al., 2012b), whereas lipid accumulation in 
the liver was absent in WT mice treated with PARP inhibitor. The differences 
between the PARP inhibitor experiments reported here and the previously reported 
phenotypes of ARTD1-/- mice may indicate functions of the ARTD1 protein in WAT 
and the liver that are independent of its activity, an effect on energy metabolism by 
PARP inhibitor treatment (not the case for ARTD1-/- mice), qualitative differences in 
the composition of the diet, or a contribution of ARTD2 or other ARTDs (Bai et al., 
2007). 
In summary, our results support a model that involves the formation of co-activator 
complexes by PAR at the promoters of PPARγ-dependent genes (Figure S5B). Most 
importantly, the presence of PAR molecules correlated with the switch from co-
activator to co-repressor complexes at promoters of PPARγ-dependent genes, 
implying a direct role for PAR in determining the transcriptional outcome at specific 
loci. These results thus demonstrate that PAR formation is required for the 
maintenance of PPARγ-dependent gene expression. Together with the beneficial 
effect observed with PARP inhibition in the mice, our results obtained in vitro 
highlight the therapeutic potential of targeting ADP-ribosylation to modulate 
adipocyte function under conditions such as obesity. 
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Methods 
Animal experiments 
A novel pan-PARP inhibitor MRLB-45696 (IC50 for PARP-1 and -2 <1 nM; 
Pirinen et al, 2013 manuscript submitted) was kindly provided by Thomas Vogt, from 
Merck Research Laboratories. Eight weeks old male C57BL/6J mice were fed with in 
house-made pellets containing vehicle or PARP inhibitor  (50 mg/kg/day) for 18 
weeks. All animal experiments were carried out according to the Swiss and EU 
ethical guidelines and have been approved by the local animal experimentation 
committee of the Canton de Vaud under license #2465. 
 
Cell culture 
For differentiation, 3T3-L1 cells were plated at 80% confluence, medium was 
changed after 2 days, and induction medium containing 1µg/ml insulin (I-9278) 
0.25 mM 3-isobutyl-1-methylxanthine (I-5879), and 0.5 µM dexamethasone (D-4902) 
(Sigma Aldrich, St. Louis, MO, USA) was added after 3 additional days. Starting at 
day 5, medium was changed every second day to DMEM containing insulin (1 
µg/ml). Cells were differentiated in the presence or absence of PARP inhibitors PJ34 
or ABT888 (both at 1 µM or 10 µM), PARG inhibitor RBPI-3, Topoisomerase II 
inhibitor Merbarone (50 µM), or PPARγ agonist Rosiglitazone (1 µM or 10 µM) 
added to the cells every 24 hours. For differentiation until day 21, ABT888 was added 
only every second day. H2O2 treatment (1 mM, 15 min) was performed in DMEM 
without FCS (and in the presence of catalase inhibitor 3-AT (30 µM) and in the 
presence or absence of PJ34 (10 µM)).  
 
Results 
 91 
GST-pulldown 
GST-PPARγ2 was coupled to magnetic GST-Beads (Pierce). 1 µg modified or 
unmodified ARTD1 (in reaction buffer, 5 pmol 40mer DNA, ±10 mM NAD, 30 mins 
at 30°C) and 1 µg His-p300 were added to the GST-PPARγ2. Pulldown was 
performed for 2 h at 4°C in pulldown buffer (50 mM Tris pH 7.5, 150 mM KCl, 
5 mM MgCl2, 0.2 mM EDTA, 20% Glycerol, 0.1% NP40) in the presence of 10 µM 
PJ34. The beads were washed 3x with wash buffer (20 mM Tris pH 7.5, 150 mM 
KCl, 5 mM MgCl2, 0.2 mM EDTA, 10% Glycerol, 0.1% Tween). 
 
Chromatin immunoprecipitation (ChIP) 
ChIP was performed as previously described (Santoro et al., 2002). For Re-ChIP 
experiments, the first ChIP (anti-ARTD1) was eluted twice in 10 mM DTT (30 mins, 
at 30°C), diluted in ChIP buffer, and the second ChIP (anti-PPARγ) was performed as 
previously described (Santoro et al., 2002).  
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Figure Legends 
Figure 1. PARP inhibitor treatment reduces body weight and adipose tissue size 
in mice.  
A-B) Weight development during chow and high-fat diet (HFD) in vehicle- and 
PARP inhibitor-treated mice. Eight weeks old male C57BL/6J mice were fed with 
chow or HFD containing vehicle (DMSO) or PARP inhibitor  (50 mg/kg/day) for 18 
weeks. Body weight gain was monitored at the given time points. Data are mean ± 
SEM, Anova two-way analysis revealed p<0.001 for both HFD and Chow. Data are 
mean ± SEM. T-test: *p<0.05, **p<0.01, ***p<0.001. n=10 C-D) Fat pad weights on 
chow and HFD. Animals were sacrificed after overnight fasting using isoflurane 
inhalation and tissues were collected upon sacrifice and flash-frozen in liquid 
nitrogen. epiWAT; epididymal white adipose tissue, scWAT; subcutaneous white 
adipose tissue, periWAT; perirenal white adipose tissue and BAT; brown adipose 
tissue. Data are mean ± SEM. Anova one way test *p<0.05, **p<0.01, ***p<0.001. 
n=10 E) Mouse adipose tissue was fixed, dehydrated, and embedded in paraffin wax. 
Sequential sections (6µm) were cut and morphological changes visualized using H&E 
staining (scale bar 200µm). Blinded analysis of mean adipocyte area in tissue sections 
from mice (N= 5-6 per treatment group) was performed F) qRT-PCR analysis of 
WAT isolated from vehicle- and PARP inhibitor-treated mice. For qRT-PCR analysis 
of tissue samples, isolated WAT from 8 mice per group was pooled and expression 
values were normalized against 36BP4. Data are mean ± SEM. T-test: *p<0.05, 
**p<0.01, ***p<0.001. 
 
Figure 2. PAR formation is required for PPARγ-dependent gene expression. A) 
Adipogenesis was induced by adding insulin, 3-isobutyl-1-methylxanthine (IBMX) 
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and dexamethasone for three days and maintaining cells in medium containing 10% 
fetal calf serum (FCS) and insulin. B) Cells were differentiated in the presence of 
10 µM ABT888 (daily treatment) until day 7, at which point RNA was isolated (n=8). 
C) Differentiating 3T3-L1 cells were treated with 10µM PARG inhibitor RBPI-3 at 
the days 1-5 and RNA was isolated on day 6 of differentiation (n=5). D) PAR 
formation is required for maintenance of PPARγ-dependent gene expression. Starting 
from day 7 of adipogenesis of 3T3-L1 cells, the culture medium containing insulin 
and 10 µM ABT888 was changed every second day. RNA was isolated at day 21 and 
gene expression was analyzed by RT-qPCR (n=4). All values represent the mean ± 
SEM, unteated samples were set as 1. T-test: *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 3. Ligand-dependent interaction of PPARγ  and ARTD1 at the PPREs of 
PPARγ-target genes. A) 3T3-L1 cells were differentiated until day 7, nuclear protein 
extracts were prepared and PPARγ was immuno-precipitated. To prevent degradation 
of PAR, extracts were treated with 10 µM PARG inhibitor (RBPI-3). B) At day 7 of 
differentiation, cells were fixed and the chromatin was first precipitated with an 
ARTD1 antibody and then with a PPARγ  antibody (n=4). C) Cells were differentiated 
and treated with 10 µM Rosiglitazone at day 2 and 5. At day 7 of differentiation, cells 
were fixed and the chromatin was immuno-precipitated with an ARTD1 antibody 
(n=2). D) PPARγ2-GST pull-down of ARTD1 in the presence or absence of a 10 µM 
Rosiglitazone preincubation. E) At day 7 of differentiation, cells were treated with 
10 µM Rosiglitazone for the indicated periods of time. Whole cell extracts were 
analyzed by Western Blot. F) At day 7 of differentiation, cells were treated for 24 or 
2 h with 10 µM Rosiglitazone in the presence or absence of 50µM Merbarone (Mer).  
Whole cell extracts were analyzed by Western Blot. G) Cells were fixed at day 7 of 
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differentiation and chromatin was immuno-precipitated with a Topoisomerase II 
antibody (n=3). H) At day 7 of differentiation, 3T3-L1 cells were fixed with PFA and 
stained with an antibody against Topoisomerase II (green) and PPARγ (red). DAPI 
was used to visualize the nuclei (blue). Cells were analyzed by confocal microscopy. 
All values represent the mean ±SEM. Values were normalized over IgG control. T-
test: *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 4: PAR formation enhances PPARγ-dependent gene expression. A) 
Hek293T cells overexpressing PPARγ2 and HA-ARTD1 were treated with 1 mM 
H2O2 (15 min) in the presence of 30 µM catalase inhibitor (3-AT). IP with an anti-HA 
antibody was performed with nuclear extracts. B) Hek293T cells overexpressing 
PPARγ2 were treated with 1 mM H2O2 (15 min) in the presence of catalase inhibitor. 
IP with an anti-PPARγ antibody was performed with nuclear extracts. C) 3T3-L1 cells 
overexpressing PPARγ2 were treated with 1 mM H2O2 (2 h) in the presence of 30 µM 
catalase inhibitor (3-AT) and in the presence or absence of 10 µM PJ34. Luciferase 
activity was measured (n=4). D) 3T3-L1 cells co-overexpressing PPARγ2 and 
ARTD1 (wild-type, n=5), ARTD1 E988K (n=4), ARTD1 Y907A/C908Y (n=3) or 
GFP (as a negative control, n=5) were treated with 1 mM H2O2 (2 h) in the presence 
of 30 µM catalase inhibitor (3-AT). E) 3T3-L1 cells overexpressing PPARγ2 were 
pretreated with 10µM PARG inhibitor (RBPI-3) and treated with 1 mM H2O2 (2h) in 
the presence of 30 µM catalase inhibitor (3-AT) (n=5). F) Cells were treated with 
1 mM H2O2 (2 h) in the  presence of 30 µM catalase inhibitor (3-AT) and in the 
presence or absence of 10 µM PJ34. The medium was then exchanged with medium 
containing fresh FCS and samples were taken after 2h (n=5). G) PAR formation is 
required for the maintenance of PPARγ-dependent gene expression. During 
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differentiation, 3T3-L1 cells were treated with 10 µM Rosiglitazone or 10 µM 
ABT888 at days 2-6 of adipogenesis (n=4). T-test: *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 5: PAR formation controls PPARγ-dependent gene expression by 
maintaining ligand induced cofactor exchange. A) PPARγ2-GST pull-down of 
ARTD1 (nonmodified or automodified, indicated by *, modified ARTD1 has a higher 
molecular weight (above 130 kDa) than unmodified and p300 in the presence or 
absence of 10 µM Rosiglitazone pretreatment of PPARγ2-GST. B) Hek293T cells 
overexpressing PPARγ2, p300 and ARTD1 were treated with 1 mM H2O2 (15 min) in 
the presence of catalase inhibitor. IP with an anti-p300 antibody was performed with 
nuclear extracts. C) Starting from day 2 of adipogenesis, 3T3-L1 cells were treated 
daily with 10 µM PJ34. At day 7, the cells were fixed with formaldehyde and the 
chromatin was immuno-precipitated with an anti-p300 antibody (n=4). D) Same 
analysis as in C for NCOR-1 (n=3). T-test: *p<0.05, **p<0.01, ***p<0.001. 
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Supplementary Information 
Supplemental Experimental Procedures 
Reagents 
RBPI-3 and inactive substance was a kind gift of Prof. Dr. Paul J. Hergenrother 
(University of Illinois, USA).  Dexamethasone (D-4902), 3-isobutyl-1-
methylxanthine (I-5879), insulin (I-9278), rosiglitazone (R-2408) and merbarone 
(M2070) were obtained from Sigma-Aldrich (St. Louis, MO). Anti-PARP (sc-7150) 
and anti-Topoisomerase II (sc-8030; used for Immunofluorescence) antibodies were 
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), anti-PPARγ rb 
(2443S), and anti-PARP (46D11) were from Cell Signaling (Cambridge, UK), anti-
p300 (554215) from BD Pharmigen (Franklin Lakes, NJ, USA), anti-PPARγ ms 
(ab41928), anti-NCOR-1 (ab24552), anti-TopoII (ab58442; used for ChIP) were 
obtained from Abcam (Cambridge, UK), and anti-tubulin (T6199) antibody was from 
Sigma-Aldrich. The anti-PAR 10H antibody was homemade. PJ34 and ABT888 were 
from Enzo Life Sciences (Farmindale, NY, USA)(ALX-270-289; ALX-270-444). 
 
Animal experiments 
A novel pan-PARP inhibitor MRLB-45696 (IC50 for PARP-1 and -2 <1 nM; Pirinen 
et al, 2013 manuscript submitted) was kindly provided by Thomas Vogt, from Merck 
Research Laboratories. Eight weeks old male C57BL/6J mice were purchased from 
Charles River and after two weeks of adaptation time, mice were fed with homemade 
pellets containing vehicle or PARP inhibitor  (50 mg/kg/day) for 18 weeks. The 
pellets were prepared as follows; the powder food and water were mixed with DMSO 
(vehicle) or with PARP inhibitor dissolved in DMSO and pellets were dried under the 
hood at least over night. Powder chow (D12450B) and high fat (D12492) diets used 
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were from Research Diets Inc. Body weights were recorded every second week and 
food intake was measured by weighting one-week food consumption in the middle of 
the experiment. Animals were sacrificed after overnight fasting using isoflurane 
inhalation. Tissues were collected upon sacrifice and flash-frozen in liquid nitrogen. 
During experiment, mice were housed under a 12h dark-light cycle and they had ad 
libitum access to water and food. 
 
Cell culture 
3T3-L1 and Hek293T cells were cultivated in Dulbecco's Modified Eagle's 
Medium (DMEM) (PAA, Pasching, Austria, supplemented with 1% (v/v) 
Penicillin/Streptavidin and 10% (v/v) fetal calf serum (Gibco, Invitrogen, CA, 
California, USA). 
 
RNA extraction with TRIzol® reagent and qPCR analysis 
TRIzol® RNA Isolation Reagent (Life Technologies, CA, California, USA) was 
applied directly to the plates and the supplier’s protocol was followed. DNase 
treatment was performed using the TURBO DNA-freeTM Kit (Life Technologies, 
Carlsbad, CA, USA). RNA was quantified with a NanoDrop (ThermoFisherScintific, 
Waltham, MS, USA) and reverse transcribed according to the supplier’s protocol 
(High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Foster City, 
CA, United States). Quantitative-real-time polymerase chain reactions (qPCR) were 
performed in triplicate with SYBR® green SensiMix SYBR Hi-ROX Kit (Bioline 
Reagents Ltd, London, UK) in a Rotor-Gene Q 2plex HRM System (Qiagen, Hilden, 
Germany). For qRT-PCR analysis of tissue samples, isolated WAT from 8 mice per 
group was pooled and expression values were normalized against 36BP4. 
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Immunofluorescence 
Cells were seeded in chamber slides and differentiated according to protocol until 
day 7. Cells were fixed with 4% PFA, washed twice with PBS, permeabilized with 
0.2% Triton X-100, and incubated with anti-Topoisomerase II and anti ARTD1 
antibody (1:150; 1:500) in PBS (containing 2% BSA and 0.1% Triton X-100, 1 h 
room temperature).  Chamber slides were incubated with secondary ms-Cy3-
Antibody and rb-Alexa-488-antibody (1 h room temperature). After washing with 
PBS, chamber slides were mounted with Vectashield containing DAPI (Vector 
Laboratories, Burlingame, CA, USA). Confocal laser scanning microscopy was 
carried out with a Leica SP 5 resonant APD system (Leica microsystems GmbH, 
Wetzlar, Germany). 
 
Histological assessment of adipose tissue 
Mouse adipose tissue (EpiWAT) was fixed in 4% paraformaldehyde overnight at 
4oC, and dehydrated prior to embedding in paraffin wax. Sequential sections (6µm) 
were cut and morphological changes visualized using hematoxylin and eosin (H&E) 
staining. Blinded analysis of mean adipocyte area in tissue sections from mice (N= 5-
6 per treatment group) was performed using Image J-macro software 
(http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Adipocytes_Tool).  
 
Whole Cell extracts and SDS-PAGE 
Whole-cell extracts (WCE) were prepared by lysing cells for 20 min in radio-
immunoprecipitation assay buffer [50 mMTris (pH 8), 400 mM NaCl, 0.5% Nonidet 
P40, 1% deoxycholate, 0.1% sodium dodecyl sulfate, 1 g/ml pepstatin, 1 g/ml 
bestatin, 2 g/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride, 10 mM 
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glycerophosphate, 1 mM NaF, and 1 mM dithiothreitol] at 4°C. Lysate was 
centrifuged (20 min, 4°C, 14’000 rpm). WCE were loaded on 7.5% 
sodiumdodecylsulfate gels and blotted with anti-PAR, anti-ARTD1, anti-PPAR, and 
anti-tubulin antibodies.  
 
Co-immunoprecipitation 
Hek293T cells were plated one day prior to calcium phosphate transfection with 
12 µg total DNA. 48 h after transfection, cells were treated with H2O2 in DMEM as 
described above. Cells were harvested in PBS, nuclei were extracted in a buffer 
containing 85 mM KCl, 0.5% NP40 and 5 mM Hepes (pH 7.4). After centrifugation 
(10 min, 6000 rpm) cells were resuspended in Buffer D (50 mM Tris pH 7.5, 50 mM 
KCl, 5 mM MgCl2, 0.2 mM EDTA, 20% Glycerol, 0.1% NP40, 0.1 mM DTT and 1x 
Proteinase Inhibitor), sonicated, and treated with DNAse I (30 min on ice). After 
centrifugation (10 min, 6000 rpm), proteins in the supernatant were quantified by 
Bradford assay. IP was performed at 4°C for 4 h with 2 µg of antibody per 150 µg of 
extract. Dynabeads G or A beads or Sepharose beads coupled to HA-antibody were 
added (10 µl/20µl of HA beads per reaction, incubation for 2 hr at 4°C). Beads were 
washed 4x with washing buffer (20 mM Tris pH 7.5, 50 mM KCl, 5 mM MgCl2, 
0.2 mM EDTA, 10% Glycerol, 0.1% Tween), 2x Laemmli buffer (20 µl) was added, 
the reaction was boiled (5 min, 95°C). SDS-PAGE and western blot analysis were 
performed as described. For the analysis of p300 the blotting buffer was 
supplemented with 0.1% SDS. 
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Luciferase assay 
Luciferase assays were performed by overexpressing a 3xPPRE-Firefly Luciferase 
construct, PPARγ2, (both generous gifts from Prof. Dr. Walter Wahli, Lausanne, 
Switzerland), a TK-Renilla construct and, when required, ARTD1 wt and mutant 
constructs. 3T3-L1 cells were transfected using TransIT-3T3 Transfection reagent 
(Mirus Bio LLC, Madison, WI, USA) according to the manufacturer’s instructions. 
Hek293T cells were transfected with calcium phosphate in 24-well plates using 10 ng 
Renilla, 100 ng PPRE-Firefly, 200 ng ARTD1, 100 ng PPARγ2 per well. Cells were 
treated with 10 µM rosiglitazone for 16 h (4 h after transfection). Prior to collection, 
cells were treated with 1 mM H2O2 in DMEM without FCS in the presence of catalase 
inhibitor 3-AT (30 µM) for 2 h in the presence or absence of 10 µM PJ34. Luciferase 
was measured using the Dual-Luciferase reporter assay kit (Promega, Madison, WI, 
USA) according to the manufacturer’s instructions.  
 
Chromatin immunoprecipitation (ChIP) 
ChIP was performed as previously described (Santoro et al., 2002). Briefly, 3T3-
L1 cells were fixed in 1% Formaldehyde in PBS. Chromatin was fragmented with a 
Bioruptor (Diagenode). Antibodies were incubated with crosslinked chromatin 
overnight at 4°C and collected with Protein A or G magnetic Dynabeads® (Life 
Technologies, Carlsbad, CA, USA) for 4 hours. After reversal of the crosslinking and 
digestion with proteinase K, DNA was extracted and analyzed by real-time PCR 
using SYBR Green and the Rotor-Gene 3000 (Corbett Life Science, now Qiagen).  
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Supplementary Figures 
 
Figure S1: PARP inhibitor treatment reduces adipose tissue formation in mice. 
A) ARTD activity measured in epiWAT isolated from vehicle- and PARP inhibitor-
treated mice on HFD after fasting o/n. Data are mean ± SEM. T-test: *p<0.05, 
**p<0.01, ***p<0.001. n=7 B) Food intake of mice fed during one week on Chow or 
HFD in the presence or absence of PARP inhibitor. Data are mean ± SEM. C) qRT-
PCR analysis of epiWAT isolated from vehicle- and PARP inhibitor-treated mice. For 
qRT-PCR analysis of tissue samples, isolated WAT from 8 mice per group was 
pooled and expression values were normalized against 36BP4. Data are mean ± SEM. 
T-test: *p<0.05, **p<0.01, ***p<0.001. 
 
Figure S2: PAR formation is required for PPARγ-dependent gene expression. A) 
3T3-L1 cells were treated during differentiation with 1 or 10µM ABT888 form day 2-
6. RNA was extracted at day 7 and gene expression was analyzed. B) 3T3-L1 cells 
were differentiated and treated with 10µM RBPI-3 (PARGi) for days 1-3. At day 4, 
whole cell extracts were analyzed by western blotting. C) 3T3-L1 cells were treated 
with 100nM FK866 and/or 10µM PJ34 during differentiation (day 2-4). Samples were 
taken at day 5 and analyzed by western blot. D) qPCR analysis of the cells used in C. 
E) WT or ARTD1-/- MEF cells were differentiated and analyzed at day 7 by western 
blotting. F) qPCR analysis of the cells used in E. 
 
Figure S3: PPARγ  and ARTD1 interact at the PPREs of PPARg target genes. A) 
3T3-L1 cells were treated during differentiation with 10µM ABT888 at day 5 and 6 
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and cells were fixed at day 0 or 7 and Chromatin was precipitated using an anti 
ARTD1 antibody. B) 3T3-L1 cells were treated daily with 10µM PJ34 starting at day 
1. At day 0, 3 or 7, cells were fixed with formaldehyde and chromatin was 
precipitated with an anti-PAR antibody. Data are mean ± SEM.  Values were 
normalized over beads and over IL6-100 as control gene. Data are mean ± SEM. T-
test: *p<0.05, **p<0.01, ***p<0.001. 
 C) Hek cells were treated with Rosiglitazone (10 µM) for the indicated times and 
whole cell extracts were analysed for PAR formation.  
 
Figure S4: PAR formation enhances PPARγ dependent gene expression. A) 3T3-
L1 cells overexpressing PPARγ2 were treated with 10µM Rosiglitazone for 16 hours 
and subsequently Luciferase activity was measured. B) Hek cells overexpressing 
PPARγ2, WT ARTD1, ARTD1 E988K, or Y907A/C908Y or GFP(-) were treated 
with 1mM H2O2 in the presence of catalase inhibitor for 2 hours.  
  
Figure S5: PAR formation controls PPARγ-dependent gene expression by 
maintaining ligand induced cofactor exchange. A) 3T3-L1 cells were treated daily 
with 10µM ABT888 starting at day 5. At day 8 the cells were fixed with 
Formaldehyde and chromatin was precipitated with a p300 antibody. Data are mean ± 
SEM. n=2. B) PAR formation is required for maintenance of PPARγ-dependent gene 
expression. 
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3.3 Unpublished results 
3.3.1 Generation of conditional knockout ARTD1-/- mice 
In order to investigate the effect of ARTD1 on adipose tissue in vivo and to rule out 
indirect effects of the ARTD1 depletion in other tissues than adipose tissue, which 
cannot be ruled out with conventional knockout mice, we decided to generate a mouse 
with a floxed ARTD1 allele. This will be used afterwards to bread an adipocyte 
specific knockout of ARTD1. A commercially available targeting vector from 
EUCOMM (European Conditional Mouse Mutagenesis Program) was used to target 
exon 4 of ARTD1 in ES cells to generate ARTD1fl/fl mice in collaboration with 
Polygene (Rümlang, Switzerland). The targeting vector contains different functional 
parts (Fig. 1A). The 5’ and 3’ homolougs arms are requird for the targeted insertion of 
the casssete. Additionally, the cassette contains loxP sites that flank exon 4 of the 
ARTD1 gene for later Cre-mediated excision. For selection, the vector contains a 
neomycin resistance gene and a lacZ gene that allows blue/white selection of clones. 
The selection cassette is flanked by Flp-recombinase target (frt) sites, which allows 
the removal of the cassette upon flippase (Flp)-mediated recombination. Outside of 
the homologous regions is a diphtheria toxin gene allowing counterselection for 
random integration of the construct. The targeting construct was transfected into ES 
cells and upon homologous recombination resulted in an integrated transgene 
(Fig.1B). To verify the correct integration site, different PCRs were established. PCR 
1 (primers GF3 and LAR3) and 2 (primers GR4 and RAF5) amplify a region that 
contains DNA sequences outside of the selection cassette and extends into the 
construct and can thus confirm the exact integration site, whereas PCR 3 (primers 
1405 and LAR3) confirms only the presence of the selection cassette (Fig. 1C). Both 
the targeting vector and a commercially available targeted ES clone from EUCOMM, 
which unforuntately did not generate chimera (data not shown) served as controls 
allowing the amplification of the expected positive signal. The long range flanking 
PCRs 1 and 2 amplified a product only when DNA from the EUCOMM cell clones 
was tested, but not using only the targeting vector or a negtive control (genomic DNA 
from mouse cells) (Fig. 1D). Serveral transfected ES-cells were analysed for the 
targeted integration of the cassette (Fig. 1E). A considerably high frequency of over 
60% of the tested clones were tested positive for a correct vector integration. 
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Figure 1: Schematic scheme of the targeting vector and validation of ES cell clones for ARTD1fl/+ 
A) The targeting vector containing loxP flanked Exon 4 of ARTD1 and selection cassette for 
transfected ES cells as well as Diphtheriatoxin for counterselction. Vector was bought from 
EUCOMM. 
B) Schematic illustration of insereted construct and Primers used for characterizing the clones  
C) Vector (v) was tested for the presence of the selection cassette (PCR 3). Previously bought 
and characterized ES-cell clones were used as a positive control (1), Marker (M). 
D) PCRs 1 and 2 for insertions were verified with positive control (+), negative control (genomic 
Raw DNA =-) and vector (v). 
E) ES cells were transfected with the vector and selected for the locus of integration. Clones 
tested positive for the integration at the desired locus are shown in bold.  
F) Selected clones were thawed and expanded and reanalysed for the presence of the construct at 
the right chromosomal location. 
 
Several positive clones were expanded and rechecked for the right integration (Fig. 
1F). The targetd ES cells were additionally injected into blastocytes to generate 
chimeras. Born chimeras are currently being bread with wt C57/BL6 mice to confirm 
germline transmission. Mice will subsequently be bread further in the C57/BL6 
background, since this strain is preferred for metabolic studies 286. The resulting 
heterzygous offspring will be crossed inter se. Homozygous ARTD1fl/fl mice will be 
crossed with mice carrying an inducible Cre-enzyme under the adipose tissue specific 
Adiponectin promoter. Adiponectin-Cre; ARTD1fl/fl mice will have an exon 4 deletion 
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of ARTD1 specifically in adipose tissue and will therefore not express a functional 
protein in WAT.  
 
3.3.2 Browning of wite adipose tissue is associated with PAR formation 
The experiments presented in this part were performed in collaboration with Dr. 
Matthias Rosenwald and Prof. Dr. Christian Wolfrum who provided the mouse 
material. White adipose tissue (WAT) can be transformed to brown-like adipose 
tissue by exposure of mice to cold or PPARγ-agonists 160,162,168. This increase is 
accompanied by an increase in UCP-1 expression 154. To investigate if PAR 
formation and ARTD1/2 are involved in this process, we treated differentiated 
adipocytes from day 7 until day 21 with PPARγ-agonist Rosiglitazone and measured 
UCP-1 expression. Treatment with Rosiglitazone increased UCP-1 expression 
drastically by a factor of about 450, while the co-treatment with the PARP inhibitor 
ABT888 abrogated this effect (Fig. 2A). Interestingly, ABT888 alone seemed to 
stimulate UCP-1 expression in untreated cells, although not to the same extent as 
Rosiglitazone. These initial expression changes need to be confirmed on the protein 
levels as the increase on mRNA level in untreated cells might not affect the basal 
UCP-1 protein levels. Nevertheless, these initial results indicate that PAR formation 
is involved in Rosiglitazone-induced UCP-1 expression in 3T3-L1 cells. 
Mice kept at 8°C over 0, 1, 4 or 7 days were sacrificed and whole cell extracts 
of the subcutaneous WAT and BAT was analysed by Westernblot for PAR formation 
(Fig. 2B). Upon exposure to cold, a distinct band around 55/60 kDa appeared, both in 
BAT and WAT. This band was stronger in the WAT than in the BAT samples and the 
band could represent auto-modified ARTD2, which was previously reported to have a 
minor effect on BAT 282. Unfortunately, the commercially available antibodies against 
ARTD2 did not allow the detection of mouse ARTD2 (only human ARTD2). 
Moreover, a high molecular weight smear around 300 kDa was detected with the anti-
PAR antibody which increased in BAT samples from day 1 and 4. These results 
indicated that PAR formation is induced upon exposure of mice to cold. 
To investigate the enzymes mainly involved in PAR anabolism and 
catabolism, mRNA levels of ARTD1, ARTD2 and PARG were analysed by qPCR 
(Fig. 2C). ARTD1 mRNA levels did not change in response to cold exposure. In 
contrast, ARTD2 levels increased significantly in BAT and showed a similar trend in 
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WAT, although this increase was not significant. The expression of PARG, the main 
PAR-metabolizing enzyme, was not changed in BAT, while in WAT there was a 
slight although non-significant decrease. These results need to be verified on protein 
levels but indicate that exposure of mice to cold induces ARTD2 expression in BAT 
and reduced PARG expression in WAT. 
 
Figure 2: WAT to BAT trans-differentiation is associated with PAR formation 
A) Cells at day 7 of differentiation were treated with 1µM Rosiglitazone and 10µM ABT888 
every second day until day 21. RNA was isolated and qPCR for UCP1 was performed. The 
values were normalized to Cyclophilin A expression. n=1 
B) C57BL/6N mice were kept in the cold (8°C) for 0-7 days. The subcutaneous white adipose 
tissue (WAT) and brown adipose tissue (BAT) was isolated and WCE were analysed by WB 
using antibodies against PAR and ARTD1.  
C) C57BL/6N mice were kept in the cold (8°C) for 0-7 days. The subcutaneous white adipose 
tissue (WAT) and brown adipose tissue (BAT) was subsequently isolated, RNA isolated from 
the tissues and analysed by qPCR. Values were normalized for 36BP4 expression. Presented 
are means ±SEM. n=4 
 
In summary, our results indicate that PAR formation is required for PPARγ-agonist 
induced UCP-1 expression. In addition, PAR formation is induced upon exposure to 
cold. Whether ARTD1- or ARTD2-mediated PAR formation is required for the trans-
differentiation of WAT to BAT will be further investigated by exposing ARTD1-/-, 
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ARTD2-/-, and wt mice to cold for several days before analyzing the browning 
potential of the different genotypes. 
 
3.3.3 Characterization of ARTD3 enzymatic activity 
Commonly used PARP inhibitors are not specific for one distinct ARTD member, but 
most of them target different family members with comparable affinity 287. In order to 
develop specific inhibitors, it is important to understand the enzymatic activities and 
biochemical properties of every single ARTD family member. While ARTD1 and 
ARTD2 are well studied, ARTD3, which is a target of many of the commonly used 
drugs, is poorly characterized 287. Moreover, there are conflicting reports about the 
enzymatic activity of ARTD3 18,107,108. One publication reported poly-ADP-
ribosylating activity for ARTD3, whereas others report none or only mono-ADP-
ribosylating activity 18,107,108. To provide additional insights into this biochemical 
questions, we investigated the ADP-ribosylating activity of ARTD3. ARTD3 from 
our (CH) or from Caldecott’s laboratory (UK) was expressed in insect cells using a 
baculo-virus system, purified with a nickel-NTA column and their enzymatic 
activities analysed at different NAD+ concentrations in the presence or absence of 
histones (Fig. 3A). ARTD3 from both sources showed only mono- or oligo-ADP-
ribosylating activity, as evidenced by the absence of any band-shift of ARTD3, which 
could only be observed for the ARTD1 sample, which served as positive control. The 
basal activity of CH-ARTD3 was slightly lower under all tested conditions compared 
to the UK-ARTD3, which became even more evident when high NAD+ 
concentrations were used. In addition, we tested how pH changes (pH range 8 to 9.5) 
would change the activity of ARTD3 (Fig. 3A). The different tested pHs did not 
affect ARTD3 enzymatic activity, neither under high, nor under low NAD+ 
concentrations. 
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Figure 3: ARTD3 is a mono-ADP-ribosyltransferase 
A) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 from Hottiger 
(CH) or Caldecott (UK) laboratories with 100nM or 10µM NAD+ (32P) and Eco linker in 
ARTD reaction buffer pH8.0 or 9.5. ARTD1 was used as a positive control. CB= coomassie 
blot.  
B) Product analysis ARTD1, short ARTD1(s) or ARTD3 were incubated with 1 mM NAD+ in 
the presence of DNA (cut plasmid DNA) and Histones (H1.4) for 45 mins at 30°C, Polymers 
were extracted and analysed on a silver gel. 
C) Product analysis of ARTD1, short ARTD1(s) or ARTD3. Proteins were incubated with 10 µM 
32P labeled NAD+ in the presence of DNA (cut plasmid DNA) and Histones (H1.4) for 30 
mins at 30°C, proteins were digested with Proteinase K and polymers were analysed on a 
sequencing gel. 
 
To test, whether DNA can activate ARTD3, a short double-stranded (ds) DNA 
consisting of the EcoRI-motif (8 bp with 2 nucleotides overhand) was used in this 
assay. ARTD1 was strongly activated by DNA while ARTD3 was not stimulated by 
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DNA (Fig. 3A). This is in contrast to other studies, which report that DNA is able to 
stimulate ARTD3 106,107. To investigate if the ARTD3 formed product was mono- or 
oligo-ADP-ribose, product analysis was performed on a silver gel which allows the 
detection of oligomers consisting of 8 or more ADP-ribose moieties (Fig. 3B). For 
ARTD1, a ladder of polymers could be detected, which was enhanced upon the 
addition of histones. For the short form of ARTD1 (aa 524-1014,), which lacks the 
DNA-binding and the BRCT domain, a similar product was observed 2. For ARTD3 
no signal could be detected, meaning that under the tested experimental conditions no 
oligomers comprised of more than 7 ADP-riboses were formed. In order to 
investigate if monomers or smaller oligomers of ADP-ribose were formed by 
ARTD3, we performed a radioactive product analysis that allows detection of mono- 
and oligo-ADP-ribose as well (Fig. 3C). As expected, ARTD1 showed a ladder-like 
pattern of ADP-ribose polymers. For ARTD10, which is a mono-ART, and for 
ARTD3 only monomers were observed, although for ARTD3 the product was only 
very weak, indicating that the enzymatic activity of ARTD3 is weak (compared to 
ARTD1 or 10) and that ARTD3 is a mono-ADP-ribosyltransferase. While a short 
dsDNA fragment was not able to stimulate ARTD3 (Fig. 3A), other structures such as 
DNA lesions or hairpins might be able to activate ARTD3. The enzymatic activity of 
ARTD3 was thus analysed in presence of DNA constructs harboring different 
structures, some of them containing nicks, gaps, flaps or overhangs (Fig. 4A). 
Although ARTD1 could be stimulated with intact dsDNA (C) or with dsDNA 
containing a nick (N), no stimulation was observed for ARTD3 with any of the tested 
constructs. These results provide evidence that ARTD3 is unlikely activated by DNA. 
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Figure 4: ARTD3 is not activated by DNA, but by Histones and RNA 
A) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 with 100nM 
or 1µM, NAD+ (32P) in ARTD reaction buffer in the presence of different DNAs. ARTD1 was 
used as a positive control. CB= coomassie blot. N=nick C=control oligo, 3’Flap=3, 5’Flap=5, 
Gap(G), hairpin (HP) or 8mer EcoLinker (E). 
B) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 from Hottiger 
(CH) or Caldecott lab (UK) with 100nM, 1µM, 10µM or 100µM NAD+ (32P) in ARTD 
reaction buffer in the presence of the Histone mix (HM). ARTD1 was used as a positive 
control. CB= coomassie blot 
C) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 with 1µM 
NAD+ (32P) in ARTD reaction buffer in the presence of 1µg histonemix (HM) or H1. CB= 
coomassie blot 
D) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 with 1µM 
NAD+ (32P) in ARTD reaction buffer in the presence or absence of 10µg Histonemix (HM), 
30µM ME0328 (ARTD3 inhibitor=ARTD3i) or 1.5µl KCN RNA and 50µg/ml 
Ethidiumbromide (EtBr) to inhibit any DNA mediated activation. CB= coomassie blot 
Since histones were described to activate ARTD1 in vitro, we investigated if histones 
could potentially also activate ARTD3. Indeed, addition of histones increased the 
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activity of ARTD3 under all tested conditions (Fig 4B,C,D). In addition to an 
increased ARTD3 auto-modification upon addition of histones, the ADP-ribosylation 
of core histones as well as H1 could be observed (Fig 4C). To rule out that this 
activation by histones was mediated by a contamination with nucleic acids, 
Ethidiumbromide (EtBr) was supplemented to the reaction (Fig 4D). EtBr was 
described to intercalate in the DNA and is therefore used as a tool for visualization of 
DNA but can also be used to clear extracts from contaminating DNA288,289. EtBr did 
not interfere with the ARTD3 stimulation by histones, suggesting that the histones 
themselves and not a contamination with nucleic acids conveyed the activation. 
ARTD1 was recently described to bind to and be activated by RNA 290-293. We thus 
investigated the effect of RNA on ARTD3 activity (Fig. 4D). Indeed, pre-incubation 
of ARTD3 with RNA increased its activity (Fig. 4D). Addition of a specific ARTD3 
inhibitor which was developed in collaboration with the Schüler laboratory (see 
published results) indeed inhibited the detected activity of ARTD3 (Fig. 4D). 
 Recently ARTD3 was described to activate ARTD1 108. However, this study 
did not consider the activation of ARTD1 by ARTD3 through co-purified nucleic 
acids (e.g. DNA or RNA). To elucidate this possibility, we tested ARTD3 purified 
from bacteria or insect cells for the stimulation of ARTD1 purified from insect cells 
(Fig. 5A). Co-incubation of ARTD3 and ARTD1 led to an increased modification of 
ARTD1 as well as for ARTD3. This stimulatory effect was best observed when 
ARTD3 was used in great molar excess to ARTD1 (25:1). Whenever this ratio was 
changed in favor of ARTD1, the effect became smaller (Fig. 5B, C). When using 
ARTD1 and ARTD3 at equimolar concentrations no stimulation could be detected, 
suggesting that only ARTD3 in great excess is able to activate ARTD1. In addition, 
this effect was only visible under low NAD+ concentrations (e.g. 100nM NAD+, Fig. 
5D). Under these conditions, auto-modification of ARTD3 was hardly detectable. To 
investigate, if ARTD3 modifies ARTD1, we took advantage of the inactive ARTD1 
Y907A/C908Y mutant (Fig. 5E). While we saw an increased auto-modification of 
ARTD1 wildtype upon ARTD3 addition, no comparable signal could be detected 
when the inactive ARTD1 mutant was used, suggesting that the detected signal was 
due to induced ARTD1 auto-modification rather than trans-modification of ARTD1 
by ARTD3. More experiments also including ARTD3 inactive mutants are required to 
confirm this conclusion.  
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In order to test if the activation of ARTD1 by ARTD3 was mediated by DNA 
contamination of ARTD3, we incubated ARTD3 in the reaction mix with either EtBr 
or DNAseI (Fig. 5G, F). Both treatments abolished the enhanced auto-modification of 
ARTD1 by ARTD3, suggesting that the stimulation is indeed caused by 
contaminating DNA. The effect of EtBr was even concentration-dependent (Fig. 5G). 
We further investigated if addition of EtBr already during the purification of ARTD3 
could prevent this artifact. Indeed, supplementing wash buffers with EtBr during the 
ARTD3 purification abrogated the activation of ARTD1 by ARTD3 (Fig. 5H). 
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Figure 5: ARTD1 is not modified by ARTD3 and stimulation of ARTD1 by ARTD3 is mediated 
by DNA contamination 
A) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 from baculo or 
bacterial origin and 20nM myc-ARTD1-his with 100nM NAD+ (32P) in ARTD reaction buffer. 
CB= coomassie blot 
B) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 and 20nM, 
50nM, 200nM or 500nM myc-ARTD1-his with 100nM NAD+ (32P) in ARTD reaction buffer. 
CB= coomassie blot 
C) In vitro radioactive ARTD3 activity assay was performed with 20 or 500nM ARTD3 and 
20nM or 500nM myc-ARTD1-his with 100nM NAD+ (32P) in ARTD reaction buffer. CB= 
coomassie blot 
Results 
 132
D) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 and 20nM 
myc-ARTD1-his with 100nM or 1µM NAD+ (32P) in ARTD reaction buffer. CB= coomassie 
blot 
E) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 and 20nM or 
myc-ARTD1-his (wt) or inactive Y907A,C908Y mutant (ARTD3mut) with 100nM NAD+ 
(32P) in ARTD reaction buffer. CB= coomassie blot 
F) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 and 20nM 
myc-ARTD1-his with 100nM NAD+ (32P) in ARTD reaction buffer. DNA dependent 
activation of ARTD1 was inhibited by the addition of 100µg/ml Ethidiumbromide (EtBr) or 1 
U DNAse1. CB= coomassie blot 
G) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 and 20nM 
myc-ARTD1-his with 100nM NAD+ (32P) in ARTD reaction buffer. DNA dependent 
activation of ARTD1 was inhibited by the addition of 100 µg/ml or 50µg/ml Ethdiumbromide. 
CB= coomassie blot 
H) In vitro radioactive ARTD3 activity assay was performed with 500nM ARTD3 ARTD3 that 
was either washed with Ethidiumbromide (w) during purification or not washed (nw) and 
20nM myc-ARTD1-his with 100nM NAD+ (32P) in ARTD reaction buffer. CB= coomassie 
blot 
 
Together, these results identify ARTD3 as a mono-ADP-ribosyltransferase that is 
activated by RNA and histones. In addition, ARTD3 could modify H1 and core 
histones. Moreover, we could provide evidence that the recently reported activation of 
ARTD1 by ARTD3 is most likely due to DNA contamination of the ARTD3 protein. 
 
3.3.4 ARTD1 does not affect sickness behavior syndrome in mice but represses 
TNFα-dependent clock gene expression 
Circadian rhythms are indispensable for homeostasis in various organisms. They are 
maintained by a complex internal network of proteins 287,294. In mammals, circadian 
rhythms are organized in a hierarchical manner. In addition to the master clock in the 
suprachiasmatic nuclei (SCN) of the anterior hypothalamus that is entrained by light-
dark cycles, there are circadian oscillators in many other organs, including the liver 
295-303. The master clock synchronizes all peripheral clocks, which in turn can respond 
to and regulate various physiological and behavioral processes such as feeding 294,304. 
The peripheral clocks can sustain circadian rhythms for a few days without input from 
the master clock. Under specific circumstances, they can even overrule the central 
clock. Imposing artificial feeding schedules in rodents for example, can completely 
uncouple the peripheral clock from the central clock system 296,300. The timing 
mechanism in central and peripheral clocks was shown to be comparable and due to 
technical reasons, most of the studies on clock functions have been performed on 
peripheral clocks 304,305. On a molecular level, circadian rhythms are maintained by 
the two main transcription factors circadian locomotor output cycles kaput (CLOCK) 
Results 
 133 
and BMAL-1 that are rhythmically transcribed 306-309. There are interacting positive 
and negative feedback loops that ensure the oscillating gene expression of clock-
genes. CLOCK-BMAL1 heterodimers bind to E box enhancers and can activate 
transcription of their target genes 306,308. CLOCK-BMAL1 activates the transcription 
of period genes (Per 1-3) and cryptochrome genes (Cry 1-2), Rev-Erbα and of clock 
control genes such as DBP, Tef and Hlf. Cry and Per proteins translocate back into the 
nucleus, where they suppress CLOCK-BMAL1 transcription 310-314. Rev-Erbα 
transcription can be suppressed by Per2 and Rev-Erbα itself suppresses BMAL1 
transcription, leading to oscillating transcription of the latter 314-318. This central 
oscillator mechanism directly controls the rhythmic transcription of clock output 
regulators such as albumin D-element binding protein (Dbp). Dysfunctions of 
circadian rhythms are implicated in a wide range of diseases such as sleeping 
disorders and depression 304,319. 
 Sickness behavior syndrome (SBS) describes symptoms such as fever, fatigue, 
depression and reduced appetite that are commonly associated with autoimmune and 
infectious diseases 320. Many studies show that SBS is induced by cytokines such as 
interleukin 1 (IL-1) or tumor necrosis factor α (TNFα). Recently, an animal model for 
SBS in autoimmune diseases, employing stimulating antibodies for CD40, was 
established 321. The crosslinking of CD40 by the antibodies activates CD40 
expressing cells, mainly dendritic cells, monocytes and macrophages 321-324. SBS in 
mice injected with anti-CD40 antibody mimics SBS in humans displaying symptoms 
such as fatigue and reduced appetite which becomes apparent in different readouts 321. 
Mice reduce their activity in both movement through the cage (measured by infrared 
measurements) and in the use of the freely accessible running wheel. In addition, their 
body weight decreases tremendously. As a sign of the ongoing inflammatory 
processes, their spleen increases massively in size. Recently, it was described that 
TNF impairs the expression of E-box driven genes, and also CD40 antibody induced 
SBS in the mouse model is entirely dependent on TNF-receptor (TNFR) and results in 
deregulation of clock genes 325,326. Another study implicated cold inducible RNA 
binding protein (CIRBP) in the control of clock gene expression 327. CIRBP is a 
RNA-binding protein that can stabilize the transcript and influence its translation by 
binding to 3’ or 5’ untranslated regions (UTRs) 327-329. The expression of CIRBP is 
induced upon mild hypothermia or hypoxia 327-329. Loss of CIRB reduced the 
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amplitude of clock gene expression 327. Moreover, the authors describe a direct 
binding of CIRBP to mRNAs of clock genes, indicating that it influences their 
stability. 
 ARTD1 was described by our group in the food entrainment of the peripheral 
liver clock to poly-ADP-ribosylate CLOCK thereby interfering with its DNA-binding 
abilities 279. We thus investigated whether ARTD1 is involved in SBS by making use 
of the aforementioned CD40 antibody injection mouse model. wt and ARTD1-/- mice 
injected with a control (iso) antibody did not show any difference in bodyweight (Fig. 
6A). As expected, wt mice treated with an anti-CD40 antibody lost around 10% of 
their bodyweight within 2 days after injection of the antibody. ARTD1-/- mice showed 
a similar significant decrease in bodyweight, suggesting that they develop SBS 
comparable to wt mice in this model. SBS was also evident when measuring 
locomoter activity using running wheels (Fig. 6B) and infrared activity detection 
devices (Fig. 6C). Upon CD40 antibody injection, wt mice display a loss in both 
measurements for locomoter activity 321. The ARTD1-/- mice displayed a comparable 
loss in activity in both measurements after the injection of anti CD40 antibody, but 
not using the control antibody. Consistent with these findings, wt as well as ARTD1-/- 
mice showed splenomegaly as evidenced by the increase in spleen weight after CD40 
antibody injection, indicating an ongoing inflammatory process (Fig. 6D). Together, 
ARTD1-/- mice displayed symptoms of SBS comparable to wt mice, indicating that 
ARTD1 is unlikely regulating SBS. 
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Figure 6: ARTD1-/- mice lose weight, show splenomegaly and decreased activity upon injection 
of CD40 antibody. 
A) Body weight loss two days post injection of CD40 mAb or control IgG2a (iso), is shown as 
percent of body weight before injection. Wt n=2; ARTD1-/- n=6 shown are single and mean 
values T-tests: Non-parametric Mann-Whitney test. P values (two-tailed): *<0.05; **<0.005; 
***<0.0005. 
B) Running wheel (RW) activity of ARTD1 -/- mice was measured for the first day after i.p. 
injection of CD40 mAb or IgG2a as control. Baselines (red dots) are the mean of three 24 h 
recordings of day-1, day-2 and day-3 prior to injection of antibodies at day 0. Injection of 
CD40 or IgG2a control. Mean of 1-h values ± SEM 
C) Same as in B but infrared (IR) measurements. 
D) Spleen weight two days post induction was measured. Wt n=2; ARTD1-/- n=6 shown are 
single and mean values T-tests: Non-parametric Mann-Whitney test. P values (two-tailed): 
*<0.05; **<0.005; ***<0.0005. 
 
In order to analyse the ARTD1 effect on clock gene expression, CLOCK mRNA 
levels were measured in the liver 2 days after injection of the anti-CD40 antibodies. 
CD40 antibody injection indeed evoked a strong immune response, which was 
accompanied by an increase of IL6, IL1β and TNFα expression in the liver of ARTD1-
/- mice (Fig. 7A). BMAL1 and CLOCK expression was significantly increased, 
whereas Per1,3 and Rev-Erbα expression was not changed (Fig. 7B). The expression 
of the clock output genes Dbp and Hlf was not affected (Fig. 7C). 
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Figure 7: Gene expression in the liver of ARTD1-/- mice is changed upon injection of an anti 
CD40 antibody.  
A) Inflammatory gene expression in mouse liver two days post injection of CD40 or isotype 
control (iso) antibody, quantified by RT-PCR normalized to 18s rRNA. Values show 
mean±SEM. T-tests: Non-parametric Mann-Whitney test. P values (two-tailed): *<0.05; 
**<0.005; ***<0.0005. 
B) Same as in A but for basic clock genes 
C) Same as in A but for Clock-output genes.  
 
The same experiments with wt mice using anti-CD40 treatment revealed that CLOCK, 
Per3 and Rev-Erbα were down-regulated which resulted in decreased expression of 
clock output genes Dbp and Hlf 321. These results overall suggested that although 
ARTD1 does not influence locomoter activity, it has an effect on clock gene 
expression in the liver. 
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 To investigate the effect of ARTD1 on clock gene expression in more detail, 
we investigated synchronized 3T3 cells treated with TNFα (Fig. 8).  
 
 
Figure 8: ARTD1 knockdown cells show increased Clock gene expression.  
A) Starvation of confluent 3T3 shMock or shARTD1 cells in 1% FCS-containing medium over 
night followed by 4 hour treatment in 1% FCS with the indicated concentrations of TNFα. 
RNA was isolated, basic clock gene expression was analysed by qPCR and normalized 
against GAPDH levels. Shown are mean of three technical replicates±SEM. 
B) Same as in A but for Clock-output genes 
C) Same as in A but for control genes of the inflammatory response and knockdown controls.  
D) Same as in A, but starved wildtype cells were preincubated with 10µM PJ434 prior to TNF 
treatment. 
 
It was earlier described that in response to TNFα stimulation 3T3 cells suppress the 
expression of clock genes and a similar result was found in mice infused with TNFα 
325. Starved 3T3 cells with reduced ARTD1 protein levels as well as mock control 
cells were treated with different TNFα concentrations for four hours and clock gene 
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expression was analysed (Fig. 8). As expected, higher concentrations of TNFα led in 
to a down-regulation of CLOCK-BMAL1 target genes (such as Dbp, Tef, Hlf and 
Per3) in both shMock and shARTD1 cells. Knockdown of ARTD1 increased 
CLOCK-BMAL1 as well as Per3 and Rev-erbα expression under all tested TNFα 
concentration as well as in unstimulated cells (Fig. 8A). The expression of the tested 
CLOCK-BMAL1 target genes were upregulated in shARTD1 cells under both 
unstimulated or TNFα treated conditions (Fig. 8B). To test if ADP-ribosylation was 
involved in the observed regulation, cells were treated with PARP inhibitor with the 
TNFα stimulation. Indeed, an up-regulation of Dbp and Per3, as well as IL6, could be 
observed in inhibitor treated cells (Fig. 8D). These results suggested that ARTD1 and 
its enzymatic activity act as a repressor for clock gene expression. 
In order to confirm that a transient knock-down of ARTD1 would generate the 
same results, 3T3 cells were transfected with siMock or siARTD1 and the experiment 
repeated as described above (Fig. 9). As expected, treatment with TNFα decreased 
clock gene expression in a concentration-dependent manner (Fig. 9A, B). Consistent 
with the previous experiments, siARTD1 cells showed slightly higher expression of 
CLOCK and BMAL1, and a striking increase in their target genes Per1-3, as well as 
the output genes Dbp, Hlf and Tef, which was already observed under unstimulated 
conditions (Fig. 9A, B). Also, IL6 expression was increased in siARTD1 cells, which 
is consistent with unpublished data from our laboratory (Fig. 9C; unpublished 
results). To investigate the effect of ARTD1 depletion on CIRBP mRNA levels, we 
measured CIRBP expression in the same samples (Fig. 9D). TNFα treatment down-
regulated CIRBP expression in a concentration dependent manner in both siMock and 
siARTD1 cells. siARTD1 treated cells showed an increase in CIRBP levels in 
comparison to siMock cells, suggesting that ARTD1 might influence CIRBP 
expression levels which could subsequently stabilize CLOCK mRNAs and thus lead 
to the observed increase in clock gene expression. 
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Figure 9: Transient knockdown of ARTD1 increases clock gene expression and CIRBP 
expression in 3T3 cells independent of FK866. 
A) 3T3 cells were transfected with anti-ARTD1 siRNA or with a mock control. 48 hours after the 
transfection cells were starved overnight in medium containing 1% FCS in the presence or 
absence of 100nM FK866. Starved cells were treated for 4 hours with the indicated 
concentrations TNFα in the presence or absence of 100nM FK866 in 1% FCS medium. RNA 
was isolated, basic cock gene expression was analysed by qPCR and normalized against 
GAPDH levels. Shown are mean of three technical replicates±SEM. Basic clock genes 
B) Same as in A but for Clock-output genes 
C) Same as in A but for control genes of the inflammatory response and knockdown controls.  
D) Same as in A CIRBP expression levels 
 
The observed change in CLOCK gene expression upon siARTD1 treatment could be 
indirectly caused by increased cellular NAD+ levels due to the lack of ARTD1 as 
NAD+ consuming enzyme and the subsequent activation of sirtuins. Experiments 
were thus repeated in presence of FK866, an inhibitor of niacinamide-
phosphoribosyl-transferase (NAMPT) to reduce cellular NAD+ levels 330. The 
addition of FK866 did not change the expression of CLOCK or clock output genes 
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neither in siMOCK nor in siARTD1 cells (Fig. 9A,B), indicating that the cellular 
NAD+ levels are less likely to contribute to the observed gene expression changes. 
Treatment of 3T3 cells with PJ34 (PARP inhibitor) however increased CLOCK gene 
expression (Fig. 8D). The discrepancy between FK866 and PARP inhibitor treatment 
might indicate that ARTD1 consumes NAD+ from cellular sources that are not 
affected by FK866 (e.g. protein-bound NAD+). Another possibility would be that 
PJ34 is inhibiting an off-target.  
 In summary, our results provide evidence that ARTD1 represses clock-gene 
expression in the liver, which, however, does not affect SBS in mice. In cell culture 
experiments, we could reproduce an effect of ARTD1 knockdown on clock gene 
expression. The effect of ARTD1 on gene expression was already observed in cells 
that were not stimulated with TNFα, but was maintained upon TNFα stimulation. 
This could indicate an effect of ARTD1 on the chromatin structure at regulatory 
regions of CLOCK genes. Also, we observed increased expression of CIRBP in 
siARTD1 cells which could indicate that the stabilization of clock genes mRNA 
might be affected indirectly (data not shown). However, further experiments, such as 
WB analysis of CIRBP or RNA stability measurements, would be required to 
determine the exact role of ARTD1 and PAR formation in this context.  
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3.3.5 Material and methods 
Embryonic stem cell genotyping 
The targeting vector for tissue specific knockouts for ARTD1 was bought from 
Eucomm (European Conditional Mouse Mutagenesis Program, Lemförde, Germany, 
http://www.mousephenotype.org/martsearch_ikmc_project/about/eucomm). 
Embryonic stem cells (ESCs) were transfected and DNA isolation was performed by 
Polygene (Rümlang, Switzerland). 
The following primers were used to genotype ESCs:  
5’-CACTGAACTGTCTCCTTAGCCAACTCTGC-3’GF3 
5’-CTAGGATTCTGTGTCTTGACCATGCACTTG-3’ GR4 
5’-CACACCTCCCCCTGAACCTGAAAC-3’ RAF5 
5’-CACAACGGGTTCTTCTGTTAGTCC-3’ LAR3 (all sequences from Eucomm) 
5’-GCTTCTACTACCTCCCAAGAAAGAGCG-3’ 1405 
For short PCR fragments GoTaq polymerase was used (Promega, Madison, WI, USA) 
according to the manufacturer’s instructions. For long PCR amplicons, the expand 
long template PCR system was used (Roche, Basel, Switzerland) employing buffer 
system 2 according to the manufacturer’s instruction. PCR program: 93°C 2:00; 
(93°C 0:10; 50°C 0:30; 68°C 8:00) x10; increase extension time at 68°C by 0:40 
every second cycle until cycle 28; 68°C 07:00; 4°C. For the improved PCR program, 
the annealing temperature was increased to 60°C. PCR amplicons were analysed on a 
1% agarose gel. 
 
Cell culture 
3T3 and 3T3-L1 cells were cultivated in Dulbecco's Modified Eagle's Medium 
(DMEM) (PAA, Pasching, Austria, supplemented with 1% (v/v) 
Penicillin/Streptavidin and 10% (v/v) fetal calf serum (Gibco, Invitrogen, CA, 
California, USA). 3T3-L1 cells were differentiated at 80% confluence. For 
differentiation, the medium was changed after 2 days and induction medium 
(containing 5µg/ml insulin (I-9278), 0.25mM 3-isobutyl-1-methylxanthine (I-5879) 
and 0.5µM dexamethasone (D-4902); all from Sigma Aldrich (St. Louis, MO, USA) 
was added for 3 additional days. From day 5 onwards, the medium was changed every 
second day to regular DMEM containing (1µg/ml). Rosiglitazone (Sigma Aldrich, St. 
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Louis, MO, USA) was supplemented at 1µM and ABT888 (Enzo Life Sciences, 
Farmindale, NY, USA) was added at 10µM every second day starting at day 7. 3T3 
cells were plated at 80% confluence. After one day, at 100% confluence, they were 
starved overnight in DMEM containing 1% FCS and 0.1% Penicillin/Streptavidin in 
the presence or absence of 100nM FK866 (Sigma Aldrich, St. Louis, MO, USA). 
Cells were pretreated for 1 hour with 10µM PJ34 (Alexis Biochemicals, San Diego, 
CA) prior to treatment with recombinant murine TNFα (Sigma Aldrich, St. Louis, 
MO, USA) at concentrations ranging from 0.01ng to 10ng for 4 hours. 
 
siRNA transfection 
15pmol siRNA (Negative control allstars (siMock), mouse siPARP1 #5, Qiagen, 
Hilden, Germany) were transfected with RNAi MAX lipofectamine (Invitrogen, 
Carlsbad, CA, USA). 2 days after transfection cells were 100% confluent. 
Knockdown was verified by qPCR. 
 
RNA isolation and qRT-PCR  
Total RNA from 3T3-L1 cells was extracted using TRIzol (Invitrogen, Carlsbad, CA). 
DNase treatment was performed using the TURBO DNA-freeTM Kit (Life 
Technologies, Carlsbad, CA, USA). Total RNA from mice tissue for the adipocyte 
study was isolated with TRIzol. Equal amounts of RNA were reverse transcribed 
using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA). Quantitative-real-time polymerase chain reactions (qPCR) were 
performed with SYBR® green SensiMix SYBR Hi-ROX Kit (Bioline Reagents Ltd, 
London, UK) in a Rotor-Gene Q 2plex HRM System (Qiagen, Hilden, Germany). 
Cyclophilin was chosen as the internal control for normalization after screening 
several candidate control genes for 3T3-L1 cells. 36BP4 was used for normalization 
of mice samples. RNA from 3T3 cells was extracted using NucleoSpin - RNA II kit 
(Macherey-Nagel, Düren, Germany). RNA from mouse tissues harvested for the 
analysis of clock gene expression was extracted by homogenization of the organ in 
peqGOLD RNA pure (PeqLab, Erlangen, Germany) according to the manufacturer’s 
instructions. Subsequently, RNA was reverse-transcribed using random hexamers 
(Fermentas, Waltham, MA, USA) and M-MuLV reverse transcriptase (Roche, Basel, 
Switzerland). Equal amounts of cDNA were amplified in an ABI 7900 HT detection 
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system (Applied Biosystems, Foster City, CA, United States) using the TaqMan 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA, United States). 
The relative levels of each RNA were calculated by the ΔΔCT method, with eEF1a1, 
18s rRNA or GAPDH as housekeeping genes.  
 
Mice 
For the clock gene analysis, C57BL/6J mice were purchased from RCC Ltd. 
(Füllinsdorf, Switzerland). ARTD1-/- mice were supplied by our laboratory. Male 
mice aged between 8–12 weeks were used. Experiments were performed according to 
Taraborelli and coworkers 321. Locomotor activity was measured by recording either 
motor activity in the cages or using freely accessible running wheels. Activity 
recordings were based on 1 min episodes by using the Chronobiology Kit software 
(Stanford Software Systems, Santa Cruz, CA, USA). Three days (day-1, -2, -3) 
preceding injection were averaged and used as baseline activity. At day 0, mice were 
injected i.p. at Zeitgeber time (ZT)5 with 200µg CD40 mAb (clone FGK4.5; rat 
IgG2a anti-mouse CD40, BioX Cell, West Lebanon, NH, USA) in 200µl PBS. As an 
antibody control, 200µg rat IgG2a isotype control (clone 2A3, BioX cell) in 200µl 
PBS was used. Two days after injection, mice were sacrificed and used for the 
analysis. 
For the adipocyte studies, experiments were performed with young adult (6–9 weeks) 
male mice kept on an inverted 12h dark/light cycle, fed ad libitum chow diet. For the 
cold stimulation, animals were housed in type II cages with 2 animals per cage. 
Following acclimatization at 23°C, air temperature was lowered to 8°C for 7 days. 
Animal experiments were performed according to the regulations of the Cantonal 
Veterinary Office (Zurich, Switzerland). 
 
Western Blotting 
Protein amounts were assessed using the DC Protein Assay (Bio-Rad). 30µg of 
protein extract was loaded and separated on 7.5% SDS-polyacrylamide gels. Gels 
were blotted on a PDVF membrane and analysed by using protein specific antibodies 
and an Odyssey-detection system using fluorescent-dye-coupled 2nd antibodies (LI-
COR Biosciences, Cambridge, UK).   
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Antibodies 
Following antibodies were used: From Santa Cruz Biotechnology, Inc (Dallas, TX, 
USA): PARP1/ARTD1 (H-250, rabbit); From Sigma Aldrich (St. Louis, MO, USA): 
tubulin (mouse). The PAR 10H (mouse) was provided by Paul O. Hassa (IVBMB, 
University of Zurich). 
 
In vitro ARTD1/3 activity assays 
Recombinant, full-length, his-tagged ARTD1 and ARTD3 proteins were generated in 
Sf21 cells using the BacPAK system (Clontech). Purification was performed in batch 
using Ni2+-beads/Nitrobond (Invitrogen). If not stated otherwise, proteins were 
washed with EtBr-containing wash buffer during purification. 20nM or 500nM HA-
ARTD3-his and 20nM, 50nM or 500nM of myc-ARTD1-his were incubated for 
10mins at 24°C with 100nM, 1µM, 10µM or 100µM 32P labeled NAD+ in ARTD 
reaction buffer (250mM Tris-HCl pH8, 20mM MgCl2, 1.25mM DTT, 5µg/ml P/B/L – 
proteinase inhibitors) in the presence or absence of 5pmol Eco Linker, or other 
DNAs, as indicated in the figure legends. For activation by histones either 1µg 
Histone Mix containing core histones from (Roche, Basel, Switzerland) or 1µg 
recombinant H1.4 was used. For activation by RNA, 0.75µg of in vitro transcribed 
RNA was used (obtained from Karolin Leger, IVBMB, Zurich, Switzerland). The 
reactions were stopped by the addition of sample buffer. The samples were seperated 
on 12% SDS polyacrylamide gels and gels were stained with coomassie, de-stained, 
and subjected to film exposure. To inhibit DNA-dependent activation, reactions were 
supplemented with 100µg/ml or 50µg/ml Ethidiumbromide (EtBr, Sigma Aldrich, St. 
Louis, MO, USA) or preincubated with 1U DNAse I (Roche, Basel, Switzerland) for 
15mins at 30°C.  
 
ADP-ribose product analysis 
For cold product analysis, a protocol described by Malanga and coworkers was 
adapted 331. Briefly, 6µg of ARTD1 and ARTD3 were incubated for 45mins at 30°C 
in reaction buffer (100mM Tris pH8.0, 10mM MgCl2 and 125mM NaCl) with 1mM 
NAD+ and 1µg NHEI-digested CMV-GFP plasmid in the presence or absence of 6µg 
H1.4. Proteins were precipitated by the addition of BSA and 40% (w/v) ice-cold TCA 
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on ice. The resulting pellet was washed with ethanol 99.8% and then with ice-cold 
diethylether. Polymers were detached using 0.5M KOH/10mM EDTA and DNAse I, 
RNAse A and proteinase K digestion. After extraction with phenol–chloroform–
isoamyl alcohol, PAR was precipitated with ethanol overnight. Following 
centrifugation, PAR was air-dried and resuspended in 50mM Tris pH 7.5 and 10mM 
EDTA. The polymers were separated on 2M urea 20% acrylamide sequencing gels 
and visualized by silver staining according to the manufacturer’s instructions (Pierce, 
Thermo Fisher Scientific, Rockford, IL, USA). 
For radioactive product analysis, 6µg of ARTD1 and ARTD3 were incubated for 
45mins at 30°C in reaction buffer (100mM Tris pH8.0, 10mM MgCl2 and 125mM 
NaCl) with 10µM NAD+ and 1µg NHEI-digested CMV-GFP plasmid in the presence 
or absence of 6µg H1.4. Proteinase K was added to the reactions and was incubated 
over night at 37°C. Reactions were separated by 10% urea-PAGE at 45W for 90min 
and exposed to an X-ray film.  
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4 Discussion and Perspectives 
4.1 ARTD1 controls adipocyte differentiation and function 
The differentiation of preadipocytes into adipocytes is driven by a tightly regulated 
cascade of transcription factors. It is accompanied by drastic changes in the chromatin 
structure and the establishment of so called transcription hotspots that, in addition to 
the recruitment of several transcription factors, are also characterized by an open and 
permissive chromatin structure. This permissive chromatin structure is established by 
cofactors that are recruited by activated transcription factors such as PPARγ and 
allows high expression of adipocyte-specific genes. In this thesis we identified a role 
for ARTD1 in adipocyte differentiation. One published paper describes an increase in 
PAR formation during the late phase of adipogenesis that was mediated by site-
specific, topoisomerase II-mediated ds-DNA breaks and was required for PPARγ-
dependent gene expression 332. In another paper, these findings were validated and 
confirmed in vivo using ARTD1-/- mice. Adipogenesis was impaired in adipose 
derived stromal cells (ASCs) obtained from ARTD1-/- mice 333. In addition, wt ASCs 
showed less differentiation when subjected to PARP inhibitor treatment. ARTD1-/- 
mice showed decreased weight gain on high fat diet, but developed hepatic steatosis. 
In our newest submitted manuscript, we present data from PARP inhibitor-treated 
mice strengthening the importance of ADP-ribosylation for adipogenesis in vivo. 
PARP inhibitor treated mice show reduced body weight, fat mass, smaller adipocytes 
and an altered PPARγ-dependent gene expression. We further investigated the 
mechanistic details of ARTD1 requirement during adipogenesis. By using different 
PARP- as well as PARG-inhibitors, we could confirm that PAR formation is required 
for PPARγ-dependent gene expression and the cofactor exchange at PPREs. In 
absence of PAR, there was increased recruitment of the corepressor NCOR-1 to 
PPARγ-target sites while p300 levels were decreased.  
Recently, a role of ARTD1-dependent PAR formation in PPARγ-dependent 5-
hydroxymethylation of PPREs was described 285. This model suggests PARylation of 
a PPARγ-co-activator complex leading to recruitment of TET proteins that induce 
region-specific demethylation (conversion to hydroxmethly-C). Although presenting a 
potentially interesting mechanism, a lot of details are still unclear. The authors only 
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analyse one PPRE of one gene, but it is completely unclear if all PPREs behave the 
same in this regard. Also, it is unclear which component of the co-activator complex 
is PARylated. Comparable to our results, the authors observe the requirement of PAR 
for the recruitment of a cofactor. In contrast, our own analysis of DNA methylation 
revealed only a slight effect upon PARP inhibitor treatment (data not shown, 
experiment performed by Süheda Erener, IVBMB, University of Zürich). In addition, 
inhibition of DNMTs during differentiation led to a decrease in gene expression (data 
not shown), which suggests that de novo methylation is beneficial for adipocyte 
differentiation. The requirement for global demethylation during adipogenesis is 
controversial and it is currently unclear if PPARγ and PPARγ ligands are involved in 
this process 334-337. Especially in regard of the establishment of transcriptional 
hotspots during differentiation, it would be interesting to analyse DNA methylation 
during adipogenesis. This could be done by performing genome wide DNA 
methylation and hydroxymethylation assays such as methylated DNA 
Immunoprecipitation (meDIP), hydroxymethylated DNA Immunoprecipitation 
(hmeDIP) or bisulfite and oxidized bisulfite sequencing 338-341. A recent study on 5-
hydroxymethalyation in 3T3-L1 cells suggests that 5-hydroxymethalyation in 3T3-L1 
cells is acquired early during differentiation and maintained throughout differentiation 
342. This dataset could be compared to the sites of hotspot formation and ARTD1 
binding.  
Adipogenesis is accompanied by the establishment of hotspots that can prime 
certain DNA sites for the binding of later transcription factors. It would be interesting 
to analyse the role of ARTD1 in these hotspots. It is unlikely that ARTD1 is involved 
in the establishment of hotspots, as we observe PAR formation and ARTD1 
recruitment to PPREs only in the late phase of adipogenesis. However, it would be 
interesting to perform a genome wide analysis of ARTD1 binding in undifferentiated 
and differentiated 3T3-L1 cells (ChIP-Seq). Such experiments would provide 
evidence, to which genes ARTD1 is recruited and reveal if prior priming by a hotspot 
is needed for ARTD1 binding. It could be that ARTD1 is important for the 
maintenance of the late enhanceosome. Shortly after induction of differentiation, 
more than 22 000 new DHS (DNAse1 hypersensitive regions) are established, of 
which at least half are gone at day 7 of differentiation 199. ARTD1 might help to 
establish whether a hotspot stays in an open chromatin conformation or is closed. 
Only 33% of all PPARγ-binding sites are remodeled before PPARγ binding 199. It 
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could also be that ARTD1 is only needed at these sites and not at those primed by 
hotspots. Genome wide analyses throughout the differentiation process would help to 
answer these questions.  
PPARγ is a ligand-dependent transcription factor. Ligands described to 
activate PPARγ include various polyunsaturated fatty acids and derivatives 
227,228,230,231,233. In addition, during adipogenesis, the cells acquire a high lipogenic 
capacity. Both the expression of enzymes important for de novo fatty acid synthesis 
as well as for triacylglycerol synthesis, are increased tremendously 237-239. So although 
there is increased fatty acid synthesis, these fatty acids are stored in form of 
triglycerides in lipid droplets 240. Cellular fatty acids can originate from different 
sources. They may be taken up as unesterified plasma fatty acids or as fatty acids 
generated by lipoprotein lipase (LPL)-mediated hydrolysis of chylomicrones in tissue 
capillaries, or originate from de novo synthesis. Fatty acids from all these sources can 
activate PPAR-mediated gene expression 241,343-345. However, there remain 
unanswered questions. The above mentioned papers describe the activation of PPARα 
and ∂ but not of PPARγ. In addition, it is currently unknown whether fatty acids 
require esterification to triglycerides and subsequent rehydrolysis (lipolysis) before 
signal transduction to the nucleus 241. Therefore it is possible, that these fatty acids 
need to be released by lipases such as ATGL or hormone sensitive lipase (HSL) in 
order to activate PPARγ 242,243. Indeed, HSL deficient mice show less PPARγ activity 
and smaller adipocytes 243. ATGL deficient mice showed less PPARα activity, which 
could be reversed by the treatment with PPARα agonists, indicating a role of ATGL 
in the generation of endogenous PPAR agonists 241. It is an intriguing possibility that 
PAR formation maintains PPARγ- dependent gene expression in the absence of a 
PPARγ-ligand. Our data indicate that a PPARγ-ligand is needed for initial activation 
of PPARγ, but once PAR formation is induced, it ensures transcriptional activation of 
PPARγ-target genes in the absence of a ligand. Consistent with this, we could reverse 
the inhibition of PPARγ-dependent gene expression due to PARP inhibitors by 
supplementing cells with an artificial PPARγ-ligand (Rosiglitazone).  
 BAT has completely different features and functions than WAT 135. However, 
PPARγ is also important for the formation of BAT 244,245,346. It would be thus of great 
interest to investigate the effect of ARTD1 and PAR formation on the differentiation 
and function of BAT. As over-activation of PPARγ is connected to increased BAT 
formation, it is likely that PAR formation is also required in this process 168. 
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Preliminary results suggest an effect of PAR formation in these processes. Inhibition 
of PAR formation inhibited the Rosiglitazone-induced increase in UCP-1 expression. 
ARTD1-/- mice were described to have an increased BAT and an increased number of 
mitochondria in their brown adipocytes, whereas ARTD2-/- mice showed no effect on 
BAT 280. We plan to further analyse the browning potential of ARTD1-/- and ARTD2-
/- mice by exposing them to cold and consecutively measuring their BAT content and 
quality of the BAT (by histological analysis). This will answer the question if ARTD1 
or ARTD2 are required for the browning of adipocytes. However, detailed 
mechanistic studies need to be performed for example by studying ARTD1 or 
ARTD2 depletion on the browning of 3T3-L1 cells. 
Binding of PPARγ and PPARγ ligand to PPREs has a stimulatory effect on 
adipogenic gene expression. However, PPARs are also important regulators of the 
immune system 347. Ligands for PPARγ and PPARα were shown to have considerable 
anti-inflammatory activities in different models for inflammatory and autoimmune 
diseases such as experimental autoimmune encephalomyelitis, inflammatory bowel 
disease, and arthritis 347-362. PPARγ expression is not restricted to adipocytes but to a 
lesser extent it is also found in the colon, the retina and in the immune system 363. 
Mice with only one copy of PPARγ and targeted knockouts for PPARγ in 
macrophages or the intestinal epithelium all showed increased susceptibility to 
chemically induced colitis 347,364-366. The suppression of transcription of inflammatory 
mediators involves both PPARγ-dependent and -independent pathways, which 
complicates the analysis of experiments and the therapeutic use 367-370. However, it is 
well documented, that PPARγ can repress the expression of inflammatory genes by a 
process that involves protein-protein interactions rather than sequence-specific DNA 
binding 371. This process is called transrepression and has been described for PPARγ 
and NF-κB in macrophages, for example 371,372. In this context, transrepression is 
mediated by ligand-dependent SUMOylation of PPARγ, which recruits the latter to 
NCOR1/HDAC corepressor complexes at inflammatory gene promoters such as 
inducible nitric oxide synthase (iNOS). This binding inhibits the stimulus (LPS)-
induced release of corepressors and maintains the promoter in a repressed state. We 
showed in this thesis, that PAR formation is required for ligand-induced cofactor 
exchange and PPARγ-dependent gene expression. It would be interesting to 
investigate if the transrepression of NF-κB by PPARγ is also dependent on PAR 
formation. It could be that the dependency on PAR distinguishes the two modes of 
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action of PPARγ-dependent transrepression and transactivation. This could be 
investigated in LPS-stimulated macrophages. It would be interesting to analyse NF-
κB-dependent gene expression in the presence or absence of PPARγ agonist and 
PARP inhibitors. In addition, the effect of PARP inhibition on the SUMOylation 
status of PPARγ could be investigated. It is known that there is a massive crosstalk 
between different PTMs 373,374. For example, PARylation was described to be affected 
by other PTMs such as methylation 19,375. The involvement of ARTD1 and PAR 
formation in transrepression is an intriguing possibility, especially because ARTD1 
has been implicated as a coregulator of NF-κB 90. After the induction of the 
inflammatory response by LPS or streptocozin, various proinflammatory cytokines 
are down-regulated in ARTD1-/- mice 90,376-383. This could also be confirmed in in 
vitro models 86-90. However, the involvement of ARTD1 enzymatic activity remains 
controversial. Early studies described PARylation of p65 and indicated that this 
modification suppressed NF-κB-dependent gene expression 384,385. On the other hand, 
ARTD1 has also been described to coregulate NF-κB-dependent gene expression 
independent of its enzymatic activity 86,88-90,382,386. The importance of PAR formation 
for the control of NF-κB-dependent gene expression needs to be further investigated 
and should be extended regarding transrepression by PPARγ.  
Roles for ARTD1 in the control of gene expression have been described in 
different physiological situations 5. Whether ARTD1 functions as a corepressor or 
coactivator depends on the transcription factors, cell types and stimuli that are used 
5(and unpublished data of our laboratory). In some contexts, ARTD1 is a coactivator 
387-390, whereas in others it acts as a corepressor 91,391-393. In this thesis we show 
evidence, that in clock-dependent gene expression ARTD1 acts as a repressor, which 
has also been reported in a previous study where ARTD1 was described to PARylate 
CLOCK-BMAL thereby interfering with their DNA-binding capacity279. In the 
presented data we observed increased CIRBP mRNA expression upon ARTD1 
depletion, providing an additional possibility to regulate the stability of certain 
mRNAs. However, further studies such as confirmation of the increased expression 
by Westernblot analysis or knockdown of CIRBP and RNA-stability measurements 
need to be performed to confirm this hypothesis. An important question is how such 
an abundant protein like ARTD1 can specifically control pathways in different ways. 
One possibility is that the availability of cofactors such as p300/NCOR, different 
adaptor molecules, or different posttranslational modifications might be responsible 
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for the different actions of ARTD1. We know from unpublished results from our lab 
that different cell lines show different transcriptional responses to the knockdown of 
ARTD1 and stimulation with LPS or TNFα (Roberta Minotti, IVBMB, University of 
Zürich). For example, macrophages express more IL6 upon ARTD1 knockdown, 
whereas mouse lung fibroblast cells show the opposite effect. Interestingly, 
macrophages also express PPARγ. It would therefore be interesting to investigate if 
the effect of ARTD1 depletion depends on the expression of PPARγ.  
This aspect is especially interesting in regard of diseases associated with 
obesity, such as Type II diabetes, cancer or atherosclerosis, where inflammatory 
aspects are important 146-149. It would be of great interest to elucidate the role of 
ARTD1 in the inflammatory component of these diseases. In analogy to our findings 
it could be that PAR formation maintains PPARγ in an activated state and 
consequently controls adipocyte genes and suppresses transrepressory activities. It 
would thus be interesting to test if PPARγ is also associated with PAR at 
inflammatory genes, for example by ChIP analysis for PAR and PPARγ and ReChIP 
analysis combining both PAR and PPARγ ChIP. For this thesis, we have analysed the 
inflammatory gene expression profiles in the liver of ARTD1-/- mice, which showed a 
reduction for various cytokines such as IL6, IL10 and IL12 333. This could indicate 
that deletion of ARTD1 indeed abrogates PPARγ-driven gene expression in 
adipocytes and increases transrepression of inflammatory genes. Also, in this regard it 
would be interesting to analyse cytokine levels of mice treated with PARP inhibitor. 
Although controversial, PPARγ was described to be involved in macrophage 
differentiation 236,394,395. In ARTD1-/- mice also MPEG1 and Pu.1 were reduced, 
which are markers for macrophage differentiation 333. This all suggests that PAR 
formation controls various functions of PPARγ.  
Given the effect of ARTD1 knockout on inflammatory gene expression in the 
liver, one could hypothesize that these animals show increased glucose tolerance. 
However, when ARTD1-/- mice were subjected to a glucose tolerance test (GTT), they 
showed reduced glucose tolerance along with increased insulin secretion 333. This was 
likely due to dyslipidemia and excessive lipid accumulation in the liver. Mice on HFD 
treated with a PARP inhibitor for 18 weeks, however, do not show an accumulation of 
fat in the liver (data not shown from Eijia Pirinen, EPFL). This suggests that in this 
process the ARTD1 protein plays a role that is independent of its enzymatic activity. 
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It would be extremely appealing to investigate this additional role in conditional and 
tissue specific ARTD1-/- models. In addition, it would be fascinating to investigate the 
glucose homeostasis in these animals that could likely reveal very different results as 
compared to the ARTD1-/- mice. Especially because there seems to be no symptoms 
of NAFLD (non alcoholic fatty liver disease), PARP inhibitors could be assessed as a 
potential treatment for obesity and associated inflammatory syndromes. It would thus 
be interesting to test PARP inhibitors in animal models of type II diabetes. ARTD1-/- 
mice were described to be protected from streptozotocin induced diabetes, which 
more closely resembles type I diabetes in human 396,397. The PARP inhibitor PJ34 was 
tested in a model for type II diabetes in db/db diabetic animals and showed a slight 
effect on serum glucose concentration 398. The effect of more specific PARP 
inhibitors should be tested in a model for type II diabetes and other obesity related 
disorders.  
 In addition, it would be interesting to investigate the association of the 
susceptibility for the development of type II diabetes with mutations in the ARTD1 or 
PARG genes. This could hint at a role of these proteins in the development of type II 
diabetes and thus indicate their potential as diagnostic markers for this disease. 
Interestingly, recent studies about metabolic signatures in type II diabetes revealed a 
downregulation of NAD+ levels in type II diabetes patients, which was connected to 
widespread transcriptional changes 399. It would thus be captivating to analyse how 
PARP inhibitor-treatment affects whole metabolic network and homeostasis in mice. 
Finally, it would be helpful to analyse the transcriptomes of different tissues of PARP 
inhibitor treated mice to be able to appreciate how PAR formation controls glucose 
homoeostasis and homeostasis of metabolites. 
 
4.2 ARDT3 is a mono-ART that is activated by histones and RNA and is 
involved in DNA double strand break repair 
The ARTD protein family consists of 18 members that can transfer ADP-ribose to 
acceptor proteins. ARTDs possess different enzymatic activities and can form either 
mono- or poly-ADP-ribose. Regarding ARTD3, it is still unclear if it catalyzes mono- 
or poly-ADP-ribosylation. In the unpublished results we showed that ARTD3 is 
weakly active and catalyzes only mono-ADP-ribosylation on itself and on target 
proteins (such as histones). In addition, ARTD3 was activated by RNA and core 
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histones and ADP-ribosylated the latter as well. Given the distinct functions of ARTD 
family members and their involvement in different cellular functions, it is extremely 
important to generate inhibitors that target certain ARTD members specifically. In 
this thesis, a paper is presented where our collaborators from the group of Prof. Dr. 
Herwig Schüler developed an inhibitor that specifically targets ARTD3 400. We could 
verify the function of this inhibitor in cells.   
Although ARTD3 contains a catalytic domain which is similar to ARTD1, its 
catalytic activity is significantly lower compared to ARTD1. While a few labs could 
detect poly-ART activity for ARTD3, others describe no or only mono-ART activity 
18,106-108. A study of human ARTD3 produced in bacteria raised the possibility that 
this enzyme might be a mono-ART 108. We provide evidence in this thesis, that also 
ARTD3 purified from insect cells was only able to transfer ADP-ribose monomers. 
This is in line with another report of our lab 18. The PARP domains of ARTD3, 
ARTD2 and ARTD1 share 35% sequence similarity and their structure is very similar 
401-404. Overall, the NAD+ binding site and the PARP signature motif are well 
conserved 402. The loops surrounding the active site show the most important 
differences in the catalytic domain that allowing the development of an ARTD3 
selective inhibitor 400,402. ARTD3 even contains a glutamate (Glu514) corresponding to 
Glu988 in ARTD1, which was suggested to convey poly-ART activity 405. Apparently, 
the presence or absence of this catalytic glutamate does not distinguish between 
mono- and poly-ART activity. 
It was demonstrated, that the catalytic and WGR domains tightly cooperate 
with their corresponding amino-terminal domains 18. This is shown by the fact, that 
the C-terminal domain of ARTD1, if replacing the corresponding domain in ARTD3 
or ARTD2, does not convey poly-ARTD activity. What conveys poly-ART activity 
is, however, not known yet and it would be intriguing to investigate this question 
using different ARTD1/3 chimera. It could for example be imagined that the proteins 
need their own WGR or that only the exchange of a few amino acids surrounding the 
catalytic core could make a difference. Establishing these chimeras and testing their 
activity is ongoing in our laboratory. In addition, it would be of great interest to 
identify the acceptor amino acids that can be modified by ARTD3 in ARTD3 itself 
(automodification) and in other target proteins (transmodification). Loseva et al. claim 
that the automodification takes place on glutamates or aspartates, because it is 
sensitive to hydroxylamine treatment 108. However, in their hands also ARTD1 
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modifications were sensitive to this treatment, although ARTD1 was shown to also 
modify lysine residues 18,19. The identity of the amino acids targeted by ARTD3 
remains to be investigated for example by mass spectrometry approaches. 
ARTD1 is strongly activated by DNA, however whether ARTD2 and ARTD3 
are activated by DNA remains controversial 2. Two studies did not observe a 
stimulation of ARTD3 by DNA 18,108. In contrast, other studies observed a slight 
increase in ARTD3 activity upon addition of DNA 106,107. In our present study 
employing different DNA constructs to answer this question no activation of ARTD3 
by DNA was observed. The three zinc fingers in the N-terminal domain of ARTD1 
are required for DNA binding and DNA-dependent activation of ARTD1. However, 
these are missing in ARTD3 as well as in ARTD2, which is only slightly activated by 
DNA 18 (and unpublished data from our lab). However, ARTD2 can be activated by 
RNA through its SAP (SAF/Acinus/PIAS-DNA-binding domain) domain 
(unpublished data from our lab). Although ARTD3 does not contain a SAP domain, 
we could show that it is also activated by RNA. ARTD3 does, however, contain a 
WGR domain that could mediate binding of nucleic acids. For example, the WGR 
domain was shown to be involved in the binding and activation of ARTD1 to ss-RNA 
293. If the WGR domain conveys the activation of ARTD3 by RNA remains to be 
investigated by employing mutants lacking this domain. 
ARTD3 can modify histone H1 and we could show that it can also modify 
core histones, a previously unknown substrate for ARTD3 107,108. Previously, it was 
shown that ARTD3 can bind to the histone variants H3C and H2BE in cells, 
supporting the idea that ARTD3 is activated by histones in vivo 108,406. Interestingly, 
addition of histones (H1 or core histones) increased ARTD3 auto- and 
transmodification activity. We excluded the possibility that the activation of ARTD3 
could be conveyed by contamination with ds-nucleic acids by supplementing 
ethidiumbromide to our reactions. However, since binding of EtBr to single-stranded 
DNA/RNA is relatively poor, it can currently not be ruled out that a contamination of 
the histones with single-stranded nucleic acid might cause this increase in ARTD3 
activity. To test this possibility further experiments including pretreatment of histones 
with RNAse or DNAse will be performed. It is notable that contradictory results were 
published by others and obtained by our laboratory regarding ARTD3 enzymatic 
activity, although sometimes even proteins of the same origin were used. This 
indicates that exact experimental conditions are critical, that ARTD3 is very labile, or 
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that some groups work with ARTD3 contaminated with other ARTD members. 
Further efforts should be invested to resolve these contradictions in order to be able to 
truly characterize ARTD3.  
Several studies have implicated ARTD3 in DNA damage repair 107,114,115,400. It 
is however only implicated in the resolution of DSBs, but not SSBs. ARTD3 is 
needed to resolve γH2Ax foci in an Aprataxin-and-PNK-Like Factor (APLF) and 
XRCC4/ DNA ligase 4-dependent manner 107. Rulten and coworkers suggest that 
ARTD3 binds to double strand breaks (DSB) and recruits APLF and XRCC4/DNA 
ligase 4, which renders the chromatin permissive for DNA ligation. Based on our 
results, we however conclude that it is not the DSBs that activate ARTD3, but rather 
another stimulus. There is ample modification of histones and histone composition 
(e.g. phosphorylation of the variant H2Ax by ATM, acetylation and ubiquitination of 
γH2Ax, H2A and H2B) during the response to DNA damage 407,408. In addition, 
acetylated histone H4 (H4K8ac) and a transient increase of the histone variant H2A.Z 
is detected at DSBs 407,409-411. It is therefore possible that histones exposed upon DNA 
damage or histone variants such as γH2Ax itself activate ARTD3. It would be 
interesting to test the activation of ARTD3 and modification of γH2Ax in vitro and in 
vivo to test this hypothesis. Given that ARTD3 has a distinct role in DNA damage 
signaling, the availability of specific inhibitors for ARTD3 is important.  
This thesis includes a paper that was published in collaboration with Prof. Dr. 
Herwig Schüler that describes the development and functionality of ARTD3 specific 
inhibitors 400. These inhibitors could be used to characterize the role of ARTD3 in 
different cellular processes and to evaluate their potential as therapeutic targets. 
General PARP inhibitors are currently evaluated in clinical trials, as monotherapies or 
in combination with radiation and other chemotherapeutics, for the treatment of 
cancer types such as advanced solid tumors and lymphoma, but so far no PARP 
inhibitor has been approved for clinical use 412-415. However, all currently tested 
PARP inhibitors are NAD+-analogues that do not specifically target ARTD1, but have 
a considerable inhibitory effect on other ARTD family members such as ARTD1, 
ARTD3 or ARTD4 287. Interestingly, PARP inhibitors seem to have a broader 
application spectrum. Preclinical studies for treatment of cardiovascular and 
neurological indications and inhibition of angiogenesis have been performed 380,386,416-
420. It would thus be of significant importance to assign the observed effects to one or 
more specific ARTD family members. It is an intriguing possibility that ARTD 
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specific inhibitors, like ARTD3 inhibitors, could be used in some of these indications 
and help reduce adverse side effect.  
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